Sasayama’s Weblog


2009/11/28 Saturday

D225GÊÑ°ÛH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¥ï¥¯¥Á¥óÉÔÁ´¤¢¤ê¤ÈWHO³Îǧ

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 20:46:27

¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø

¤³¤Î¾ðÊó¤Ï11·î28Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ­¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ­»ö¤Ç¤Ï¡¢²¼µ­¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ­»ö½ç¤Ç¤¹¡£

¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ(11·î25Æü»þÅÀ)
³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊÑ°Û¤¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ(11·î22Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ(11·î19Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ (11·î9Æü»þÅÀ)

2009ǯ11·î28Æü
¡¡
¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¤Çȯ¸«¤ÎD225GÊÑ°Û¥¦¥¤¥ë¥¹¤Ë¤Ä¤¤¤Æ¤Ï¡¢»ä¤Î¥Ö¥í¥°µ­»ö¡Ö¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ¡×¤ò¤´»²¾È¤¤¤¿¤À¤­¤¿¤¤¤¬¡¢¤³¤³¤Ë¤­¤Æ¡¢¥¤¥®¥ê¥¹¤ÎMill Hill¤Ë¤¢¤ëWHO¤ÎÃϰ襻¥ó¥¿¡¼¤ÎNIMR( National Institute for Medical Research) ¤¬¡¢¶âÍËÆü¤Ë¡¢¤³¤ì¤é¤ÎD225GÊÑ°Û¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¤Ï¡¢¸½ºß¤Î¥ï¥¯¥Á¥ó¤Ï¸úÎϤòȯ¤·¤Ê¤¤( D225G Vaccine Failure¡¢¥ï¥¯¥Á¥óÉÔÁ´¡¢¥ï¥¯¥Á¥ó¤òÀܼ路¤Æ¤â½½Ê¬¤Ê¹³ÂΤ¬ÆÀ¤é¤ì¤Ê¤¤)¤È¤Î³Îǧ¤ò¤·¤¿¤¬¡¢¤³¤ì¤Ë¤Ä¤¤¤Æ¤ÎWHO¤«¤é¤Î¸ø¼°Åª¤Ê¸«²ò¤ÎɽÌÀ¤Ï¤µ¤ì¤Ê¤¤¤Þ¤Þ¤Ë¤¢¤ë¤è¤¦¤À¡£(¤³¤Î¥Ú¡¼¥¸¤Î²¼Éô¤Ë¤¢¤ë11·î26Æü¤ÎWHO¤ÎDr Keiji Fukuda»á¤Î¥Ð¡¼¥Á¥ã¥ëµ­¼Ô²ñ¸«»²¾È)

¤¹¤Ê¤ï¤Á¡¢¾åµ­¤Î¥í¥ó¥É¥ó¤ÎMillHill¤Ë¤¢¤ëWHO¤Î¸¦µæ½ê¤Ç³Îǧ¤·¤¿¤È¤³¤í¤Ë¤è¤ë¤È¡¢¥¦¥¯¥é¥¤¥Ê¤«¤é¸¡ÂΤΤҤȤÄA/Lviv/N6/2009¤Ë¡¢¥ï¥¯¥Á¥ó¤ËÂФ·¤ÆÄ㤤¥ê¥¢¥¯¥¿¡¼(ÄãÈ¿±þÍÛÀ­)¤ò»ý¤Ä¥¦¥¤¥ë¥¹¤¬¤¢¤ê¡¢¤½¤Î¾¤Î¥¦¥¤¥ë¥¹¤Ë¤Ï¡¢¥¿¥ß¥Õ¥ëÂÑÀ­¤¬¤¢¤Ã¤¿¤È¤Î¤³¤È¤Ç¤¢¤ë¡£

¤³¤ì¤Ï¡¢D225GÊѰۤˤè¤Ã¤Æ¡¢ÌȱÖÈ¿±þ¤¬²óÈò(ÌȱÖƨÈò¡¢ immunological escape)¤µ¤ì¤¿¤È¤Î¸«Êý¤¬¤µ¤ì¤Æ¤¤¤ë¡£

»²¹Í
¡ÖD225G Evades Immune Response¡×

¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¥Ë¥å¡¼¥è¡¼¥¯¥¿¥¤¥à¥º»æ¤ÎDonald McNeil»á¤Îµ­»ö¡ÖExperts Say Swine Flu Mutations Do Not Warrant New Alarm ¡×¤Ë¤ª¤¤¤Æ¤â¡¢D222GÊÑ°Û¤äD225GÊѰۤˤĤ¤¤Æ¤Î¥ï¥¯¥Á¥óÉÔÁ´·üÇ°¤¬¼¨¤µ¤ì¤Æ¤¤¤ë¡£
»²¹Í¡ÖVaccine Failure Confirmed in New York Times by UK National Institute for Medical Research ¡×

¤Þ¤¿¡¢¤³¤Î¥µ¥¤¥È¡ÖMill Hill Designates Ukraine with D225G a Low Reactor¡× ¤Ç¤Ï¡¢¸½ºß¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥ï¥¯¥Á¥ó¤¬¡¢¤â¤¦¤·¤Ð¤é¤¯¤¹¤ë¤È¡¢ÌµÍѤΤâ¤Î¤È¤Ê¤ê¤«¤Í¤Ê¤¤¡¢¤È¤Î¸«Êý¤â¤·¤Æ¤¤¤ë¡£

ÌäÂê¤Ï¡¢¥¦¥¤¥ë¥¹¸¡ÂΤκμ褬¡¢¸½ºß¤Ï¡¢¾åµ¤Æ»¤«¤é¤Î¤ß¤ÎºÎ¼è¤È¤Ê¤Ã¤Æ¤¤¤ë¤È¤³¤í¤«¤é¡¢ÇÙÁÈ¿¥¤Ë¤È¤É¤Þ¤Ã¤Æ¤¤¤ëD225GÊѰۤΥ¦¥¤¥ë¥¹¤¬¡¢È¯¸«¤µ¤ì¤Ë¤¯¤¤¾õÂ֤Ǥ¢¤ê¡¢¸½ºßȯ¸«¤µ¤ì¤Æ¤¤¤ë°Ê¾å¤ÎD225GÊÑ°Û¥¦¥¤¥ë¥¹¤¬¡¢À¤³¦Ãæ¤ËÌ¢±ä¤·¤Æ¤¤¤ë²ÄǽÀ­¤¬¤¢¤ë¤³¤È¡¢¤½¤·¤Æ¡¢¤½¤ì¤ËÂФ¹¤ë¥ï¥¯¥Á¥ó¤¬¡¢D225GÊÑ°Û¡¦D225EÊÑ°Û¡¦D225NÊÑ°Û¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¤Ï¡¢¥ï¥¯¥Á¥óÉÔÁ´¤Ç¤¢¤ë¡¢¤È¤¤¤¦¤³¤È¤Ç¤¢¤ë¡£

¡ÖWHO Silence on D225G Vaccine Mismatch Confuses Media¡×¤Ç¤Ï¡¢
¡Ö4ÇÜÎ̤Υ說¥Á¥ó¤òÀܼ路¤Ê¤±¤ì¤Ð¡¢¥¿¥¤¥¿¡¼(ÎϲÁ¡Ë¤¬Áý²Ã¤·¤Ê¤¤¤È¤¤¤¦¤³¤È¤Ï¡¢¡Ø¥ï¥¯¥Á¥ó¤Î¥ß¥¹¥Þ¥Ã¥Á¡Ù¤È¤â¤¤¤¨¡¢¤³¤Î¥ï¥¯¥Á¥óÀܼï¤Ë¤è¤Ã¤Æ¤Ï¡¢¥¿¥¤¥¿¡¼¤ò¸º¾¯¤µ¤»¤ë¿·¤¿¤ÊÊÑ°Û¤ò¸º¾¯¤¹¤ë¤³¤È¤Ë¤Ï¤Ä¤Ê¤¬¤é¤Ê¤¤¤¬¡¢ÌîÀ¸¥¿¥¤¥×¤ÎÊÑ°Û¥¦¥¤¥ë¥¹¤Î¤ß¤ò¸º¾¯¤µ¤»¤ë¤³¤È¤Ë¤Ä¤Ê¤¬¤ë¡£¤½¤Î·ë²Ì¡¢¥ß¥¹¥Þ¥Ã¥Á¤·¤¿¥ï¥¯¥Á¥ó¤ò³¤±¤Æ»È¤Ã¤Æ¤¤¤¯¤È¡¢¥ï¥¯¥Á¥óÂÑÀ­¥¦¥¤¥ë¥¹¤ÎÁý²Ã¤òÀ¸¤à¤³¤È¤Ë¤Ê¤ë¡£¡×
¤È¤·¤Æ¤¤¤ë¡£

¤Þ¤¿¡¢¥Õ¥é¥ó¥¹¤«¤é¤ÎÊóÆ»¤Ç¤Ï¡¢¥¢¥¸¥å¥Ð¥ó¥ÈÆþ¤ê¤Î¥ï¥¯¥Á¥ó¤Ç¤Ê¤±¤ì¤Ð¡¢¥¿¥¤¥¿¡¼(ÎϲÁ¡Ë¤¬Áý²Ã¤·¤Ê¤¤¤È¤ÎÉ÷À⤬ή¤ì¤Æ¤¤¤ë¤è¤¦¤Ç¤¢¤ë¡£
(” Ces nouvelles mutations doivent au contraire inciter tous les Fran½æMais ½æA aller se faire vacciner, avec adjuvant.”¡Ö¤³¤ì¤é¤ÎÊѰۤϡ£µÕ¤Ë¡¢¤¹¤Ù¤Æ¤Î¥Õ¥é¥ó¥¹¿Í¤ò¤·¤Æ¡¢¥¢¥¸¥å¥Ð¥ó¥ÈÆþ¤ê¥ï¥¯¥Á¥óÀܼï¤Ø¤È¡¢¸þ¤«¤ï¤»¤ë¡£¡×¡Ö“Ces mutations du virus H1N1 doivent ½æStre prises tr½æQs au s½æPrieux“¡×¤è¤ê)

D225GÊÑ°Û¥¦¥¤¥ë¥¹¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤ì¤Þ¤Ç¤Î¥¦¥¯¥é¥¤¥Ê¡¢¥Î¥ë¥¦¥§¥¤¡¢¹á¹Á¤Ë³¤¤¤Æ¡¢¥Õ¥é¥ó¥¹¤Ç¤â¡¢Æ±ÍͤÎÊÑ°Û¥¦¥¤¥ë¥¹¤¬³Îǧ¤µ¤ì¤¿¡£

¥Õ¥é¥ó¥¹¤Ç¤ÎD225GÊÑ°Û¥¦¥¤¥ë¥¹¤òÍ­¤·¤Æ¤¤¤ë´µ¼Ô¤Ï¡¢Æó¿Í¤ª¤ê¡¢¤½¤Î¤¤¤º¤ì¤â½ÅÂ֤Ǥ¢¤ê¡¢¤½¤Î¤¦¤Á¤Î°ì¿Í¤Ë¤Ï¡¢¥¿¥ß¥Õ¥ëÂÑÀ­¤¬¸«¤é¤ì¤¿¤È¤¤¤¦¡£

¥Ö¥é¥¸¥ë¤Ç¤âƱ¼ï¤ÎÊÑ°Û¥¦¥¤¥ë¥¹¤¬¡¢¸«¤Ä¤«¤Ã¤Æ¤¤¤ë

»²¹Í
2009ǯ11·î26Æü¤ÎWHO¤Î¥Ð¡¼¥Á¥ã¥ëµ­¼Ô²ñ¸«¤Ç¤Î¥¦¥¤¥ë¥¹ÊѰۤ˴ؤ¹¤ëÉôʬȴ¿è

(Transcript of virtual press conference with Kristen Kelleher, Communications Officer for pandemic (H1N1) 2009, and Dr Keiji Fukuda, Special Adviser to the Director-General on Pandemic Influenza, World Health Organization 26 November 2009 )

Dr Keiji Fukuda:
Now the last point that I want to address before I throw it open to questions is that in the last several days we have also seen a lot of reports in the media about a mutation and this was specifically raised because it was Norway which recently reported seeing mutations in three patients who had severe disease.

Since then there have been additional reports of the same mutation being seen in viruses in a number of other countries, such as Brazil, China, Japan, Ukraine and the US [CORRECTION FOR ACCURACY: AND MEXICO].

The question is whether this mutation again suggests that there is a fundamental change going on in viruses out there or whether there is a turn for the worse in terms of the severity.

I think that the answer right now is that we are not sure.

I want to answer why we are not sure in a way which explains why more investigations are needed.

As you know these influenza viruses change frequently.

Their gene properties change because these are viruses which frequently undergo mutations and so mutations in and of themselves are not necessarily important and in fact, if every mutation was reported out there, it would be like reporting changes in the weather - saying that there is a temperature difference of one degree one hour and then an hour later, saying there is a temperature increase or decrease of one¡¡degree.

This kind of information does not really help anybody.

But, what we try to do when we see reports of mutations is to identify whether these mutations are leading to any kind of changes in the clinical picture - do they cause more severe disease or less severe disease and also we try to look at whether these viruses are increasing out there, suggesting that there may be a change in the epidemiology.

With this particular mutation we have seen that it is reported in people who have severe disease and we have also seen that it is also been reported in people who have milder disease.

Right now one of the questions is, is it really associated with severe disease more often.

The second point that though, is are these viruses becoming more common or are they relatively infrequent.

So again, this requires looking at more viruses over time to get a sense of whether there is a change in the overall prevalence or number of these viruses.

It is these kinds of investigations which require time and it is these kinds of questions which have to be answered before we can fully talk about the importance of one mutation or another mutation.

»²¹Í¡¡225¥Ý¥¸¥·¥ç¥ó¤Ç¤ÎÊÑ°Û°ìÍ÷

RPKVRDQEGRI,>A/Kansas/UR06-0068/2007(H1N1)
RPKVRGQAGRI,>A/Index/1977(H1N1)
RPKVRDQSGRM,>A/Denver/1957(H1N1)
RPKVRDQAGRM,>A/Index/early human
RPKVRDQAGRM,>A/Brevig Mission/1/1918(H1N1)
RPKVRGQAGRM,>A/Index/early swine
RPKVRGQAGRM,>A/swine/Jamesburg/1942(H1N1)
RPKVRGQAGRM,>A/New Jersey/1976(H1N1)
RPKVRDQEGRM,>A/******/index/2009/02/01
RPKVRGQEGRI,>A/Taiwan/01/1986///
RPKVRGQEGRI,>A/Beijing/262/1995///
RPKVRDQEGRI,>A/New Caledonia/20/1999///
RPKVRDQEGRI,>A/Solomon Islands/3/2006/08/21/
RPKVRDQEGRI,>A/Brisbane/59/2007/07/01/
RPKVREQAGRM,>A/swine/Germany/2/1981(H1N1)=1578
RPKVRDQAGR-,>A/******-match/1-2/07(H3N2)
RPKVRDQPGRM,>A/UK/1/1933(H1N1)
RPKVRDQAGRM,>A/Puerto Rico/8-1/1934(H1N1)
RPKVRGQEGRI,>A/Texas/36/1991(H1N1)
RPKVRNQEGRI,>A/Chile/1/1983(H1N1)

¡ÖOne of the D225G cases is a low reactor? ¡×¤è¤ê

»²¹Í
¡ÖWHO Confirms That The H1N1 Swine Flu Has Mutated In Ukraine – But That We Should Not Worry¡×

D225GÊÑ°Û´ØÏ¢¥Ó¥Ç¥ª



¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢2,950±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

2009/11/26 Thursday

ÀÖ¾¾ÇÀÁ꤬Âç³ã¼¤Ë¼Õºá¤È¤¤¤¦¤¬¡¢¤ª¤«¤·¤¯¤Í?

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 13:51:13

2009/11/26(Thu)
¡¡
ÀÖ¾¾¹­Î´ÇÀÁ꤬¡¢º£Æü¡¢£±£±·î£²£¶Æü¤Î½©Åĸ©Âç³ã¼¤Î»ë»¡¤Ë¤ª¤¤¤Æ¡¢¡ÖÂç³ã¼¤Ï¹ñ¤ÎÀ¯ºö¤ËËÝÏ®¤µ¤ì¡¢¶ìÏ«¤µ¤ì¤Æ¤­¤¿¡£¹ñ¤ÎÀÕǤ¤À¡×¤È¼Õºá¤·¤¿¤È¤¤¤¦¤Î¤Ç¤¹¤¬¡¢ÀÖ¾¾¤µ¤ó¡¢¤Þ¤º°ìÈ֤μպá¤ÎÁê¼ê¤ò´Ö°ã¤Ã¤Æ¤Ï¤¤¤Þ¤»¤ó¤Ç¤·¤ç¤¦¤«?

Âç³ã¼¤Î²áµî¤Î¸ºÈ¿¤ä¤Ö¤ê¤Ç¡¢°ìÈÖÌÂÏǤò¤³¤¦¤à¤Ã¤¿¤Î¤Ï¡¢½©Åĸ©Æâ¤ÎÈóÆþ¿¢¼Ô¤Ç¤¢¤ë°ìÈÌÇÀ²È¤Ê¤Î¤Ç¤¹¡£

¤½¤·¤Æ¡¢¤½¤Î¸ºÈ¿Çˤê¤Î¤½¤Î¤Ä¤É¡¢¸©Æ⸺ȿĴÀ°¤ä¸©´Ö¸ºÈ¿Ä´À°(ÅÔÆ»Éܸ©´ÖÄ´À°)¤Ç¡¢°ìÈÖ¸ª¿È¤Î¶¹¤¤»×¤¤¤ò¤·¤¿¤Î¤â¡¢¸©Æâ°ìÈÌÇÀ²È¤Ê¤Î¤Ç¤¹¡£

¤ª¤½¤é¤¯¡¢Âç³ã¼¤Î¸©ÆâÆþ¿¢¼Ô¤â¤½¤¦¤À¤Ã¤¿¤Ë°ã¤¤¤¢¤ê¤Þ¤»¤ó¡£

¤Ê¤¼¤Ê¤é¡¢¸©Æâ¤Ë¤¢¤ë¼«Ê¬¤Î½Ð¿È¤Î¼¤Ç¤Ï¡¢¸ºÈ¿½ç¼é¤·¤Æ¤¤¤ë¤Î¤Ë¡¢¼«Ê¬¤¬¸©ÆâÆþ¿¢¤·¤¿Âç³ã¼¤Ç¤Ï¡¢Æ²¡¹¤È¸ºÈ¿Çˤê¤ò¤·¤Æ¤¤¤¿¤ó¤Ç¤¹¤«¤é¡£

¤Ç¤¹¤«¤é¡¢¤â¤·¡¢¡Ö¹ñ¤ÎÀ¯ºö¤ËËÝÏ®¡×¤µ¤ì¤¿¤È¤·¤Æ¡¢¼Õ¤ë¤Î¤Ç¤¢¤ì¤Ð¡¢Âç³ã¼¤è¤ê¤âÀè¤Ë¡¢½©Åĸ©Æâ°ìÈÌÇÀ²È¤ËÀè¤Ë¼Õ¤ë¤Î¤¬¶Ú¤Ã¤Æ¤â¤ó¤Ç¤Ï¤Ê¤¤¤Ç¤·¤ç¤¦¤«¡£

¤Ê¤¼¤Ê¤é¡¢Âç³ã¼¤Ë¤â¡¢½ç¼éÇÉ(¸ºÈ¿½ç¼éÇÉ)¤â¤¤¤¿¤·¡¢Èà¤é¤Î¤è¤¦¤ÊÈó½ç¼éÇÉ(¥ä¥ßÊÆÇÉ¡á²á¾êºîÉÕ¤±ÇÉ)¤â¤¤¤¿¤ï¤±¤Ç¤¹¤«¤é¡¢Èó½ç¼éÇɤΤ«¤¿¤¬¤¿¤Ï¡¢¤½¤ÎÅö»þ¡¢¸ºÈ¿¤ò¼é¤é¤Ê¤¤¤³¤È¤Ë¤è¤ê¡¢°ìÄê¤Îµ¡²ñÍø±×¤òÆÀ¤Æ¤¤¤¿¤Ï¤º¤Ê¤Î¤Ç¤¹¤«¤é¡£

¤Ç¤¹¤«¤é¡¢¤³¤ÎÏÀÍý¤Ç¤¹¤È¡¢Åö»þ¤Î¥ä¥ßÊÆÇɤˤϡ¢¤³¤Î»þÅÀ¤Ç¥³¥ó¥×¥é¥¤¥¢¥ó¥¹°ãÈ¿¤ò¤·¤Æ¤¤¤¿¤ï¤±¤Ç¤¹¤«¤é¡¢¹ñ¤ÎÉÔºî°Ù¤ÏÌ䤨¤Þ¤»¤ó¤¬¡¢Åö»þ¡¢¸ºÈ¿¤ò½å¼é¤·¤Æ¤¤¤¿ÇÀ̱¤Ë¤Ï¡¢¹ñ¤ÎÉÔºî°Ù¤òÌ䤦¸¢Íø¤¬¤¢¤ë¤È¤¤¤¦¤³¤È¤Ë¤Ê¤Ã¤Æ¤·¤Þ¤¤¤Þ¤¹¤è¡£

¤½¤ì¤Ç¤¤¤¤¤Î¤Ç¤¹¤«?

Åö»þ¤Î½ç¼éÇɤϡ¢º£Æü¤ÎÀÖ¾¾È¯¸À¤ò´ð¤Ë¤·¤Æ¡¢¹ñÇåÁʾ٤˻ý¤Á¹þ¤ß¤Þ¤¹¤è¡£

ÀÖ¾¾¹­Î´ÇÀÁê¤Ï¡¢ÌÀ¤é¤«¤Ë¡¢¼Õ¤ë½ç½ø¤ò´Ö°ã¤¨¤Æ¤¤¤ë¤È¤·¤«¤¤¤¨¤Þ¤»¤ó¡£

¤³¤ì¤Ç¤Ï¡¢¤Þ¤µ¤Ë¡¢¡ØÀµÄ¾¼Ô¤¬Çϼ¯¤ò¸«¤ë¡Ù¤Î¹½¿Þ¤Ç¤¹¡£

¤Þ¤ë¤Ç¡¢ÀïÁè¤Î³«ÀÇÔÀï¤ÎÀÕǤ¤ò¡¢½¾·³Ê¼¤ËÂФ·¤Æ¤Ç¤Ê¤¯¡¢¤Þ¤º¡¢Æ¨Ë´Ê¼¤ËÂФ·¤Æ¡¢¤ªÏͤӤÇƬ¤ò²¼¤²¤Æ¤¤¤ë¤Î¤È¡¢¤ª¤ó¤Ê¤¸¹½¿Þ¤Ç¤¹¡£

º£²ó¤Î¼«¼çºîÉÕ¤±ÇɤθÍÊ̽êÆÀÊä½þ¤Ë¤«¤±¤ë»×ÏǤʤɤˤĤ¤¤Æ¤Ï¡¢¤³¤ÎÅÚÌç¹ä¤µ¤ó¤Î¥µ¥¤¥È¡Ø¸ºÈ¿ÇËþ¤Î¾ÝħŪÉñÂæ¤È¤Ê¤ë¤«Âç³ã¼(¸ºÈ¿Êä½õ¶â¤Ç¼Ú¶â¥Á¥ã¥éºîÀï)¡Ù¤Ê¤ó¤«¤ò¸«¤ë¤È¤è¤¯¤ï¤«¤Ã¤Æ¤¯¤ë¤«¤â¤·¤ì¤Þ¤»¤ó¡£

¤Ä¤Þ¤ê¡¢Âç³ã¼¤Î¼«¼çºîÉÕ¤±ÇɤˤȤäơ¢¶á»þ¤Î¥³¥áÈÎÇä´Ä¶­¤ÎÊѲ½¤Ç¡¢¤³¤ì¤Þ¤Ç¥³¥ó¥×¥é¥¤¥¢¥ó¥¹°ãÈ¿¤Ç¥¹¥­¥ß¥ó¥°¤·¤Æ¤­¤¿¤è¤¦¤ÊÍ¥°Ì¤ÊÈÎÇäÀïά¹½ÃÛ¤¬Æñ¤·¤¯¤Ê¤Ã¤Æ¤­¤Æ¤¤¤ëÃæ¤Ç¡¢¤³¤³¤Ç¸ºÈ¿½å¼éÀë¸À¤ò¤·¡¢¸ÍÊ̽êÆÀÊä½þ¥¹¥­¡¼¥à¤Ë¤Ê¤À¤ì¹þ¤à¤³¤È¤Ë¤è¤Ã¤Æ¡¢¼«¼çºîÉÕ¤±Ï©Àþ¤Îž´¹¡¦Å±ÂàÈñÍѤ趻ñ¤È¤·¤Æ¡¢¸ÍÊ̽êÆÀÊä½þ¥¹¥­¡¼¥à¤òÎßÀÑÉéºÄÀ°Íý¤Î¥Ä¡¼¥ë¤È¤·¤ÆÍøÍѤ·¤è¤¦¤È¤·¤Æ¤¤¤ë¤Î¤Ç¤Ï¤Ê¤¤¤«¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ä¤¤¤Æ¤Îµ¿¿´°Åµ´¤¬¡¢¸©Æâ°ìÈÌÇÀ²È¤ÎÃæ¤Ë¤Ï¤¢¤ë¤È¤¤¤¦¤³¤È¤Ç¤¹¤Í¡£

¤³¤Î¤«¤®¤ê¤Ë¤ª¤¤¤Æ¡¢¸©Æâ°ìÈÌÇÀ²È¤Ï¡¢¤Þ¤¿¤·¤Æ¤â¡¢Èà¤é¤ÎƧ¤ßÂæ¤Ë¤µ¤ì¤Æ¤·¤Þ¤¦¤È¤¤¤¦¤ï¤±¤Ç¤¹¡£

¤¿¤È¤¨¤Æ¸À¤¨¤Ð¡¢¤³¤ó¤Ê¤È¤³¤í¤Ç¤·¤ç¤¦¤«¤Í?

¡Ö¥Þ¥ó¥·¥ç¥ó¤Î´ÉÍýÁȹ礬¡¢¥Þ¥ó¥·¥ç¥ó´ÉÍýÈñ¤òʧ¤Ã¤Æ¤¤¤ëÆþµï¼Ô¤Ë¸Â¤Ã¤Æ¡¢¤³¤ì¤«¤é¡¢´ÉÍýÈñ¤òÂçÉý¤ËÃͲ¼¤²¤¹¤ë¤È·èÄꤷ¤¿¤È¤¿¤ó¤Ë¡¢¤³¤ì¤Þ¤Ç¡¢¥Þ¥ó¥·¥ç¥ó´ÉÍýÁȹç¤Ë´ÉÍýÈñ¤òʧ¤Ã¤Æ¤³¤Ê¤«¤Ã¤¿ÉÔÎÉÆþµï¼Ô¤¬¡¢¤³¤ì¤«¤é¤Ï¡¢´ÉÍýÈñ¤ò¤Ï¤é¤¤¤Þ¤¹¤è¡¢¤È¤¤¤Ã¤Æ¡¢µÞ¤ËÂÖÅÙ¤òÊѲ½¤µ¤»¤Æ¡¢´ÉÍýÁȹç¤ËÆþ²ñ¤·¤Æ¤­¤¿¡£¤¸¤ã¤¢¡¢¤³¤ì¤Þ¤Ç¤ÎÂÚǼ¤·¤Æ¤­¤¿ÉÔÎÉÆþµï¼Ô¤ÎÂÚǼ´ÉÍýÈñÎßÀÑʬ¤Ï¡¢Íø©ʬ¤â´Þ¤á¤Æ¡¢¤³¤³¤Ç¡¢¥Á¥ã¥é¤Ë¤·¤Æ¤·¤Þ¤¦¤Î?¡×
¤Ã¤Æ¤¤¤¦´¶¤¸¤Ç¤·¤ç¤¦¤«¡£
¡Ö¥Þ¥ó¥·¥ç¥ó¤Î½¤Á¶ÀÑΩ¶â¤ÎÉÔ­ʬ¤Ï¡¢¤³¤ì¤Þ¤Ç¡¢»Ä¤ê¤ÎÆþµï¼Ô¤ÎÉéôʬ¤Ç¤Þ¤«¤Ê¤Ã¤Æ¤­¤¿¤Î¤Ë¡£¡×¤Ã¤Æ¸À¤¦¤Î¤¬¡¢¤³¤ì¤Þ¤Ç¸ºÈ¿½å¼é¤·¤Æ¤­¤¿½©Åĸ©Æâ°ìÈÌÇÀ²È¤Î¸À¤¤Ê¬¤È¤Ê¤ë¤Î¤Ç¤·¤ç¤¦¡£

¤À¤ó¤À¤ó¡¢Åܤ꤬¤³¤ß¾å¤²¤Æ¤­¤Æ¤¤¤Þ¤¹¡£

¤ª¤½¤é¤¯¡¢½©Åĸ©Æâ°ìÈÌÇÀ²È¤â¡¢Âç³ã¼¤Î½ç¼éÇɤΤ«¤¿¤¬¤¿¤â¡¢Æ±¤¸µ¤»ý¤Á¤Ç¤·¤ç¤¦¡£

Äɵ­¡¡£²£°£°£¹Ç¯£±£²·î9Æü¡¡¼«¤é¿Ê¤ó¤Ç½©Åĸ©°ìÈÌÇÀ̱¤Î¿´¤ÎÃæ¤Ë¤¢¤ë¥È¥é¤ÎÈø¤òƧ¤ó¤Ç¤·¤Þ¤Ã¤Æ¤¤¤ëÀÖ¾¾ÇÀÁê

ºòÆü¡¢ÀÖ¾¾ÇÀÁê¤Ï¡¢µ­¼Ô²ñ¸«¤Ç¡¢¡Ø½©Åĸ©¤ò¸ÍÊ̽êÆÀÊä½þ¤ÎÂоݤ«¤é¤Ï¤º¤¹¡Ù¤È¤Î¶Ú°ã¤¤È¯¸À¤ò¤µ¤ì¤Æ¤¤¤ë¤è¤¦¤Ç¤¹¡£

ÀÖ¾¾¤µ¤ó¤Ï¡¢¾åµ­¤ÎÂç³ã¼¤Ç¤Î¼«¤é¤Î·ÚΨ¤Êȯ¸À¤Ç¡¢¤¤¤Ã¤¿¤ó¤ÏÉõ°õ¤µ¤ì¤«¤±¤¿¥Ñ¥ó¥É¥é¤ÎÈ¢¤ò¼«¤é·ÚΨ¤Ë³«¤±¡¢½©Åĸ©°ìÈÌÇÀ̱¤Î˺¤ì¤«¤±¤Æ¤¤¤¿¥ä¥ßÊÆÇɤȤβáµî¤Î¸©Æâ³Î¼¹¤ò¤Õ¤¿¤¿¤Ó»×¤¤½Ð¤µ¤»¡¢¼«¤é¡¢»öÂÖ¤ò¤ä¤ä¤³¤·¤¯¤µ¤ì¤Æ¤¤¤ë¤³¤È¤Ë¡¢¤Þ¤À¡¢¤ªµ¤¤Å¤­¤Ç¤Ê¤¤¤é¤·¤¤¤Î¤Ç¤¹¤¬¡£

°Ê²¼¤Ï¡¢ºòÆü¤ÎÂç¿Ãȯ¸À¤ÎÆâÍƤǤ¹¡£(¤Á¤ç¤Ã¤È¡¢¼è¤êα¤á¤Î¤Ê¤¤»¨ÃÌÄ´¤Ê¤Î¤Ç¡¢ÆɤߤŤ餤¤Î¤Ç¤¹¤¬¡£¤È¤¯¤Ë”¤¢¤ì”¤È¤¤¤¦¸ÀÍÕ¤¬¤ª¹¥¤­¤Î¤è¤¦¤Ç¡¢¤³¤ÎÆü¤Îµ­¼Ô²ñ¸«¤Ç¤â¡¢£±£³²ó¤âϢȯ¤µ¤ì¤Æ¤¤¤Þ¤¹¤Í¡£
¸½ºß¤Î¥Ú¥Ê¥ë¥Æ¥£¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È¡ÖÇÀÀ¯²þ³×»°Âкö¤ÎÃå¼Â¤Ê¿ä¿Ê¤Ë¤Ä¤¤¤Æ¡×¤´»²¾È)

¡Öº£Æü¤Ï¡¢¤Á¤ç¤Ã¤È»þ´Ö¤¬¤¢¤ë¤ó¤Ç¤æ¤Ã¤¯¤êÏä·¤Þ¤¹¤¬¡¢
Î㤨¤Ð¡¢¤³¤Î´Ö¡¢Âç³ã¼¤Ø¹Ô¤Ã¤Æ¤­¤¿¤È¡¢
¤½¤¦¤¹¤ë¤È¡¢Âç³ã¼¤Ç¡¢¤¢¤ì¤À¤±È¿Ìܤ·¹ç¤Ã¤Æ¤¤¤¿¿Í¤¿¤Á¤¬¡¢º£¡¢ËÜÅö¤ËÃçÎɤ¯¤Ê¤Ã¤Æ¡¢º£¤Þ¤Ç¡¢¸ºÈ¿¤ä¤Ã¤Æ¤­¤¿¿Í¡¢È¿ÂФ·¤Æ¤­¤¿¿Í¡¢¤½¤ì¤¬ËÜÅö¤Ë°ì¤Ä¤Ë¤Ê¤Ã¤Æ¡¢¤³¤ì¤òµ¡²ñ¤Ëϲò¤·¤Æ¡¢¤ß¤ó¤Ê¤Ç¤¤¤¤Âç³ã¼¤òºî¤í¤¦¤È¤¤¤¦¤³¤È¤Ç¤Ê¤Ã¤Æ¤¤¤ë¤ó¤Ç¤¹¤Í¡£
¤È¤³¤í¤¬¡¢¸©¤ÎÃλö¤äÇÀÀ¯Éô¤¢¤¿¤ê¤Î¡¢¤½¤¦¤¤¤¦ÃÏÊý¤Î´´Éô¤¬Íý²ò¤·¤Æ¤Ê¤¤¤È¡¢
º£¡¢²¿¤ò¸À¤Ã¤Æ¤¤¤ë¤«¤È¤¤¤¦¤È¡¢¡Ö¤¤¤ä¤¤¤ä¡¢¤½¤ó¤Ê¤ȿ¤·¤Æ¤­¤¿¡¢¤¢¤ì¤ä¤Ã¤Æ¤­¤¿¤ä¤Ä¤ÏÂÌÌܤÀ¡×¤È¡¢
Æä˼«Ì±Åޤθ©µÄ²ñ²¿¤«¡¢¡Ö¤¢¤ó¤ÊÍ°°æ(Å°)¤ß¤¿¤¤¤Ê¤ä¤Äµö¤»¤ë¤«¡×¤È¡¢¡Ö¤¢¤ó¤Ê¼Ô¤Ïº£¤Þ¤Ç¤É¤ª¤ê¡¢³ä¤êÅö¤Æ¤Ï30¥Ñ¡¼¥»¥ó¥È¤À¡×¤Ê¤ó¤Æ¤¤¤¦¤³¤È¤ò¡¢Ê¿µ¤¤Ç¸À¤Ã¤Æ¤¤¤ë¤ï¤±¤Ç¤¹¡£
¤¸¤ã¤¢¡¢30¥Ñ¡¼¥»¥ó¥È¤Ç¡¢¤¸¤ã¤¢¡¢Í°°æ¤µ¤ó¤Ë¤ä¤ì¤È¸À¤Ã¤¿¤Ã¤Æ¡¢º£¤Þ¤Ç¤Ïºî¤é¤Ê¤¤30¥Ñ¡¼¥»¥ó¥È¤À¤«¤é¡¢¤½¤ó¤Ê¤â¤Î¤Ï¡¢10¥Ñ¡¼¥»¥ó¥È¤À¤Ã¤Æ¤Ê¤ó¤À¤Ã¤Æ¡¢´Ø·¸¤Ê¤¤¤ó¤À¤±¤É¤â¡¢º£Å٤Ϸè¤á¤é¤ì¤¿À¸»º¿ôÎÌÌÜɸ¤ò¼é¤ë¤È¸À¤Ã¤Æ¤¤¤ë¤ï¤±¤Ç¤¹¤«¤é¡¢¼é¤ë¤¿¤á¤Ë¤Ï¡¢ºÎ»»¤ò¹ç¤ï¤»¤è¤¦¤È»×¤Ã¤¿¤é¡¢¤³¤ì¤Ï¡¢¤Þ¤¢¡¢Á´Éô¡¢º£¤Þ¤Ç¡¢Ï»½½²¿¤È¤«¤Þ¤Ç¤Ï¤¤¤«¤Ê¤¤¤Ë¤·¤Æ¤â¡¢¾¯¤Ê¤¯¤È¤â¡¢¤³¤ì¤Ï¤â¤¦¡¢Î¾Êý¤Ë¸À¤Ã¤Æ¤¤¤ë¤Î¤Ç¤¹¤±¤ì¤É¤â¡¢º£¤Þ¤Ç¡¢¤¢¤ó¤¿¡¢¿Í¤Î¤¢¤ì¤ò¤«¤µ¾å¤²¤·¤Æ¡¢¤¿¤¯¤µ¤ó¤â¤é¤¤¤¹¤®¤Æ¤¤¤¿¤ó¤À¤«¤é¡¢¤³¤ì¤Ï¡¢¤Á¤ã¤ó¤È¸º¤é¤¹¤Î¤Ç¡¢¸º¤ê¤Þ¤¹¤è¤È¡¢
¤·¤«¤·¡¢¤¢¤Ê¤¿¤â¡¢°ì¤Ú¤ó¤Ë¡¢¤ß¤ó¤Ê¤È°ì½ï¤È¤¤¤¦¤ï¤±¤Ë¤Ï¤¤¤«¤Ê¤¤¤«¤é¡¢¤¤¤í¤¤¤í¤Ê·Ð°Þ¤â¤¢¤ë¤Î¤À¤«¤é¡¢¤Þ¤¢¡¢¤½¤³¤½¤³¤Î¤È¤³¤í¤Ç²æËý¤·¤Ê¤µ¤¤¤è¤È¤¤¤¦¤³¤È¤ò¡¢Ëͤϡ¢¸½ÃϤǸÀ¤Ã¤Æ¤­¤¿¤Î¤Ç¤¹¤±¤ì¤É¤â¡¢
¤·¤«¤·¡¢¤½¤¦¤¤¤¦¤³¤È¤¬¼é¤é¤ì¤º¤Ë¡¢¥Ú¥Ê¥ë¥Æ¥£¡¼¤Ï¤Ê¤·¤À¤È¤¤¤¦¤Î¤¬¡¢¤³¤ÎÂçÊý¿Ë¤Ç¤¹¤«¤é¡¢¥Ú¥Ê¥ë¥Æ¥£¡¼¤Ï¤³¤ì¤«¤é¤â¤ä¤Ã¤Æ¤¤¤¯¤ó¤À¤ß¤¿¤¤¤Ê¤³¤È¤ò¡¢¾¡¼ê¤Ë¡¢ÃÏÊý¤Î¤½¤¦¤¤¤¦¿Í¤¿¤Á¤¬¸À¤Ã¤Æ¤¤¤ë¤È¡¢
¤Þ¤º¡¢¸©Á´ÂΤǡ¢Âç³ã¼¤ò¡¢¤Þ¤ºº¹¤òÉÕ¤±¤Æ¡¢Âç³ã¼¤ÎÃæ¤Ç¡¢¤Þ¤¿º¹¤òÉÕ¤±¤Æ¡¢¤ªÁ°¤ÏÍè¤Ê¤¤¤è¤¦¤Ë¤ä¤ë¤ó¤À¤ß¤¿¤¤¤Ê¤³¤È¤ò¤ä¤Ã¤Æ¤¤¤ë¤³¤È¤¬¤¢¤ë¤â¤Î¤Ç¤¹¤«¤é¡¢
¤³¤ì¤Ï¡¢8Æü¤Ã¤Æº£Æü¤À¤Ã¤±¡£
º£Æü¡¢Ã´Åö¤ÎÀÕǤ¼Ô¤ò¸½ÃϤ˹Ԥ«¤»¤Æ¡¢¤â¤·¤â¡¢¤½¤ó¤Ê¤Õ¤¦¤Ç¤ä¤ë¤ó¤À¤Ã¤¿¤é¡¢½©Åĸ©Á´ÂΤò¡¢¤½¤ÎÂоݤ«¤é³°¤·¤Þ¤¹¤è¤È¡¢
À¸»º¿ôÎÌÌÜɸ¤ò¼é¤ë¿Í¤¿¤Á¤â´Þ¤á¤Æ¡¢Á´Éô¡¢¸©Á´ÂΤ¬¡¢ºÇ½é¤«¤é³ä¤êÅö¤Æ¡¢°ã¤¦Êý¸þ¤Ç¤ä¤Ã¤Æ¤¤¤ë¤ï¤±¤Ç¤¹¤«¤é¡¢¤³¤ì¤ÏˡΧ°ãÈ¿¤À¤«¤é¡¢¤ä¤í¤¦¤È¡¢¤Þ¤À·è¤Þ¤Ã¤¿¤ï¤±¤¸¤ã¤Ê¤¤¡¢¤ä¤í¤¦¤È¤·¤¿¤È¤·¤¿¤é¡¢¤³¤ì¤ÏˡΧ°ãÈ¿¤Ë¤Ê¤ë¤ó¤Ç¡¢¤½¤¦¤¤¤¦¤³¤È¤â¤¢¤êÆÀ¤Þ¤¹¤è¤È¤¤¤¦¤³¤È¤ò¡¢Âç¿Ã¤Î°Õ»×¤À¤È¸À¤Ã¤Æ¡¢¤Ï¤Ã¤­¤ê¸À¤Ã¤Æ¤³¤¤¤È¸À¤Ã¤Æ¤ª¤­¤Þ¤·¤¿¡£
¤Þ¤¢¡¢Íý²ò¤ò¤·¤Æ¤¤¤¿¤À¤±¤ì¤Ð·ë²Ì¤È¤·¤Æ¤½¤¦¤Ê¤é¤Ê¤¤¤È»×¤¤¤Þ¤¹¤¬¡¢¤Þ¤À¤Þ¤À¡¢ÃÏÊý¤Ø¹Ô¤¯¤È¡¢»þÂ夬ÊѤï¤Ã¤¿¤È¡¢¤â¤¦º£¤Þ¤Ç¤Î»ÅÁȤߤϡ¢É´È¬½½Åٰ㤦¤ó¤À¤È¤¤¤¦¤³¤È¤òÍý²ò¤·¤Æ¤¤¤Ê¤¤¿Í¤Ï¡¢»ÄÇ°¤Ê¤¬¤é¡¢¤Þ¤À¤¤¤ë¤È¤¤¤¦¤³¤È¤Ç¡¢¤½¤ÎÊդμñ»Ý¤ò¡¢¤­¤Á¤Ã¤ÈÍý²ò¤·¤Æ¤â¤é¤¨¤ë¤è¤¦¤Ë¤ä¤Ã¤Æ¤¤¤¯¤È¤¤¤¦¤³¤È¤¬¡¢»ä¤ÏɬÍפÀ¤È»×¤Ã¤Æ¤Þ¤¹¡£
¤À¤«¤é¡¢¤³¤ì¤«¤é¤¬¡¢¤à¤·¤í¡¢ÂçÊѤÀ¤Ê¤È»×¤Ã¤Æ¤¤¤Þ¤¹¤¬¤Í¡£¡×
http://www.maff.go.jp/j/press-conf/min/091208.html


Äɵ­¡¡¸½ºß¤Î¥Ú¥Ê¥ë¥Æ¥£¤ÎÁ¼Ã֤γµÍ×

ÌÜɸ̤ãÀ®¤ÎÅÔÆ»Éܸ©¡¦Ãϰ衦ÇÀ¶È¼Ô¤Ø¤ÎÂнè¡Ê ¥Ú¥Ê¥ë¥Æ¥£¡Ë

¡Ê £± ¡Ë ÌÜɸ¤òãÀ®¤·¤¿¤«¤É¤¦¤«¤Ï¡¢Åö³ºÃÏ°èÁ´ÂΤȤ·¤Æ¤Î¼ç¿©ÍѺîÉÕÌÌÀÑ¡Ê Á´¿å°ðºîÉÕÌÌÀѤ«¤é²Ã¹©ÍÑÊÆ¡¦¿·µ¬¼ûÍ×ÊƤκîÉÕÌÌÀѤò¹µ½ü¤·¤¿¤â¤Î¡Ë ¤ÇȽÄꤹ¤ë¤³¤È¤ò´ðËܤȤ¹¤ë¡Ê ºî¶·¤Ë¤è¤ëÀ¸»º¥ª¡¼¥Ð¡¼¤¬È¯À¸¤·¤¿¾ì¹ç¤Ï¡¢½¸²Ù±ß³ê²½ÂкöÅù¤ÇÂбþ¡Ë¡£
¤¿¤À¤·¡¢Åö³ºÃÏ°èÁ´ÂΤȤ·¤Æ¤Î¼ç¿©ÍÑÈÎÇä¿ôÎÌ¡Ê Áí¼ý³ÏÎ̤«¤é¤¯¤ºÊÆ¡¦²Ã¹©ÍÑÊÆ¡¦¿·µ¬¼ûÍ×ÊÆ¡¦¶èʬ½Ð²ÙÊƤÎÈÎÇäͽÄê¿ôÎ̤ò¹µ½ü¤·¤¿¤â¤Î¡Ë ¤¬À¸»º¿ôÎÌÌÜɸ¤ÎÈÏ°ÏÆâ¤È¤Ê¤Ã¤Æ¤¤¤ë¾ì¹ç¤âãÀ®¤È¤¹¤ë¡£

¡Ê £² ¡Ë £² £° ǯ»º¤ÎÀ¸»ºÄ´À°¤¬ÌÜɸ̤ã¤È¤Ê¤Ã¤¿ÅÔÆ»Éܸ©¡¦ÃÏ°è¤Ë¤Ä¤¤¤Æ¤Ï¡¢
­¡ £² £° ǯ»º¤Î»ºÃϤŤ¯¤êÂкö¤¬¡¢Í½ÄêÄ̤ê¸òÉÕ¤µ¤ì¤Ê¤¤¤³¤È¤¬¤¢¤êÆÀ¤ë¡£
­¢ £² £± ǯ»º¤Î³Æ¼ïÊä½õ»ö¶È¡¦Í»»ñ¤Ë¤Ä¤¤¤Æ¡¢ÉÔÍø¤Ê¼è°·¤¤¤ò¼õ¤±¤ë¤³¤È¤¬¤¢¤êÆÀ¤ë¡£
­£ £² £± ǯ»º¤Î»ºÃϤŤ¯¤êÂкö¤Ë¤Ä¤¤¤Æ¡¢ÉÔÍø¤Ê¼è°·¤¤¤ò¼õ¤±¤ë¤³¤È¤¬¤¢¤êÆÀ¤ë¡£
¤Ê¤ª¡¢´Ø·¸¼Ô¤ÏÌÜɸ̤ãÀ®¤È¤Ê¤é¤Ê¤¤¤è¤¦Á´ÎϤò¤¢¤²¤ë¤³¤È¤È¤·¡¢Ì¤Ã£¤È¤Ê¤Ã¤¿ÅÔÆ»Éܸ©¡¦ÃÏ°è¤Î¶ñÂÎŪ¤Ê¼è°·¤¤¤Ë¤Ä¤¤¤Æ¤Ï¡¢£² £° ǯ»º¤ÎÀ¸»ºÄ´À°¤Î¥¹¥Æ¡¼¥¸¤´¤È¤Î¿ä¿Ê¾õ¶·¡¦Ã£À®¾õ¶·Åù¤ò¸«¤Ê¤¬¤é¡¢Å¬Àڤʥ¿¥¤¥ß¥ó¥°¤Ç·èÄꤹ¤ë¡£

¡Ê £³ ¡Ë ǧÄêÇÀ¶È¼Ô¤Ç¤¢¤ë¤³¤È¤¬Í×·ï¤È¤Ê¤Ã¤Æ¤¤¤ëÇÀÎÓµù¶È¶âÍ»¸ø¸Ë¤Î¥¹¡¼¥Ñ¡¼£Ì »ñ¶â¤Ë¤Ä¤¤¤Æ¤Ï¡¢º£¸å¡Ê Ê¿À®£± £¶ ǯ£¸ ·î¤Î¼ÚÍѾڽñÊѹ¹°Ê¹ß¤Î¼ÚÆþ¤ì¤ËŬÍÑ¡Ë¡¢À¸»ºÄ´À°Èó¼Â»Ü¤È¤Ê¤Ã¤¿¤³¤È¤òÍýͳ¤ËǧÄêÇÀ¶È¼Ô¤ÎǧÄ꤬¼è¤ê¾Ã¤µ¤ì¤¿¾ì¹ç¤Ë¤Ï¡¢·«¾å½þ´Ô¤òµá¤á¤ë¤È¤È¤â¤Ë¡¢ÇÀÎӿ建Ĺ´ü¶âÍ»¶¨²ñ¤«¤é¤ÎÍø»Ò½õÀ®¤ÎÁ¼ÃÖ¤òÄä»ß¤¹¤ë¡£
¥¹¡¼¥Ñ¡¼£Ì »ñ¶â°Ê³°¤ÎÀ¯ºöÍ»»ñ¡¢Í»»ñ»ÄÊä½õ¤ò¤Ï¤¸¤á¤È¤¹¤ë³Æ¼ïÀ¯ºö»Ù±çÁ¼Ã֤ˤĤ¤¤Æ¤Ï¡¢ºÒ³²»ñ¶â¤Ê¤É°ìÄê¤ÎʬÌî¤ò½ü¤­¡¢À¸»ºÄ´À°Èó¼Â»Ü¼Ô¤ò¤½¤ÎÂоݤȤ·¤Ê¤¤Êý¸þ¤Ç¸¡Æ¤¤¹¤ë¡£

»²¹Í¡¡»ä¤Î¥Ö¥í¥°µ­»ö¤Ë¤ª¤±¤ëÂç³ã¼ÌäÂêµ­»ö

¡Ö½©Åĸ©¤Î郎¥Ú¥Ê¥ë¥Æ¥£¤ò²Ê¤¹¤È¤¤¤Ã¤¿¤«¤Ë¤Ä¤¤¤Æ¤Ï¡¢·ë¶É¼¨¤»¤Ê¤«¤Ã¤¿¡¢º£Æü¤ÎÀÖ¾¾ÇÀÁêµ­¼Ô²ñ¸«¤Î¤ß¤Ã¤È¤â¤Ê¤µ¡×
¡ÖÀÖ¾¾ÇÀÁê¡Ö½©ÅĤò¸ÍÊ̽êÆÀÊä½þ¤«¤é³°¤¹¡×¥È¥ó¥Ç¥â´ª°ã¤¤È¯¸À¤Î¥½¡¼¥¹¤Ï?¡×
¡ÖÀÖ¾¾ÇÀÁ꤬Âç³ã¼¤Ë¼Õºá¤È¤¤¤¦¤¬¡¢¤ª¤«¤·¤¯¤Í?¡×

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

2009/11/25 Wednesday

Renho»á¤Î¥Þ¥ë¥·¥§¡¦¥¸¥ã¥Ý¥ó´ØÏ¢¤Ä¤Ö¤ä¤­

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 23:06:20

2009/11/25(Wed)
¡¡
°Ê²¼Renho»á¤Î¤Ä¤Ö¤ä¤­¤«¤é°úÍÑ

¡ÖºòÆü¡¢ÇÀ¿å¾Ê¤Î¥Þ¥ë¥·¥§¡¦¥¸¥ã¥Ý¥ó¤òôÅö¤¹¤ë¶ÉŤ«¤éºî¶ÈÃæ¤Ë°Õ¸«½ñ¤ò¤¤¤¿¤À¤­¤Þ¤·¤¿¡£Ãæ¿È¤Ï»ö¶È»Åʬ¤±¤Ë·¸¤Ã¤¿Ì±´Ö¤Î»Åʬ¤±¿Í¤¬¥¹¡¼¥Ñ¡¼¤Ë̳¤á¤Æ¤¤¤¿¤Î¤Ç¡¢»Åʬ¤±¤Ç¼è¤ê¾å¤²¤¿¥Þ¥ë¥·¥§¡¦¥¸¥ã¥Ý¥ó»ö¶È¤ËÍø³²´Ø·¸¤¬¤¢¤ë¤È¤¤¤¦»ØŦ¤Ç¤·¤¿¡£¤Ç¤â¡¢¤³¤ÎÊý¤Ï8ǯÁ°¤ËÂ࿦¤·¤Æ¤¤¤ë¡£
¤½¤Î¸å¡¢¤³¤ÎÊý¤Ï»ÔµÄ²ñµÄ°÷¡¢Éû»ÔŤò·Ð¸³¤µ¤ì¤Æ¤¤¤Þ¤¹¤¬¡¢¥Þ¥ë¥·¥§¡¦¥¸¥ã¥Ý¥ó»ö¶È¤ò»Åʬ¤±¤¹¤ëΩ¾ì¤Ë¤Ê¤¤¤È¤¤¤¦ÇÀ¿å¾Ê²ÝŤλØŦ¤Ï¤¢¤Æ¤Ï¤Þ¤é¤Ê¤¤¤Î¤Ç¤Ï¡¢¤È»×¤¦¡£»ö¶È¼«ÂΤ¬ÇѻߤÈȽÃǤµ¤ì¤¿¸å¡¢¤³¤ÎÊý¤Î¤³¤È¤ò¿ïʬĴ¤Ù¤¿¤è¤¦¤Ç¤¹¤¬¡¢¤½¤ÎÎϤò¿·¤¿¤Ê»ö¶È³«ÂóÄ´ºº¤Ë¸þ¤±¤Æ¤Û¤·¤¤¤È¤â»×¤¤¤Þ¤·¤¿¡£
¤¹¤ß¤Þ¤»¤ó¡£°Õ¸«¥Ú¡¼¥Ñ¡¼¤ò¤¤¤¿¤À¤¤¤¿¤Î¤ÏÇÀ¿å¾Ê¶ÉŤǤ¹¡£°ìÉô²ÝĹ¤È½ñ¤¤¤Á¤ã¤¤¤Þ¤·¤¿¡£»ÞÌîÅý³ç¤È¤âÏ䷹礤¡¢¤³¤Î¥Ú¡¼¥Ñ¡¼¤ÏÊóÆ»¿Ø¤Ë¸ø³«¤·¤Þ¤¹¡£¡×
http://twitter.com/renho_sha¡¡¤è¤ê
°Ê¾å°úÍѽª¤ï¤ê

¥Þ¥ë¥·¥§¡¦¥¸¥ã¥Ý¥ó¤Î»ö¶È»Åʬ¤±·ë²Ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤Î¥µ¥¤¥È¤´»²¾È

¤Þ¤¢¡¢¤Ä¤Ö¤ä¤­¤Ç¤Ï¤¢¤Ã¤Æ¤â¡¢»Åʬ¤±¿Í¤Ç¤¢¤ëRenho»á¤´¼«¿È¤¬¡¢¡¢ÇÀÎӿ建¾Ê¤¬Áä¶Ì¤Ë¤¢¤²¤¿»Åʬ¤±¿Í¤Î¸Çͭ̾»ì¤òÆÃÄê¤Ç¤­¤ë¤è¤¦¤Ê¤Ä¤Ö¤ä¤­¤ò¤·¤Æ¤·¤Þ¤¦¤³¤È¤Ï¡¢¤½¤Î¤³¤È¼«ÂΡ¢»Åʬ¤±¿Í¼º³Ê¤È¤â¤ª¤â¤ï¤ì¡¢¤¤¤«¤¬¤Ê¤â¤Î¤«¤È¤Ï¡¢»×¤¤¤Þ¤¹¤¬¤Í¡£
(¤â¤Ã¤È¤â¡¢¡Ö¤Ê¤ê¤¹¤Þ¤·¡×¤Ã¤Æ¤Î¤¬Twitter¤Ë¤¤¤ë¤è¤¦¤Ç¤¹¤Î¤Ç¡¢¤Û¤ó¤â¤Î¤Î¤Ä¤Ö¤ä¤­¤«¤É¤¦¤«¤Ï¡¢¤ï¤«¤ê¤Þ¤»¤ó¤¬¡£)

¤È¤¤¤¦¤³¤È¤Ç¡¢Renho»á¤Î¤Ä¤Ö¤ä¤­¤Ç¡¢·ë²Ì¡¢ÆÃÄꤵ¤ì¤¿ÏÃÂê¤Î»Åʬ¤±¿Í¤Ç¤¢¤ë»³Æâ·É¤µ¤ó¤Î²áµî¤Î·ÐÎò¤ò¤Ê¤é¤Ù¤Æ¤ß¤ë¤È

1947ǯÀ¸¤Þ¤ì¡£¹âÅç¹âÅù³Ø¹»¤ò·Ð¤Æ¡¢1970ǯ¡¢Áá°ðÅÄÂç³ØÂ裱À¯¼£·ÐºÑ³ØÉô·ÐºÑ³Ø²Ê´¶È¡£1974ǯ¡¢¥¤¥º¥ß¥ä³ô¼°²ñ¼ÒÆþ¼Ò¡Ê°áÎÁÈÎÇä¡¢¹­¹ðÀëÅÁôÅö¤ò·Ð¤ÆŹÊÞ³«È¯¤Ë½¾»ö¡Ë¡£2001ǯ10·î¡Á2004ǯ12·î¡¢º£ÄÅÄ®µÄ²ñµÄ°÷¡£2005ǯ2·î¡Á2005ǯ5·î¡¢¹âÅç»ÔµÄ²ñµÄ°÷¡£2005ǯ5·î¤è¤ê¹âÅç»ÔÉû»ÔĹ

¤È¤¤¤¦¤³¤È¤Ç¡¢¤Þ¤¢¡¢ÇÀÎӿ建¾Ê¤¬¤½¤ó¤Ê¤Ëµ¤¤Ë¤¹¤ë¸ºß¤Ç¤Ï¤Ê¤µ¤½¤¦¤Ç¤¹¤Í¡£

¤³¤Î¤Ê¤«¤Î¥¤¥º¥ß¥ä¤Ç²¿¤ò¤ä¤Ã¤Æ¤¤¤¿¤«¤È¤¤¤¦¤³¤È¤Ê¤ó¤Ç¤·¤ç¤¦¤¬¡£(¡Ö¤Þ¤ë¤È¤¯»Ô¾ì¡×¤Ê¤ó¤Æ¤Î¤òÌäÂê¤Ë¤·¤Æ¤¤¤ë¤ó¤Ç¤·¤ç¤¦¤«¤Í¡£)

°Ê²¼¤Ï¹½ÁÛÆüËܤÎÂè129²óJ.I.¥Õ¥©¡¼¥é¥à¡¡2008.04.23
ÃÏÊýµÄ²ñ¤ÏɬÍפ«¡¡¤Ç¤Î»³Æâ·É¤µ¤ó¤Îȯ¸ÀÌÏÍÍ

¤Á¤Ê¤ß¤Ë¡¢»Åʬ¤±¿Í¤ÎÃæ¤Ë¤Ï¡¢»³Æâ·ÉÁ°Éû»ÔĹ¤È¥Ú¥¢¤À¤Ã¤¿¡¢³¤Åì±ÑÏÂÁ°»ÔŤâ¤Ï¤¤¤Ã¤Æ¤¤¤ë¤È¤¤¤¦¤³¤È¤Ç¡¢·ë¹½¡¢¤³¤Î»Åʬ¤±¿Í¤Î¿ÍÁª¤Ã¤Æ¡¢¹½ÁÛÆüËܲÃÆ£»á¤Î¸Ä¿ÍŪ¤Ê¤Ò¤­¤Ç¤ä¤Ã¤Æ¤¤¤ë¤è¤¦¤Ê¡¢¤Á¤È¡¢¤¤¤¤²Ã¸º¤Ê´¶¤¸¤Ï¼õ¤±¤Þ¤¹¤Í¡£

º£²ó¤Î»Åʬ¤±¿Í¤Î¿ÍÁª¤â¡¢¹½ÁÛÆüËܤβáµî¤ÎJ.I.¥Õ¥©¡¼¥é¥à½ÐÀʼԤ«¤éÁª¤ó¤À¤è¤¦¤Ê´¶¤¸¤â¸«¼õ¤±¤é¤ì¤Þ¤¹¤Í¡£

¤Þ¤¢¡¢¤³¤ì¤Þ¤Ç¡¢²È·×Êí¤·¤«¸«¤¿¤³¤È¤¬¤Ê¤¤¤Ò¤È¤¬¡¢Âç´ë¶È¤Îºâ̳½ôɽʬÀϤ·¤Æ¤¤¤ë¤Ã¤Æ´¶¤¸¤Ç¤·¤ç¤¦¤«¡£

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 09:52:08

¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø

¤³¤Î¾ðÊó¤Ï11·î25Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ­¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ­»ö¤Ç¤Ï¡¢²¼µ­¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ­»ö½ç¤Ç¤¹¡£

D225GÊÑ°ÛH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¥ï¥¯¥Á¥óÉÔÁ´¤¢¤ê¤ÈWHO³Îǧ (11·î28Æü»þÅÀ)
³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊÑ°Û¤¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ(11·î22Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ(11·î19Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ (11·î9Æü»þÅÀ)

£²£°£°£¹Ç¯£±£±·î£²£µÆü
¡¡
¥¦¥¯¥é¥¤¥Ê¤ä¥Î¥ë¥¦¥§¥¤¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎÊѰۤˤĤ¤¤Æ¤Ï¡¢Á°¤Î»ä¤Î¥Ö¥í¥°µ­»ö
¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´¡×
¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ¡×
¡Ö³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊÑ°Û¤¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ¡×
¤Ê¤É¤Ç¾Ò²ð¤·¤¿¡£

¤³¤³¤Ë¤­¤Æ¡¢¹á¹Á¤Ç¤â¡¢¥Î¥ë¥¦¥§¥¤¤ÈƱ¤¸ÊÑ°Û¤ò»ý¤Ä¥¦¥¤¥ë¥¹¤¬³Îǧ¤µ¤ì¤¿¤È¤¤¤¦¡£

¤³¤³¤Ç¡¢¤Á¤ç¤Ã¤È¡¢À°Íý¤ò¤·¤Æ¤ª¤³¤¦¡£

ÊѰۤϡ¢£²£²£µ¥Ý¥¸¥·¥ç¥ó¤Ë¤ª¤±¤ëÊѰۤǤ¢¤ë¡£

¥¦¥¯¥é¥¤¥Ê¤Î¾ì¹ç

10¸¡ÂΤΤ¦¤Á¡¢4¸¡ÂΤˡ¢HA¤Ë¤ª¤¤¤Æ¡¢D225GÊÑ°Û¤ò¼¨¤·¤Æ¤¤¤¿¤È¤¤¤¦¡£

D225GÊÑ°Û¤òµ¯¤³¤·¤Æ¤¤¤ë¥¦¥¤¥ë¥¹Ì¾¤Ï²¼µ­¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£

A/Lviv/N6/2009
A/Ternopil/N11/2009
A/Ternopil/N10/2009
A/Lviv/N2/2009

¤³¤Î¤¦¤Á¡¢1¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢¹¢¤«¤é¤Î¤â¤Î¤Ç¤¢¤ê¡¢3¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢ÇÙÁÈ¿¥¤«¤é¤Î¤â¤Î¤Ç¤¢¤Ã¤¿¡£

¥Î¥ë¥¦¥§¥¤¤Î¾ì¹ç

£µ·î¤«¤é£±£°·î¤Ë¤«¤±¤ÆºÎ¼è¤·¤¿¸¡ÂΤΤ¦¤Á¡¢¤¹¤Ù¤Æ¤¬£²£²£µ¥Ý¥¸¥·¥ç¥ó¤Ë¤ª¤±¤ëÊÑ°Û¤¬¸«¤é¤ì¤¿¡£

¤½¤Î¤¦¤Á¡¢£µ¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢D225EÊѰۤǤ¢¤Ã¤¿¡£

¥¦¥¤¥ë¥¹Ì¾¤Ï¡¢²¼µ­¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£

A/Norway/4023/2009
A/Norway/3478/2009
A/Norway/3059/2009
A/Norway/2690/2009
A/Norway/2674/2009

£±¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢¥ï¥¤¥ë¥É¡¦¥¿¥¤¥×¤È¤Îº®¹çʪ¤È¤ß¤é¤ì¤ëD225¤Ç¤¢¤ê¡¢D225GÊѰۤǤ¢¤Ã¤¿¡£

¥¦¥¤¥ë¥¹Ì¾¤Ï¡¢²¼µ­¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£

A/Norway/2924/2009

¹á¹Á¤Î¾ì¹ç

¥Î¥ë¥¦¥§¥¤¤ÈƱÍͤÎÊÑ°Û¤¬¸«¤é¤ì¤¿¤È¤ÎÊóÆ»¤À¤¬¡¢¶ñÂÎŪ¤Ê¥¦¥¤¥ë¥¹Ì¾¤Ï¡¢È¯É½¤µ¤ì¤Æ¤¤¤Ê¤¤¡£

¤³¤Î¥µ¥¤¥È¡ØÕó²È¡§¹Ã·¿H1N1ή´¶ÚμïÉÂÆÇ ÃæÔ¢6·î½¢Öá⤸½¡Ù¤Ë¤è¤ë¤È¡¢ÊѰۤϡ¢D225GÊÑ°Û¤ÈD225EÊÑ°Û(H3¥Ù¡¼¥¹¤Ç225¤Ç¤¢¤ê¡¢H1¥Ù¡¼¥¹¤Ç222¤Ç¤¢¤ë¡£HA´ð°ø222°Ì氨´ð»À°ÌóÚÚΰÛ)¤Ç¤¢¤ê¡¢¤½¤Î°ìÎã¤Ï¡¢º£Ç¯6·î¤Ë¥¤¥®¥ê¥¹¤«¤é¤Îµ¢¹ñ¼Ô¤«¤é¸«¤Ä¤«¤Ã¤¿¤â¤Î¤Ç¡¢¤â¤¦°ìÎã¤Ï¡¢9·î¤ËÞ¶¹¾¾ÊÞ¶¹¾îвÊÂçÕܤÇȯ¸«¤µ¤ì¤¿¤â¤Î¤Ç¤¢¤ë¤È¤Î¤³¤È¤Ç¤¢¤ë¡£

¤Þ¤¿¡¢¤³¤Î¥µ¥¤¥È¤Ë¤è¤ì¤Ð¡¢¸½ºß¡¢Ãæ¹ñ¤Ç¤Ï¡¢8Îã¤Î225Úΰۤ¬¤¢¤ë¤È¤¤¤¦¡£

»²¹Í
¡ÖMutation detected in Hong Kong toddler ¡×
¹á¹Á¤Î¿·¤·¤¤H1N1ÊѼï¾ðÊó¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤Î¥µ¥¤¥È¤´»²¾È

¡Ö¹á¹Á±ÒÀ¸½ðº¬Ú¡挪°Ò¸øÉÛŪÚμïÉÂÆÇ»ñÎÁ¡¤Üý查³º½ð´Æ¬·ÏÅýÁ½¿Ê¹ÔŪ¹Ã·¿Î®´¶ÉÂÆÇÜëËÜŪ´ð°ø½øÎ󡤷ë²Ì⤸½ºß³º½ð¿Ê¹ÔŪ123¸Ä´ð°ø½øÎ󸦵桤¶ÃæÍ­°ì¸ÄÉÂÆÇÜëËÜÁ½½Ð¸½ÚμÉÂÆÇŪ´ð°ø½øÎóËòçÐ挪°Ò½Ð¸½ÅªÃ×Ì¿ÚμïÉÂÆÇÁêƱ¡£ ¡×
(¹á¹Á±ÒÀ¸½ð´ÆÆÄ·ÏÅý¤Ï123¸Ä¤ÎH1N1·¿¥¤¥ó¥Õ¥ë¤ÎDNAÇÛÎó¤ËÂФ¹¤ë¸¦µæ¤ò¹Ô¤¤¡¢ÃË»ù¤Î¥µ¥ó¥×¥ë¤¬¥Î¥ë¥¦¥§¡¼¤Çή¹Ô¤·¤Æ¤¤¤ëÊÑ°Û¥¦¥¤¥ë¥¹¤ÈƱ¤¸¤Ç¤¢¤ë¤³¤È¤òȯ¸«¤·¤¿¡£Æ±¥¦¥¤¥ë¥¹¤Ï¡¢¥¿¥ß¥Õ¥ë¤ä¥ì¥ì¥ó¥¶¤ËÂФ·¡¢¹³ÌôÀ­¤Ï¸½¤ì¤Æ¤¤¤Ê¤¤¤È¤¤¤¦¡£)
¡ÖËܹÁ1歲ÃËƸÈïñä½Ð´¶À÷Úμï¹ÃήÉÂÆÇ(çÐ挪°ÒÉÂÆÇÁêƱ)¡¤Á½ºß7·îÄìÆþ½»º»ÅÄ°Ò¼¤»Ûîб¡¡£»ñÎÁÔ¦ÊÒ¡×

¼õÍÆÂÎÊѰۤˤĤ¤¤Æ

¥Ñ¥¿¡¼¥óǧ¼±¼õÍÆÂÎÅÁã¤ò¾ã³²¤¹¤ëÊÑ°Û¤¬¤¢¤Ã¤¿¤«¤É¤¦¤«¤¬¡¢ºÇÂç¤Î¥Ý¥¤¥ó¥È¤Î¤è¤¦¤Ç¤¢¤ë¡£

¤¹¤Ê¤ï¤Á¡¢¤³¤Î¤³¤È¤Ï¡¢¤Ê¤¼¡¢¥¦¥¯¥é¥¤¥Ê¤Ç¡¢¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ç»àË´¤·¤¿´µ¼Ô¤ÎÇÙÁÈ¿¥¤ËÊÑ°Û¤¬¸«¤é¤ì¤¿¤Î¤«¡¢¤È¤¤¤¦¤³¤È¤Ë´Ø·¸¤·¤Æ¤¯¤ë¡£

¤¹¤Ù¤Î¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ºÙ˦¤Ë¼è¤êÉÕ¤¯¤¿¤á¤Ë¡¢¥·¥¢¥ë»À¤òɬÍפȤ¹¤ë¡£

¥·¥¢¥ë»À¤Ë¤Ï¡¢¤¤¤í¤¤¤í¤Ê²½³ØŪ¤Ë¤³¤È¤Ê¤ë¼ïÎब¤¢¤ê¡¢¤½¤ì¤Ë¤è¤Ã¤Æ¡¢¥¦¥¤¥ë¥¹¤È¤Î¿ÆÏÂÀ­¤¬¤³¤È¤Ê¤ë¡£

Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¥·¥¢¥ë»À¤¬¥¬¥é¥¯¥È¡¼¥¹¤Ë¦Á 2,3 ·ë¹ç¤·¤¿¤â¤Î¡ÊSA¦Á2,3Gal¡Ë¤òǧ¼±¤·¡¢

¥Ò¥È¡¦¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¼ç¤È¤·¤Æ¥·¥¢¥ë»À¤¬¥¬¥é¥¯¥È¡¼¥¹¤Ë¦Á2,6·ë¹ç¤·¤¿¤â¤Î (SA¦Á2,6Gal )¤òǧ¼±¤¹¤ë¡£

¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤È¡¢¥Ò¥È¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤È¤Ç¤Ï°Û¤Ê¤ê¡¢

¥Ò¥È¡¦¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤Î¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢¡¢¥Ò¥È¤Î¾åÉôµ¤Æ»¤ÎÉ¡Ç´Ëì¡¢ÉûÉ¡¹Ð¡¢°öƬ¡¢µ¤´É¡¤µ¤´É»Ù¤Î¾åÈéºÙ˦¤Ë¤·¤«¤Ê¤¤¤¬¡¢

Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤Î¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢¥Ò¥È¤Î¸ÆµÛ´ï¤Î¿¼Éô¡Ê¸ÆµÛºÙµ¤´É»Ù¤ÈÇÙ˦ºÙ˦¤Î°ìÉô¤Ç¤¢¤ê¡¢¸ÆµÛºÙµ¤´É»Ù¤È˦¤ÈII·¿ÇÙ˦¾åÈéºÙ˦¤È¤Î´Ö¤Î·ë¹çÉô¤Ç¤¢¤ëÈóÀþÌÓµ¤Æ»ºÙ˦-nonciliated bronchiolar cells-¤Ë¤¢¤ë¡£¡Ë¤Ë¡¢Â¿¤¯Â¸ºß¤¹¤ë¡£

¥¦¥¤¥ë¥¹¤Î¡Ö¼õÍÆÂηë¹ç¥É¥á¥¤¥ó¡×(receptor-binding domain )(RBD)¤Ç¤ÎÊÑ°Û¤¬¡¢¥Ø¥Þ¥°¥ë¥Á¥Ë¥ó¤ò¥Ò¥È¼õÍÆÂΤ˷ë¹ç¤·°×¤¯¤·¡¢¿Í¤Ø¤Î´¶À÷¤ÎÍưפµ¤ò·èÄê¤Å¤±¤Æ¤¤¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£

¤³¤Îreceptor-binding site(RBD)¤Ï¡¢£È£Á¤Ë¤è¤Ã¤Æamino acids position ¤Î²¿ÈÖÌܤ˰ÌÃÖ¤¹¤ë¤«¤¬°Û¤Ê¤Ã¤Æ¤¤¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£

¤³¤³¤Ç¡¢¥Ñ¥¿¡¼¥óǧ¼±¼õÍÆÂÎÅÁã¤ò¾ã³²¤¹¤ëÊÑ°Û¤¬¤¢¤ì¤Ð¡¢ÇÙÁÈ¿¥¤Ë¤ª¤±¤ë¥ì¥»¥×¥¿¡¼¤¬¡¢¥Ò¥È¡¦¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤òǧ¼±¡ÊSA¦Á2,3Gal¡Ë¤¹¤ë¤³¤È¤â¤¢¤ê¤¦¤ë¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£

¤Ä¤Þ¤ê¡¢¥Ò¥È¤«¤éʬΥ¤µ¤ì¤¿H1N1¥¦¥¤¥ë¥¹¤¬¡¢¥Ò¥È¤ª¤è¤ÓÄ»¤ÎξÊý¤Î¼õÍÆÂΤ˷ë¹ç¤Ç¤­¤ëÂÎÀ©¤¬¡¢ÊѰۤˤè¤Ã¤Æ¡¢À°¤¦¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£

¤¢¤ë¤¤¤Ï¡¢Ç§¼±¤ÎÂоݤ¬¡¢Ä»¤ÎSA¦Á2,3Gal¤È¥Ò¥È¤ÎSA¦Á2,6Gal¤È¤Îº®¹çʪ¤Ç¤¢¤Ã¤¿¾ì¹ç¤â¡¢ÇÙÁÈ¿¥¤Ç¡¢SA¦Á2,3Gal°Ê³°¤Îº®¹çʪ¤òǧ¼±¤¹¤ë¤³¤È¤â¤¢¤ê¤¦¤ë¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£

¥¦¥¤¥ë¥¹¤Ë¹¥¤Þ¤ì¤ë¥·¥¢¥ë»À¤ò¥³¥ó¥È¥í¡¼¥ë¤¹¤ë¤Î¤Ï¡¢¥Ý¥¸¥·¥ç¥ó190¤È¥Ý¥¸¥·¥ç¥ó225¤Ç¤ÎÊѰۤǤ¢¤ë¤È¤¤¤ï¤ì¤ë¡£

¤½¤³¤Ç¡¢D225GÊÑ°Û¤Þ¤¿¤ÏD225EÊÑ°Û¤¬¡¢¼õÍÆÂÎÊѰۤˤª¤¤¤Æ¡¢Ä»¤ÎSA¦Á2,3Gal¤È¥Ò¥È¤ÎSA¦Á2,6Gal¤È¤Î¤É¤Á¤é¤Îǧ¼±¤Ë±Æ¶Á¤òµÚ¤Ü¤¹¤«¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¤Î¤À¤¬¡£

D225GÊѰۤϡ¢Ä»¤ÎSA¦Á2,3Gal¤È¥Ò¥È¤ÎSA¦Á2,6Gal¤È¤ò¤È¤â¤Ë¥¿¡¼¥²¥Ã¥È¤Ë¤·¤¦¤ë¡¢¤È¤µ¤ì¤ë¡£

¤³¤ì¤é¤Ë¤Ä¤¤¤Æ¤Ï¡¢»ä¤Î°ÊÁ°¤Î¥Ö¥í¥°µ­»ö
¡Ö¿Í´Ö¤Î¾åµ¤Æ»¤¬¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¤Î¾ì½ê¡×¤È¤¤¤¦Àµ·î°ÊÍèÏÃÂê¤ÎÏÀʸ¡×
¡ÖH5N1¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤Î¥Ò¥È·¿¼õÍÆÂΤؤηë¹ç¤ò²Äǽ¤Ë¤¹¤ë¥Ø¥Þ¥°¥ë¥Á¥Ë¥ó¤ÎÊÑ°Û¡×
¡ÖHaemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors¡×
¤Ê¤É¤â¤´»²¾È

¤Ê¤¼¡¢D225GÊÑ°Û¤¬ÇÙ¤òľ·â¤¹¤ë¤Î¤«?

¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤¬Ç§¼±¤¹¤ëSA¦Á2,3Gal¼õÍÆÂΤ¬II·¿ÇÙ˦¾åÈéºÙ˦( Type II Alveolar Epithelial Cells )¤Î¾å¤Ë¤¢¤ë¤¿¤á¤È¤¤¤ï¤ì¤Æ¤¤¤ë¡£

¤³¤ÎII·¿ÇÙ˦¾åÈéºÙ˦¤Ï¡¢¥µ¥¤¥È¥«¥¤¥ó¤Îȯ¸½¤ò´Þ¤àÌȱÖËɸæ¤È¤È¤â¤Ë¡¢ÇÙ¤ÎɽÌÌÄ¥ÎϤòÄ´À°¤¹¤ëÌò³ä¤òô¤Ã¤Æ¤¤¤ë¡£

D225GÊѰۤˤè¤Ã¤Æ¡¢H1N1¥Ò¥È¡¦¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤¬¡¢ËÜÍè¤Ï¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤¬Ç§¼±¤¹¤ëSA¦Á2,3Gal¼õÍÆÂΤòǧ¼±¤·¤Æ¤·¤Þ¤¦¤³¤È¤Ë¤è¤Ã¤Æ¡¢II·¿ÇÙ˦¾åÈéºÙ˦¤Ë¤È¤ê¤Ä¤­¡¢¥µ¥¤¥È¥«¥¤¥ó¤Îȯ¸½¤òÂ¥¤¹¡¢¤È¤¤¤¦¤³¤È¤Î¤è¤¦¤À¡£

¤·¤«¤·¡¢°ìÊý¡¢°Ê²¼¤Î¤è¤¦¤ÊÀâ¤â¤¢¤ë¤è¤¦¤À¡£

¤¹¤Ê¤ï¤Á¡¢D225GÊѰۤϡ¢´¶À÷¤òÁ˳²¤¹¤ëÊѰۤǤ⤢¤ë¤Î¤Ç¡¢Áý¿£¤Ï¤È¤Þ¤é¤Ê¤¤¤¬¡¢´¶À÷¤Ï°ìÄê¤Î²Õ½ê¤Ç¤È¤É¤Þ¤ë¤È¤¤¤¦¤³¤È¤Ç¡¢¥¦¥¯¥é¥¤¥Ê¤Ê¤É¤Ç¡¢ÇÙÁÈ¿¥¤Ê¤É°ìÄê¤ÎÉôʬ¤Î¤ß¤¬¥¦¥¤¥ë¥¹¤Ë¤ª¤«¤µ¤ì¤Æ¤¤¤ë¤Î¤Ç¤Ï¤Ê¤¤¤Î¤«¡¢¤È¤¤¤¦¸«Êý¤À¡£
¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ÖThe D225G change in 2009 H1N1 influenza virus is not a concern¡×¤ò¤´»²¾È

»²¹Í¡Ö1918 RBD D225G in Lung Cases in the United States¡×
¡ÖCytokine Regulation in Type II Alveolar Epithelial Cells as the Mechanism for Interstitial Pneumonia by Gefitinib¡×

¥¹¥Ú¥¤¥óÉ÷¼Ù¤ÈD225GÊѰۤȤδط¸

¾åµ­¤ÎD225GÊÑ°Û¤Þ¤¿¤ÏD225EÊѰۤϡ¢£±£¹£±£¸Ç¯¤È£±£¹£±£¹Ç¯¤Î¥¹¥Ú¥¤¥óÉ÷¼Ù¤Ë¤ª¤¤¤Æ¤â¡¢¸«¤é¤ì¤¿ÊѰۤǤ¢¤ë¡£

¤½¤Î¥¦¥¤¥ë¥¹Ì¾¤Ï¡¢¼¡¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£

A/New York/1/1918
A/London/1/1919

ÊÑ°Û¥¦¥¤¥ë¥¹¤Ç¤Ê¤¤A/South Carolina/1/18 ¤Ï¡¢alpha(2,3)(Ä»¥¦¥¤¥ë¥¹Ç§¼±)¤ò¹¥¤ß¡¢A/New York/1/1918 ¤Ï¡¢alpha(2,3)(Ä»¥¦¥¤¥ë¥¹Ç§¼±) ¤È¡¡alpha(2,6)(¥Ò¥È¡¦¥¦¥¤¥ë¥¹Ç§¼±)¡¡¤È¤ÎξÊý¤ò¹¥¤ó¤À¡£

A/South Carolina/1/18 ¤Ï¡¢¥Ý¥¸¥·¥ç¥ó225¤Ë¤ª¤¤¤Æ¡¢ÊÑ°Û¤·¤Æ¤ª¤é¤ºD¤Ç¤¢¤Ã¤¿¡£

A/New York/1/1918 ¤Ï¡¢¥Ý¥¸¥·¥ç¥ó225¤Ë¤ª¤¤¤Æ¡¢ÊÑ°Û¤·¤Æ¤ª¤ê¡¢G¤Ç¤¢¤Ã¤¿¡£

A/New York/1/1918 ¤Ï¡¢¥Ý¥¸¥·¥ç¥ó190¤Ë¤ª¤¤¤Æ¡¢D¤«¤éE¤Ë¡¢D190EÊÑ°Û¤·¤Æ¤¤¤¿¡£

¤³¤ÎD190EÊѰۤϡ¢alpha(2,3)(Ä»¥¦¥¤¥ë¥¹Ç§¼±)¤È¤Î¥Ð¥¤¥ó¥É¤ò¹¥¤à¡£

¤³¤ÎD190EÊÑ°Û¤ÈD225GÊѰۤȤ¬¡¢Æ±»þ¤Ëµ¯¤³¤ë¤È¡¢¤½¤Î¥¦¥¤¥ë¥¹¤Î¦Á(2,6)¤Ø¤Î¼è¤êÉÕ¤­(¥Ð¥¤¥ó¥Ç¥£¥ó¥°)¤Ï¡¢Ãø¤·¤¯¼å¤Þ¤ë¤È¤¤¤¦¡£

1918¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤òÍѤ¤¤Æ¤Î¡¢SC18¤È¸Æ¤Ð¤ì¤ë¡¢1918Âçή¹Ô¤Î¸¶°ø¥¦¥¤¥ë¥¹¤È¡¢SC18¤È¤Ï1¤Ä¤À¤±¥¢¥ß¥Î»À¤¬°Û¤Ê¤ëNY18¤È¡¢2¸Ä¤Î¥¢¥ß¥Î»À¤¬°ã¤¦AV18¤È¸Æ¤Ð¤ì¤ë¥¦¥¤¥ë¥¹¤È¤òÈæ³Ó¤·¤¿·ë²Ì¡¢¤³¤Î¤¦¤ÁAV18¤È¸Æ¤Ð¤ì¤ë¥¦¥¤¥ë¥¹¤Ï¡¢D190EÊÑ°Û¤ÈD225GÊѰۤȤòƱ»þ¤Ëµ¯¤³¤·¤Æ¤ª¤ê¡¢¤³¤ÎAV18¥¦¥¤¥ë¥¹¤Ï¡¢¦Á(2,6)¤Ø¤Î¼è¤êÉÕ¤­(¥Ð¥¤¥ó¥Ç¥£¥ó¥°)¤¬¤Þ¤Ã¤¿¤¯¤Ê¤«¤Ã¤¿¤È¤¤¤¦¡£
»²¹Í¡ÖMIT explains spread of 1918 flu pandemic¡×

CDC¤ÎNancy J. Cox »á¤ò¤Ï¤¸¤á¤È¤¹¤ë59¿Í¤«¤é¤Ê¤ë¸¦µæ¥Á¡¼¥à¤ÎH1N1 ¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤Î°äÅÁ»ÒʬÀϤˤè¤ì¤Ð¡¢8¤Ä¤Î¥»¥°¥á¥ó¥È¤Î¤¦¤Á¡¢¥Ø¥Þ¥°¥ë¥Á¥Ë¥ó(H)¤ò´Þ¤à3¤Ä¤Î°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ï¡¢1918ǯ¤Î¥¹¥Ú¥¤¥óÉ÷¼Ù¤ÎH1N1¤ËͳÍ褹¤ë¤â¤Î¤Ç¤¢¤ê¡¢¤½¤Î¸å¡¢¤º¤Ã¤ÈÆڤ˸ºß¤·¤Æ¤¤¤¿¤â¤Î¤Ç¤¢¤ë¤¬¡¢¤½¤Î´Ö¤Ë¤ª¤¤¤Æ¤â¡¢ÊѰۤϤ·¤Æ¤¤¤Ê¤«¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£

°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ç¤Ï¡¢¥Ý¥ê¥á¥é¡¼¥¼B(PB)°äÅÁ»Ò¤Ï¥Ò¥ÈͳÍ衢¾¤ÎÆó¤Ä¤ÏĻͳÍè¤Ç¤¢¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£

¤Þ¤¿¡¢1918ǯ¤ÎH1N1¤ÈH5N1¤È¤Ï¡¢ÆÇÀ­¤¬¤¢¤ë¤³¤È¤ò¼¨¤¹°äÅÁ»Ò¥»¥°¥á¥ó¥È¤ò¡¢Æ±¤¸NS1¥»¥°¥á¥ó¥È¤Ë¤ª¤¤¤ÆÍ­¤·¤Æ¤¤¤ë¤¬¡¢º£²ó¤Î¿·H1N1¤Ï¡¢¤½¤¦¤Ç¤Ï¤Ê¤¤¤È¤¤¤¦¡£

´¶À÷À­¤ò¼¨¤¹°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ë¤ª¤¤¤Æ¤â¡¢º£²ó¤Î¿·H1N1¤Ï¡¢1918ǯ¤ÎH1N1¤Ë¤¢¤Ã¤¿¤â¤Î¤ò¼º¤Ã¤Æ¤¤¤ë¤È¤¤¤¦¡£

»²¹Í1.
¤³¤ì¤Þ¤ÇD225GÊÑ°Û¤ò¤ß¤»¤¿¥¦¥¤¥ë¥¹Ì¾°ìÍ÷
(¥¦¥¯¥é¥¤¥Ê¤È¥Î¥ë¥¦¥§¥¤¤Îʬ¤ò½ü¤¯)

01¡¡A/******/index/2009/02/01 (A/swine-flu/index/2009-02-01(H1N1))
02¡¡A/Hiroshima/201/2009/06/17
03¡¡A/Georgia/01/2009/04/27
04¡¡A/Zhejiang-Yiwu/11/2009/09/06
05¡¡A/Zhejiang/DTID-ZJU03/2009/09/07
06¡¡A/Zhejiang/DTID-ZJU02/2009/09/07
07¡¡A/Sao Paulo/53206/2009/07/19
08¡¡A/Sao Paulo/53225/2009/08/01
09¡¡A/New York/04/2009/04/
10¡¡A/Catalonia/NS1706/2009/07/29
11¡¡A/Mexico/InDRE4114/2009//
12¡¡A/Texas/11/2009/04/23
13¡¡A/Texas/05/2009/04/15
14¡¡A/Mexico/3955/2009/04/02
15¡¡A/Cancun-NY/Index/2009/04/15

»²¹Í2.
¤³¤ì¤Þ¤ÇD225EÊÑ°Û¤ò¤ß¤»¤¿¥¦¥¤¥ë¥¹Ì¾°ìÍ÷

¡ÖRhiza Labs FluTracker Forum¡×¤«¤é

A/Norway/4023/2009(H1N1)¡¡¡¡¡¡
A/Norway/3478/2009(H1N1)
A/Norway/3059/2009(H1N1)
A/Norway/2690/2009(H1N1)
A/Norway/2674/2009(H1N1)
(A/Catalonia/S1761/2009(H1N1)
A/Catalonia/S1758/2009(H1N1)
A/Catalonia/S1748/2009(H1N1)
A/Catalonia/S1698/2009(H1N1).
A/Catalonia/S1674/2009(H1N1)
A/Catalonia/S1672/2009(H1N1)
A/Serbia/3547/2009(H1N1)
A/Catalonia/S1641/2009(H1N1)
A/Catalonia/S1637/2009(H1N1)
A/Catalonia/S1632/2009(H1N1)
A/Catalonia/S1606/2009(H1N1)
A/Catalonia/S1605/2009(H1N1)
A/Catalonia/S1604/2009(H1N1)
A/Nagasaki/HA-44/2009(H1N1)
A/Catalonia/S1592/2009(H1N1)
A/Catalonia/S1587/2009(H1N1)
A/Catalonia/S1545/2009(H1N1)
A/Catalonia/S1479/2009(H1N1)
A/Catalonia/S1478/2009(H1N1)
A/Catalonia/S1436/2009(H1N1)
A/Catalonia/S1379/2009(H1N1)
A/Catalonia/S1369/2009(H1N1)
A/Catalonia/S1350/2009(H1N1)
A/Catalonia/S1333/2009(H1N1)
A/Catalonia/S1331/2009(H1N1)
A/Catalonia/S1304/2009(H1N1)
A/Catalonia/S1300/2009(H1N1)
A/Catalonia/S1286/2009(H1N1)
A/Catalonia/S1273/2009(H1N1)
A/Catalonia/S1272/2009(H1N1)
A/Catalonia/S1269/2009(H1N1)
A/Catalonia/S1265/2009(H1N1)
A/Catalonia/S1260/2009(H1N1)
A/Catalonia/S1254/2009(H1N1)
A/Catalonia/S1249/2009(H1N1)
A/Catalonia/S1248/2009(H1N1)
A/Catalonia/S1237/2009(H1N1)
A/Catalonia/S1236/2009(H1N1)
A/Catalonia/S1227/2009(H1N1)
A/Catalonia/S1222/2009(H1N1)
A/Catalonia/S1215/2009(H1N1)
A/Catalonia/S1209/2009(H1N1)
A/Catalonia/S1205/2009(H1N1)
A/Catalonia/S1199/2009(H1N1)
A/Catalonia/S1187/2009(H1N1
A/Catalonia/S1183/2009(H1N1)
A/Catalonia/S1182/2009(H1N1)
A/Catalonia/S1165/2009(H1N1)
A/Catalonia/S1161/2009(H1N1)
A/Catalonia/S1120/2009(H1N1)
A/Almati/01/2009(H1N1)
A/Changsha/78/2009(H1N1)
A/California/25/2009(H1N1)
A/Milan/83/2009(H1N1)
A/Milan/80/2009(H1N1)
A/Ancona/05/2009(H1N1)
A/Catalonia/378/2009(H1N1)
A/Italy/172/2009(H1N1)
A/Sapporo/1/2009(H1N1)
A/Catalonia/387/2009(H1N1)
A/Hong Kong/2369/2009(H1N1)
A/Athens/893/2009(H1N1)
A/Paris/2591/2009(H1N1)
A/New Jersey/01/2009(H1N1)

»²¹Í3.¥Ý¥¸¥·¥ç¥ó225¤Ç¤ÎÊÑ°Û

D225N
¥Ö¥é¥¸¥ë¡¦¥µ¥ó¥Ñ¥¦¥í¤ä¥Ë¥å¡¼¥è¡¼¥¯¤Ç¸«¤é¤ì¤¿ÊÑ°Û

D225G
¥Ö¥é¥¸¥ë¡¦¥µ¥ó¥Ñ¥¦¥í¡¢Ãæ¹ñ¡¦Zhejiang¡¢ÆüËÜ¡¦¹­Åç¡¢¥¢¥á¥ê¥«¡¦¥Æ¥­¥µ¥¹¡¢¥¢¥á¥ê¥«¡¦¥¸¥ç¡¼¥¸¥¢¡¢¥¢¥á¥ê¥«¡¦¥Ë¥å¡¼¥è¡¼¥¯¡¢¥á¥­¥·¥³¡¢¥¹¥Ú¥¤¥ó¡¦¥«¥¿¥í¥Ë¥¢¤Ç¸«¤é¤ì¤¿ÊÑ°Û

D225E
ÆüËÜ¡¦Ä¹ºê¡¢ÆüËÜ¡¦»¥ËÚ¡¢Ãæ¹ñ¡¦¹á¹Á¡¢¥¢¥á¥ê¥«¡¦¥Ë¥å¡¼¥¸¥ã¡¼¥¸¡¼¡¢¥¢¥á¥ê¥«¡¦¥«¥ê¥Õ¥©¥ë¥Ë¥¢¡¢¥Õ¥é¥ó¥¹¡¦¥Ñ¥ê¡¢¥¹¥Ú¥¤¥ó¡¦¥«¥¿¥í¥Ë¥¢¡¢ ¥«¥¶¥Õ¥¹¥¿¥ó¡¦¥¢¥ë¥Þ¥È¥¤¡¢Ãæ¹ñ¡¦Ä¹º»¡¢¥¤¥¿¥ê¥¢¡¦¥ß¥é¥Î¡¢¥¤¥¿¥ê¥¢¡¦¥¢¥ó¥³¡¼¥Ê¡¢¥®¥ê¥·¥ã¡¦¥¢¥Æ¥Í¡¢¤Ç¸«¤é¤ì¤¿ÊÑ°Û

¤½¤Î¾»²¹Í¥µ¥¤¥È
¡ÖRe: Sequences at Genbank! ¡×
¡Ö225G Preliminary Worldwide Tracking & Evaluation ¡×

H1N1ÊÑ°Û¤òÅÁ¤¨¤ëÃæ¹ñ¤Î¥Æ¥ì¥Ó¡ÖH1N1±Ö¾ðÁî¹çÊóÆ» - ¸áÌëºÇÁ°Àþ 20091122¡×


¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

2009/11/23 Monday

¥«¥Ê¥À¤Ç»ÈÍÑÃæ»ß¤È¤Ê¤Ã¤¿¥ï¥¯¥Á¥ó¤Ë¤Ä¤¤¤Æ¤Î¾ÜºÙ¾ðÊó

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 10:04:33

2009ǯ11·î23Æü
¡¡
null¾ðÊ󤬺øÁ¤Æ¤¤¤ë¤è¤¦¤Ê¤Î¤Ç¡¢¤³¤³¤Ç¡¢¤Á¤ç¤Ã¤ÈÀ°Íý¤·¤Æ¤ß¤Þ¤·¤ç¤¦¤Í¡£

¥«¥Ê¥À¤Î±ÒÀ¸Åö¶É¤Ï11·î£²£²Æü¤Þ¤Ç¤Ë¡¢±Ñ°åÌôÉÊÂç¼ê¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¤¬À½Â¤¤·¤¿¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Î¥ï¥¯¥Á¥ó£±£·Ëü²óʬ¤Î»ÈÍѤòÃæ»ß¤¹¤ë¤³¤È¤ò·è¤á¤Þ¤·¤¿¡£

¤½¤ÎÍýͳ¤È¤·¤Æ¡¢Àܼï¸å¤ËÄ̾ï¤è¤ê¤â¹â¤¤ÈæΨ¤Ç½Å¤¤¥¢¥ì¥ë¥®¡¼²á¾êÈ¿±þ(¥¢¥Ê¥Õ¥£¥é¥­¥·¡¼¥·¥ç¥Ã¥¯)¤¬È¯À¸¤·¤¿¤¿¤á¤Ç¤¹¡£

¤È¤¯¤Ë¡¢¥«¥Ê¥ÀÃæÉô¤Î¥Þ¥Ë¥È¥Ð½£¤Ç¡¢¥°¥é¥¯¥½À½¤Î°ìÄêÎ̤Υ說¥Á¥ó¤Ë¤Ä¤¤¤Æ¡¢Ä̾¡Á£²Îã¤Ë¤È¤É¤Þ¤ë½Å¤¤ÉûºîÍѤ¬£¶ÎãȯÀ¸¤·¤¿¤È¤Î¤³¤È¤Ç¤¹¡£

¥«¥Ê¥ÀÀ¯Éܤ¬»ÈÍÑÃæ»ß¤òµá¤á¤¿¤Î¤Ï¡¢¼¡¤Î¥ï¥¯¥Á¥ó¤Ç¤¹¡£

À½ÉÊ̾¡ÖArepanrix¡×

À½Â¤¥í¥Ã¥ÈÈÖ¹æ¡ÖA80CA007A¡×

¥ê¥³¡¼¥ëÂоݿôÎÌ¡Ö172,000Éþ¡×

½Ð²ÙÀè
British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Prince Edward Island

ÉûÈ¿±þÊó¹ð
11·î7Æü»þÅÀ¤Ç660Ëü²óʬ¶¡µë¡¢¤¦¤Á¡¢ÉûÈ¿±þÊó¹ð634Îã¡¢¤¦¤Á½Å¾ÉÎã36¡¢¤¦¤Á»àË´4Îã

¡ÖArepanrix¡×¥ï¥¯¥Á¥ó¤Î³µÍ×

¡ÖArepanrix¡×¥ï¥¯¥Á¥ó¤Ï¡¢¥°¥é¥¯¥½¡¦¥¹¥ß¥¹¥¯¥é¥¤¥ó¼ÒÀ½¤Î¥¢¥¸¥å¥Ð¥ó¥È(AS03)Æþ¤ê¤Î¥ï¥¯¥Á¥ó¤Ç¤¹¡£

¥¦¥¤¥ë¥¹¤ÎÇÝÍܤϡ¢È¯°é·ÜÍñÇÝÍÜË¡(embryonated egg culture)¤Ë¤è¤Ä¤Æ¤¤¤Þ¤¹¡£

¥¢¥¸¥å¥Ð¥ó¥ÈAS03¤Ï¡¢¥¹¥¯¥ï¥ì¥ó¤ò»ÈÍѤ·¤Æ¤¤¤ë¤¿¤á¡¢¥¢¥á¥ê¥«¤Î¥°¥é¥¯¥½¤Î¥ï¥¯¥Á¥ó¤Ç¤Ï»È¤ï¤ì¤Æ¤¤¤Þ¤»¤ó¡£

¡ÖArepanrix¡×¥ï¥¯¥Á¥ó¤Ï¥«¥Ê¥À¡¦¥Ð¡¼¥¸¥ç¥ó¤Ç¤Î¾¦ÉÊ̾¤Ç¤¢¤ê¡¢¤³¤ì¤Ï¡¢Æ±¼Ò¤Î¡ÖPandemrix ¡×¤È¼Â¼Á¡¢Æ±¤¸¤â¤Î¤Ç¤¹¡£
»²¾È¡ÖPademrix and Arepanrix adjuvanted vaccines, made by GSK¡×

¤½¤Î¡ÖPandemrix ¡×¤Ï¡¢º£²óÆüËܤ¬Í¢Æþ¤Î¥°¥é¥¯¥½¤Î¥ï¥¯¥Á¥ó¤Ç¤¹¡£

¡Ö¥Ñ¥ó¥Ç¥à¥ê¥¯¥¹¡×(Pandemrix)¤Ï¡¢¥â¥Ã¥¯¥¢¥Ã¥×(mock-up)¥ï¥¯¥Á¥ó¤Ç¤¹¡£
ÂоݤȤ¹¤ë¥¦¥¤¥ë¥¹³ô¤¬ÆÃÄꤵ¤ì¤Æ¤¤¤Ê¤¤Ãʳ¬¤Ç¡¢¥â¥Ç¥ë¥¦¥¤¥ë¥¹¤òÍѤ¤¤ÆºîÀ½¤µ¤ì¤¿¥ï¥¯¥Á¥ó¤Ç¡¢À½Â¤¾µÇ§¤Ï¤³¤ÎÃʳ¬¤ÇÆÀ¤Æ¤¤¤Þ¤¹¡£
Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹H5N1Âбþ¥ï¥¯¥Á¥ó¤È¤·¤Æ³«È¯¤µ¤ì¤¿¥ï¥¯¥Á¥ó¤Î¥â¥Ç¥ë¥¦¥¤¥ë¥¹¤ò¡¢A/Vietnam/1194/2004(H5N1)¤«¤éA/California/7/2009 (H1N1)¤ËÆþ¤ìÂؤ¨¤Æ¡¢À½Â¤¤·¤Æ¤¤¤ë¤â¤Î¤Ç¤¹¡£

¥«¥Ê¥À¤Î¡ÖArepanrix¡×¤âÆüËܤØÍ¢Æþ¤Î¡ÖPandemrix¡×¤â¡¢²¼µ­¤Î¥Ó¥Ç¥ª¤Ë¤¢¤ê¤Þ¤¹¤è¤¦¤Ë¡¢Æó¤Ä¤ÎÍÆ´ï¤ÈÃí¼Í´ï¤¬¥ï¥ó¥»¥Ã¥È¤Ë¤Ê¤Ã¤¿¤â¤Î¤Ç¤¹¡£
1.¥µ¥¹¥Ú¥ó¥·¥ç¥ó(Suspension)-¿ÉþÍÑÍÆ´ï¤Ë¥¢¥ó¥Á¥²¥ó(antigen)¤¬Æþ¤Ã¤Æ¤¤¤Þ¤¹¡£
2.¥¨¥Þ¥ë¥¸¥ç¥ó(Emulsion)-¥¢¥¸¥å¥Ð¥ó¥È(adjuvant)¤¬Æþ¤Ã¤Æ¤¤¤Þ¤¹¡£

¤³¤Î1¤È2¤ò¡¢¥ß¥Ã¥¯¥¹¤·¤Æ»È¤¤¤Þ¤¹¡£
¤¿¤À¡¢º®¹ç¤¹¤ëÁ°¤Ë¡¢Æó¤Ä¤¬¡¢Éô²°¤Î²¹Å٤ˤʤé¤Ê¤±¤ì¤Ð¤¤¤±¤Þ¤»¤ó¡£
»ÈÍÑÊýË¡¤Î¾ÜºÙ¤Ï¡¢¤³¤Î¥µ¥¤¥È¡ÖPandemrix suspension and emulsion for emulsion for injection¡×¤ò¤´Í÷¤¯¤À¤µ¤¤¡£

¤³¤ì¤é¤Î¤³¤È¤«¤é¡¢¤³¤ì¤é¤Î¥ï¥¯¥Á¥ó¤Ï´ÉÍý¤¬Æñ¤·¤¤¤È¤µ¤ì¤Æ¤¤¤Þ¤¹¡£

¡ÖArepanrix¡×¤Î¥Ñ¥Ã¥±¡¼¥¸¤Ë¤Ï¡¢¡ÖBubble Wrap¡×¤È¡ÖShoe Box¡×¤È¤ÎÆó¼ïÎब¤¢¤ê¤Þ¤¹¡£

¡ÖArepanrix¡×¥ï¥¯¥Á¥ó¤Ï¡¢»°Àé¿Í°Ê¾å¤Î¼£¸³¤ò·Ð¤Æ¤¤¤ë¤È¤µ¤ì¤Æ¤¤¤Æ¤Þ¤¹¤¬¡¢¤½¤ì¤¬¡¢H5N1¤Î¥â¥Ã¥¯¥¢¥Ã¥×¥ï¥¯¥Á¥ó¤ÎÁ°Ãʳ¬¤Ç¤Î¼£¸³¤ò´Þ¤ó¤Ç¤¤¤ë¤Î¤«¤¬ÌÀ¤é¤«¤Ç¤¢¤ê¤Þ¤»¤ó¡£¡£

¥«¥Ê¥À¤Ç¤Ï¡¢À¸¸å6¥ö·î¤«¤é3ºÐ°Ê²¼¤ÎÍÄ»ù¤Ë¤Ä¤¤¤Æ¤Ï¡¢Æó²óÀܼ»°ºÐ¤«¤é10ºÐ°Ê²¼¤Î»Ò¶¡¤ËÂФ·¤Æ¤Ï·ò¹¯¾õÂ֤˱þ¤¸¤Æ¡¢Æó²óÀܼ·ò¹¯¤Ê»°ºÐ¤«¤é10ºÐ°Ê²¼¤Î»Ò¶¡¤ËÂФ·¤Æ¤Ï¡¢°ì²óÀܼï¤ò¿ä¾©¤·¤Æ¤¤¤Þ¤¹¡£

¤·¤«¤·¡¢Arepanrix¤Ë¤Ä¤¤¤Æ¤Ï¡¢60ºÐ°Ê¾å¡¢10ºÐ¤«¤é17ºÐ¤Þ¤Ç¡¢À¸¸å6¥ö·î¤«¤é35¥ö·î¤Þ¤Ç¡¢¤³¤Î¤¤¤º¤ì¤ÎÀ¤Âå¤Ë¤Ä¤¤¤Æ¤Î clinical data¤¬ÌÀ¤é¤«¤Ë¤µ¤ì¤Æ¤¤¤Þ¤»¤ó¡£

¥¢¥Ê¥Õ¥£¥é¥­¥·¡¼¥·¥ç¥Ã¥¯(anaphylactic shock )¤Î¸¶°ø¤È¤·¤Æ¤Ï¡¢¥¢¥¸¥å¥Ð¥ó¥È(AS03)¤Ë´Þ¤Þ¤ì¤Æ¤¤¤ë³¦Ì̳èÀ­ºÞ¤Ç¤¢¤ëpolysorbate 80(Tween80)¤¬¸¶°ø¤È¤Î¸«Êý¤¬Í­ÎϤΤ褦¤Ç¤¹¡£
»²¹Í¡ÖPolysorbate 80 in medical products and nonimmunologic anaphylactoid reactions.
Coors EA, Seybold H, Merk HF, Mahler V
.¡×

¥«¥Ê¥À¤Ç¤Ï¡¢¤³¤Î¤Û¤«¡¢¥¢¥¸¥å¥Ð¥ó¥È¤¬Æþ¤Ã¤Æ¤¤¤Ê¤¤¡¢Ç¥ÉØÍѤΥ說¥Á¥ó¤È¤·¤Æ¡¢¥ª¡¼¥¹¥È¥é¥ê¥¢CSL Ltd¼Ò¤«¤é¡¢¡ÖPanvax¡×¤ò 200000Éþ¡¢Í¢Æþ¤·¤Æ¤¤¤Þ¤¹¡£

¤Ê¤ª¡¢»ä¤Î¥Ö¥í¥°µ­»ö¡ØH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥ï¥¯¥Á¥óÀܼï²ó¿ô¤Ï¡¢10ºÐ°Ê¾å¤Ï1²óÀܼï¤Ë¤¹¤Ù¤·¡Ù¤Ë°ÊÁ°10·î½é½Ü¤Ë½ñ¤­¤Þ¤·¤¿¤è¤¦¤Ë¡¢¥«¥Ê¥À¤Ç¤Ï¡¢65ºÐ°Ê¾å¤Î¤«¤¿¤Ë¡¢µ¨ÀáÀ­ÍѤΥ說¥Á¥ó¤òÀܼ魯¤ë¤È¡¢¤«¤¨¤Ã¤Æ¡¢H1N1¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ë¤«¤«¤ê¤ä¤¹¤¯¤Ê¤ë¤Î¤Ç¡¢µ¨ÀáÀ­ÍÑ¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥ï¥¯¥Á¥ó¤ÎÀܼï¤Ï¡¢2010ǯ¤Ë¤Ê¤ë¤Þ¤Ç¡¢ÂԤ俤ۤ¦¤¬¤¤¤¤¡£¡×¤È¤Î¸¦µæÀ®²Ì¤¬the B.C. Centre for Disease Control¤«¤éȯɽ¤µ¤ì¤Æ¤¤¤Þ¤¹¡£

¤³¤ì¤È¡¢º£²ó¤Î°ì·ï¤È¤Î´Ø·¸¤Ï¡¢º£¤Î¤È¤³¤í¤ï¤«¤Ã¤Æ¤¤¤Þ¤»¤ó¡£

¤Þ¤¢¡¢¤Á¤ç¤Ã¤È¡¢ÈéÆù¤Ê¸«Êý¤Ë¤Ï¤Ê¤ê¤Þ¤¹¤¬¡¢ÆüËܤǤϡ¢¤¹¤Ã¤¿¤â¤ó¤À¤ÎÀ¯Ì³´±¤ÎÀ¯¼£¼çƳ¤Î±¦±ýº¸±ý¤ÎËö¡¢¹ñ»º¥ï¥¯¥Á¥ó¤Î°ì²óÀܼ郎·è¤Þ¤ê¡¢·ë²Ì¡¢Åö½é·×²è¤Î¤«¤Ê¤ê¤Î¿ô¤ÎÍ¢Æþ¥ï¥¯¥Á¥ó¤¬ÉÔÍפȤʤꤽ¤¦¤Ê¤Î¤Ç¤¹¤«¤é¡¢¤³¤Î¥«¥Ê¥À¤Î°ì·ï¤ò¡¢¸üÀ¸Ï«Æ¯¾Ê¤Ï¡¢¥Í¥¿¤Ê¤ê°ø±ï¤Ê¤ê¥¹¥±¡¼¥×¥´¡¼¥È¤Ê¤êÅϤê¤ËÁ¥¤Ê¤ê¤Ë¤·¤Æ¡¢Í¢ÆþÂǤÁÀÚ¤ê¤Ç¤­¤ì¤Ð¡¢·ë²Ì¡¢Í¢Æþ¥ï¥¯¥Á¥ó²á¾êºß¸Ë¤Ø¤ÎÀÕǤƨ¤ì¤¬¤Ç¤­¤ë¤Î¤«¤â¤·¤ì¤Þ¤»¤ó¤Í¡£

°Ê¾å

»²¹Í
¥¢¥¸¥å¥Ð¥ó¥È(AS03)¤ÎÉûºîÍÑ(ÉûÈ¿±þ)¤È¤ß¤é¤ì¤Æ¤¤¤ë¾É¾õ¤Ë¤Ï¼¡¤Î¤â¤Î¤¬¤¢¤ë¤è¤¦¤Ç¤¹¡£

¡ÖALERT Canadians: Toxic Ingredients in the Arepanrix H1N1 Vaccine will Harm Your Health¡×¤«¤é

Pain(áÖÄË)
Redness(ȯÀÖ)
Swelling(¼ðı)
Fatigue(¤±¤óÂÕ´¶)
Headaches(ƬÄË)
Arthralgia (joint inflammation)(´ØÀáÄË)(´ØÀá¤Î±ê¾É)
Myalgia (muscle inflammation)(¶ÚÆùÄË)(¶ÚÆù¤Î±ê¾É)
Shivering(¿Ì¤¨)
Sweating(ȯ´À)
Swollen lymph nodes(¥ê¥ó¥ÑÀá¤Î¼ðÂç)
Fever(ȯǮ)
Vomiting(ÓÒÅÇ)
Tingling or numbness of the hands or feet(¼ê­¤Î¡¢¤¦¤º¡«¤­´¶¡¢¤Þ¤¿¤Ï¡¢¤·¤Ó¤ì´¶)
Shortness of breath(©ÀÚ¤ì)
Vasculitis (inflammation of the blood vessels)(·ì´É±ê)(·ì´É¤Î¼ðı)

Serious adverse reactions are as follows(°Ê²¼¤Ï¿¼¹ï¤ÊÍ­³²È¿±þ)

Blood and lymphatic system disorders (lymphadenopathy)(·ì±Õ¤ä¥ê¥ó¥Ñ·Ï°Û¾ï)(¥ê¥ó¥ÑÀá¼ðı¾É)

Psychiatric disorders (insomnia)(Àº¿À¾ã³²)(ÉÔ̲¾É)

Nervous system disorders (dizziness, paraesthesia, inflammation of the central nervous system, inflammation of nerves, autoimmune disorders affecting myelin sheaths of nerves such as Guillain-Barré Syndrome)(¿À·Ð·Ï¼À´µ)(Ìܤޤ¤.Ãγа۾ï¾ã³².Ãæ¿õ¿À·Ð·Ï±ê¾É.¿À·Ð±ê¾É.¥®¥é¥ó¥Ð¥ì¡¼¾É¸õ·²¤Î¤è¤¦¤Ê¿À·Ð¤Î¿ñ¾ä¤Ë±Æ¶Á¤òÍ¿¤¨¤¦¤ë¼«¸ÊÌȱְ۾ï.)

Ear and labyrinth disorders (vertigo)(¼ª¼À´µ¤ä¼ªÌÂÏ©¼À´µ)(Ìܤޤ¤)

Respiratory, thoracic and mediastinal disorders (dyspnoea)(¸ÆµÛ´ï¤ä¶»Éô¤ä½Ä³Ö¤Î°Û¾ï)(¸ÆµÛº¤Æñ)

Gastrointestinal disorders (nausea, diarrhea, abdominal pain, vomiting, dyspepsia, stomach discomfort)(°ßIJ°Û¾ï)(ÅǤ­µ¤.²¼Î¡.Ê¢ÄË.ÓÒÅÇ.¾Ã²½ÉÔÎÉ.°ß¤ÎÉÔ²÷´¶)

Skin and subcutaneous tissue disorders (pruritus, rash)(ÈéÉæ¤äÈé²¼ÁÈ¿¥¤Î°Û¾ï)(ÁßáÚ¾É.ȯ¿¾)

Musculoskeletal and connective tissue disorders (back pain, musculoskeletal stiffness, neck pain, muscle spasms, pain in extremity)(¶Ú¹ü³Ê°Û¾ï¡¢·ë¹çÁÈ¿¥°Û¾ï)(ÇØÄË.¶Ú¹ü³Ê¤Î¶Å¤ê.ðôÉôáÖÄË.¶ÚÚ»½Ì.»Í»è¤ÎÄˤß)

General disorders and administration site conditions (bruising, asthenia, chest pain, malaise)(¤µ¤Þ¤¶¤Þ¤Ê°Û¾ï´¶¡¢ÅêÍ¿Éô°Ì¤Î¾õÂÖ)(ºÃ½ý.̵ÎϾÉ.¶»ÄË.É԰´¶)

»²¹Í
¡ÖÍ¢Æþ¥ï¥¯¥Á¥ó¤Î°ÂÁ´À­¡¦Èó°ÂÁ´À­¡¡Ááʬ¤«¤ê°ìÍ÷¡×

Arepanrix¤Î»ÈÍÑÊýË¡¤Î¥Ó¥Ç¥ª

(¤³¤Î¥Ó¥Ç¥ª¤ò¸«¤ë¤è¤¦¤Ë¡¢Arepanrix¤Ï¡¢Æó¤Ä¤Î¥³¥ó¥Ý¡¼¥Í¥ó¥È(antigen¤Èadjuvant)¤«¤é¤Ê¤Ã¤Æ¤¤¤ë¤Î¤Ç¡¢Èó¾ï¤Ë´ÉÍý¤¬Æñ¤·¤¤¤È¤µ¤ì¤Æ¤¤¤ë¡£)


¥¢¥¸¥å¥Ð¥ó¥ÈÆþ¤ê¥ï¥¯¥Á¥ó¤Î¥ê¥¹¥¯¤Ë¤Ä¤¤¤Æ¤ÎDr. Roby Mitchell¤Î¥Ó¥Ç¥ª


¥«¥Ê¥À¤Ç¤Î¥ï¥¯¥Á¥ó»ÈÍÑÃæ»ß¤òÅÁ¤¨¤ë¥Æ¥ì¥Ó


¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

2009/11/22 Sunday

³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊÑ°Û¤¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 19:01:49

¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø

¤³¤Î¾ðÊó¤Ï11·î22Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ­¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ­»ö¤Ç¤Ï¡¢²¼µ­¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ­»ö½ç¤Ç¤¹¡£

D225GÊÑ°ÛH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¥ï¥¯¥Á¥óÉÔÁ´¤¢¤ê¤ÈWHO³Îǧ (11·î28Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ(11·î25Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ(11·î19Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ (11·î9Æü»þÅÀ)

2009/11/22(Sun)
¡¡
­¡Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¥·¥¢¥ë»À¤¬¥¬¥é¥¯¥È¡¼¥¹¤Ë¦Á 2,3 ·ë¹ç¤·¤¿¤â¤Î¡ÊSA¦Á2,3Gal¡Ë¤òǧ¼±¤·¡¢
¥Ò¥È¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¼ç¤È¤·¤Æ¥·¥¢¥ë»À¤¬¥¬¥é¥¯¥È¡¼¥¹¤Ë¦Á2,6·ë¹ç¤·¤¿¤â¤Î (SA ¦Á2,6Gal )¤òǧ¼±¤¹¤ë¡£

­¢¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤È¡¢¥Ò¥È¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤È¤Ç¤Ï°Û¤Ê¤ë¡£

­£¥Ò¥È¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤Î¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢¡¢¥Ò¥È¤Î¾åÉôµ¤Æ»¤Î¾åÈéºÙ˦¤Ë¤·¤«¤Ê¤¤¡£

­¤Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¾ì¹ç¤Î¥Ò¥È¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉۤϡ¢¥Ò¥È¤Î¸ÆµÛ´ï¤Î¿¼Éô¡Ê¸ÆµÛºÙµ¤´É»Ù¤ÈÇÙ˦ºÙ˦¤Î°ìÉô¡Ë¤Ë¡¢Â¿¤¯Â¸ºß¤¹¤ë¡£

­¥¤³¤Î¥Ò¥È¤Î¸ÆµÛ´ï¤Ë¤ª¤±¤ë¥Ò¥È¡¦¥¦¥¤¥ë¥¹¤ÈÄ»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¥ì¥»¥×¥¿¡¼Ê¬ÉÛ¤ÎÁê°ã¤Ï¡¤H5N1 ¥¦¥¤¥ë¥¹¤¬¿Í¤«¤é¿Í¤ØÅÁÇŤ·¤Ë¤¯¤¤»ö¼Â¤Ë¤â´Ø·¸¤·¤Æ¤¤¤ë¡£

­¦¥Ò¥È¤¬Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ò¸úΨ¤è¤¯ÅÁÇŤ¹¤ë¤¿¤á¤Ë¤Ï¡¤HA ¤¬¥Ò¥È¡¦¥¦¥¤¥ë¥¹¤Î¥ì¥»¥×¥¿¡¼¤òǧ¼±¤Ç¤­¤ë¤è¤¦¤ËÊÑ°Û¤¹¤ëɬÍפ¬¤¢¤ë¡£

­§¥Ò¥È¤¬¡¢Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ë´¶À÷¤¹¤ë¤È¡¢½ÅÆƤʲ¼Éô¸ÆµÛ´ï¾ã³²¤ò°ú¤­µ¯¤³¤¹¤³¤È¤¬¤¢¤ë¤Î¤Ï¡¢¤³¤Î¥ì¥»¥×¥¿¡¼¤ÎʬÉÛ(¸ÆµÛ´ï¤Î¿¼Éô¤ËÄ»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Î¥ì¥»¥×¥¿¡¼¤¬¤¢¤ë¡£)¤Î°ã¤¤¤È¡¢¥¦¥¤¥ë¥¹¤ÎÊѰۤˤè¤ë¤È¤³¤í¤¬Â礭¤¤¤È¸«¤é¤ì¤ë¡£

­¨º£²ó¡¢¥¦¥¯¥é¥¤¥Ê¤Ç¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¡¢¤¤¤º¤ì¤â½ÅÆƤǡ¢¤·¤«¤â¡¢¤½¤Î»àË´¼Ô¤ò´Þ¤á¤¿½ÅÆƼԤÎÇ٤ǤΥ¦¥¤¥ë¥¹¤¬¡¢¤¤¤º¤ì¤â¡¢D225GÊÑ°Û¤ò¤ª¤³¤·¤ª¤ê¡¢¾åµ¤Æ»¤Ç¤ÎD225GÊÑ°Û¤¬1¤Ä¤·¤«¤Ê¤«¤Ã¤¿¤È¤¤¤¦¤³¤È¤¬¡¢¾åµ­¤Î¤³¤È¤È´Ø·¸¤¢¤ë¤Î¤«¡£

­©¥Ý¥¸¥·¥ç¥ó225ÊѰۤϡ¢H3N2¤Ë¤è¤¯¸«¤é¤ì¤ë¥¢¥Þ¥ó¥¿¥¸¥óÂÑÀ­ÊѰۤǤ¢¤ê¡¢H1N1¤Ë¤ª¤¤¤Æ¤â¡¢·à¾ÉÀ­¤òÉÕÍ¿¤·¤¦¤ëÊѰۤǤ¢¤ë¤µ¤ì¤Æ¤¤¤ë¡£

¥¢¥Þ¥ó¥¿¥¸¥óÂÑÀ­ÊѰۤǤ¢¤ë¤³¤È¤È¡¢¥¦¥¯¥é¥¤¥Ê¤È¤Î´Ø·¸¤Ï¤¢¤ë¤Î¤«?

­ª¤Þ¤¿¡¢1918ǯ¤Î¥¹¥Ú¥¤¥óÉ÷¼Ù¤Ë¤ª¤¤¤Æ¡¢ºÎ¼è¤µ¤ì¤¿Æó¤Ä¤Î¥¦¥¤¥ë¥¹¡¡A/New York/1/1918 ¤È¡¡A/London/1/1919¡¡¤Ë¤â225¤Ë¤ª¤¤¤Æ¡¢Æ±ÍͤÎD225GÊÑ°Û¤¬¸«¤é¤ì¤¿¤³¤È¤È¤Î´Ø·¸¤Ï¤¢¤ë¤Î¤«¤É¤¦¤«¡£

­«1918ǯ¤Î¥¦¥¤¥ë¥¹¤Î¥·¡¼¥±¥ó¥¹Ê¬ÀϤˤª¤¤¤Æ¡¢¼õÍÆÂÎÆÃÀ­¤Ï¡¢¡ÖSA ¦Á2,6Gal¡× ¤È¡¢¡ÖSA¦Á2,3Gal¡×¤È¡¢¡ÖSA¦Á2,3Gal¤ÈSA ¦Á2,6Gal¤È¤Îº®¹ç¡×¤È¤Î»°¤Ä¤Î¥¿¥¤¥×¤¬¸«¤é¤ì¤¿¡£

­¬¼õÍÆÂÎÆÃÀ­¤Î¡ÖSA¦Á2,3Gal¡×¤«¤é¡ÖSA ¦Á2,6¡×¤Ø¤ÎÊѲ½¼«ÂΤϡ¢·à¾ÉÀ­¤òÉÕÍ¿¤¹¤ë¤â¤Î¤Ç¤Ï¤Ê¤¤¡£
¡ÖSA¦Á2,3Gal¤ÈSA ¦Á2,6Gal¤È¤Îº®¹ç¡×¤Ë¤Ä¤¤¤Æ¤Ï¤É¤¦¤«?

­­CDC¤ÎNancy J. Cox »á¤ò¤Ï¤¸¤á¤È¤¹¤ë59¿Í¤«¤é¤Ê¤ë¸¦µæ¥Á¡¼¥à¤ÎH1N1 ¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤Î°äÅÁ»ÒʬÀϤˤè¤ì¤Ð¡¢8¤Ä¤Î¥»¥°¥á¥ó¥È¤Î¤¦¤Á¡¢¥Ø¥Þ¥°¥ë¥Á¥Ë¥ó(H)¤ò´Þ¤à3¤Ä¤Î°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ï¡¢1918ǯ¤Î¥¹¥Ú¥¤¥óÉ÷¼Ù¤ÎH1N1¤ËͳÍ褹¤ë¤â¤Î¤Ç¤¢¤ê¡¢¤½¤Î¸å¡¢¤º¤Ã¤ÈÆڤ˸ºß¤·¤Æ¤¤¤¿¤â¤Î¤Ç¤¢¤ë¤¬¡¢¤½¤Î´Ö¤Ë¤ª¤¤¤Æ¤â¡¢ÊѰۤϤ·¤Æ¤¤¤Ê¤«¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£
°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ç¤Ï¡¢¥Ý¥ê¥á¥é¡¼¥¼B(PB)°äÅÁ»Ò¤Ï¥Ò¥ÈͳÍ衢¾¤ÎÆó¤Ä¤ÏĻͳÍè¤Ç¤¢¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£
¤Þ¤¿¡¢1918ǯ¤ÎH1N1¤ÈH5N1¤È¤Ï¡¢ÆÇÀ­¤¬¤¢¤ë¤³¤È¤ò¼¨¤¹°äÅÁ»Ò¥»¥°¥á¥ó¥È¤ò¡¢Æ±¤¸NS1¥»¥°¥á¥ó¥È¤Ë¤ª¤¤¤ÆÍ­¤·¤Æ¤¤¤ë¤¬¡¢º£²ó¤Î¿·H1N1¤Ï¡¢¤½¤¦¤Ç¤Ï¤Ê¤¤¤È¤¤¤¦¡£
´¶À÷À­¤ò¼¨¤¹°äÅÁ»Ò¥»¥°¥á¥ó¥È¤Ë¤ª¤¤¤Æ¤â¡¢º£²ó¤Î¿·H1N1¤Ï¡¢1918ǯ¤ÎH1N1¤Ë¤¢¤Ã¤¿¤â¤Î¤ò¼º¤Ã¤Æ¤¤¤ë¤È¤¤¤¦¡£

»²¹Í¡¡´ØÏ¢¤¹¤ë»ä¤Î¥Ö¥í¥°µ­»ö

¡Ö¤ä¤Ï¤ê¿··¿¤Ç¤Ï¤Ê¤«¤Ã¤¿¡¢º£²ó¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¡×
¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ¡×
¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´¡×

¤½¤Î¾´ØÏ¢¥µ¥¤¥È
¡ÖRole of sialic acid binding specificity of the 1918 influenza virus hemagglutinin protein in virulence and pathogenesis in mice.¡×
¡Övirus: alpha2,6-sialyllactose-avian flu citations¡×

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¥Ç¥Õ¥ì¡¦¥¹¥Ñ¥¤¥é¥ë¤«¤éƨ¤ì¤é¤ì¤¦¤ë¥Þ¥¤¥Ê¥¹¶âÍø¤Î¥¹¥­¡¼¥à¤òÆüËܤǤ⸡Ƥ¤¹¤Ù¤­¤È¤­

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 11:23:24

2009ǯ11·î22Æü
¡¡
nullºòÆü¡¢È·»³Ì±¼çÅÞÀ¯¸¢¤Î¡Ö¥Ç¥Õ¥ìÀë¸À¡×¤Ë¤Ä¤¤¤Æ¤Î¤¢¤Þ¤ê¤Î̵ºö¤µ¤ò¥Ö¥í¥°¡Ö¤Ê¤ó¤Ç¡¢¤¤¤Þ¤µ¤é¡¢¥Ç¥Õ¥ìÀë¸À¤Ê¤Î?¡×¤Ë½ñ¤­Ï¢¤Í¤Æ¤¤¤ë¤¦¤Á¤Ë¡¢ÅÓÃ椫¤é¡¢¥¹¥¦¥§¡¼¥Ç¥óÃæ±û¶ä¹Ô¤ä¥¤¥ó¥°¥é¥ó¥É¶ä¹Ô¤ÇÌܻؤµ¤ì¤Æ¤¤¤ë¡Ö¥Þ¥¤¥Ê¥¹¶âÍø¡×¤ÎÏÃÂê¤Ø¤È¡¢ÅÓÃææÀþ¤·¤Æ¤·¤Þ¤¤¡¢¤½¤Î¤¦¤Á¤Ë¡¢¤½¤³¤ÎÉôʬ¤À¤±¤¬¡¢ÈîÂç²½¤·¤Æ¤·¤Þ¤Ã¤¿¤Î¤Ç¡¢¤³¤³¤Ç²þ¤á¤Æ¡¢¤½¤³¤Î¥Þ¥¤¥Ê¥¹¶âÍø¤ÎÉôʬ¤À¤±¤ò¼è¤ê¾å¤²¤Æ¡¢¤³¤³¤ÇºÆ½Ò¤·¤Æ¤ß¤¿¤¤¡£

ÆüËܤΥǥե졦¥¹¥Ñ¥¤¥é¥ë¤ÎºÇÂç¤Î¸¶°ø¤Ï¡¢À¯ºö¶âÍø¤ÎÈóÉéÀ©Ìó¤Ë¤¢¤ê

¤Ä¤Þ¤ê¡¢ÆüËܤ¬¥Ç¥Õ¥ì¡¦¥¹¥Ñ¥¤¥é¥ë¤Ê¤ê¥Ç¥Õ¥ì¤Îæ«(Liquidity Trap)¤Ë´Ù¤Ã¤Æ¤¤¤ë¤½¤ÎºÇÂç¤Î¸¶°ø¤È¤·¤Æ¡¢À¯ºö¶âÍø¤ÎÈóÉéÀ©Ìó¤È¤¤¤¦ÌäÂ꤬¤¢¤ë¡£

¤³¤ì°Ê¾å¡¢À¯ºö¶âÍø¤ò²¼¤²¤Æ¤·¤Þ¤¦¤È¶âÍ»À¯ºö¤½¤Î¤â¤Î¤Î̵Îϲ½¤¬¤ª¤³¤Ã¤Æ¤·¤Þ¤¦¡¢¤½¤Î¤Þ¤µ¤Ë¡¢À¤³¦¤Î°­¤·¤­ÌÏÈÏÎ㤬¡¢ÆüËܤΥ¼¥í¤Ë¶á¤¤À¯ºö¶âÍø¤Ç¤¢¤ê¡¢¤³¤Î¤³¤È¤³¤½¤¬¡¢ÆüËܤΡּº¤ï¤ì¤¿½½Ç¯¡×¤òÀ¸¤ó¤À¸µ¶§¤È¤â¤¤¤¨¤ë¤È¤¤¤¦¤³¤È¤À¡£

¥Ð¥¹¥±¥Ã¥È¡¦¥Ü¡¼¥ë¤Ç¡¢¤¢¤Þ¤ê¤ËÄ㤤°ÌÃ֤ǥɥê¥Ö¥ë¤ò·«¤êÊÖ¤·¤Æ¤¤¤ë¤È¡¢¤½¤Î¥É¥ê¥Ö¥ë¼«ÂΤ¬ÉÔ²Äǽ¤È¤Ê¤ê¡¢¤Ä¤¤¤Ë¤Ï¡¢¥Ü¡¼¥ë¤¬¾²¤ËÄä»ß¤·¤Æ¤·¤Þ¤¦¤Î¤ÈƱ¤¸ÍÍÁê¤À¡£

Äã¶âÍøÀè¿Ê¹ñÆüËܤòÄɤ¤±Û¤¹ÈóÉéÀ©Ìó²óÈò¥¹¥­¡¼¥àºî¤ê¤ÎÆ°¤­

¥ê¡¼¥Þ¥ó¡¦¥·¥ç¥Ã¥¯¤ò¶­¤Ë¤·¤Æ¡¢À¤³¦³Æ¹ñ¤¬Äã¶âÍø¤Ø¤È¤Ê¤À¤ì¤òÂǤäƤ¤¤ë¡£

¸½»þÅÀ¤Ç¤¹¤Ç¤ËÀ¯ºö¶âÍø¤¬1¥Ñ¡¼¥»¥ó¥È¤òÀڤäƤ¤¤ë¹ñ¤Ï¡¢ÆüËÜ(0.1¡ó)¥«¥Ê¥À(0.25%)¥¢¥á¥ê¥«(0.25%)¥¹¥¦¥§¡¼¥Ç¥ó(0.25%)¥¤¥®¥ê¥¹(0.5%)¹á¹ÁSAR(0.5%)¤È¤Ê¤Ã¤Æ¤¤¤ë¡£

¤·¤«¤·¡¢¤³¤³¤ËÍè¤Æ¡¢¤½¤ì¤é¤ÎÀ¯ºö¶âÍø¤ò¸Â³¦¤Ë¤Þ¤Ç²¼¤²¤Æ¤·¤Þ¤Ã¤¿¹ñ¤ÎÃæ¤Ë¤Ï¡¢¤¹¤Ç¤Ë¡¢ÆüËܤÈƱÍͤÎÈóÉéÀ©Ìó¤Ç¤Î¶âÍ»À¯ºö¤Î¹Ô¤­µÍ¤Þ¤ê¤ò¸«±Û¤·¡¢Äã¶âÍøÀèÇÚ¹ñ¤ÎÆüËܤòÄ̤ê±Û¤·¤Æ¡¢ÈóÉéÀ©Ìó¤òÈò¤±¤¦¤ëÁ¼Ã֤Ȥ·¤Æ¡¢¥Þ¥¤¥Ê¥¹¶âÍø¤ÎÀ¯ºö¤ò»î¹Ô¤·»Ï¤á¤Æ¤¤¤ë¡£

¥¹¥¦¥§¡¼¥Ç¥ó¤È¥¤¥®¥ê¥¹¤À¡£

¡Ö¥Í¥Ð¡¼¥¢¥²¥¤¥ó¡ª¿¿¼îÏѡפʤé¤Ì¡Ö¥Í¥Ð¡¼¥¢¥²¥¤¥ó¡ª¥¸¥ã¥Ñ¥ó’¥º¡¦¥í¥¹¥È¡¦¥Ç¥£¥±¡¼¥É¡×(Never Again¡ª Japan’s ¡ÈLost Decade¡É)¤È¤¤¤Ã¤¿¤È¤³¤í¤Ê¤Î¤À¤í¤¦¡£

¥Þ¥¤¥Ê¥¹¶âÍø¥¹¥­¡¼¥à¤ÎÆó¿Í¤ÎÍýÏÀŪ¼çƳ¼Ô-Willem Buiter¤ÈGreg Mankiw-

¤³¤ì¤é¤Î¥Þ¥¤¥Ê¥¹¶âÍø¤ÎÍýÏÀŪ¤Ê¼çÃì¤È¤Ê¤Ã¤Æ¤¤¤ë¤Î¤¬¡¢¡Ö¤Ê¤ó¤Ç¡¢¤¤¤Þ¤µ¤é¡¢¥Ç¥Õ¥ìÀë¸À¤Ê¤Î?¡×¤Ë¤â½ñ¤¤¤¿¤è¤¦¤Ë¡¢Willem Buiter»á¤ÈGreg Mankiw»á¤Ç¤¢¤ë¡£

Á°¼Ô¤ÎWillem Buiter»á¤Ï¡¢¥Ç¥Õ¥ì¤Î櫤«¤éƨ¤ì¤ë¤¿¤á¤Ë¤Ï¡¢Æó¤Ä¤Î¥ª¥×¥·¥ç¥ó¤·¤«¤Ê¤¤¤È¤·¤Æ¤¤¤ë¡£

¤Ò¤È¤Ä¤Ï¡¢¼ûÍ×´­µ¯ºö¤Ç¤¢¤ê¡¢¤â¤¦¤Ò¤È¤Ä¤Ï¡¢¡ÉTaxing currency¡É¤Ë¤è¤Ã¤Æ¡¢¡ØÉé¤Î̾ÌܶâÍø¡Ù(negative nominal interest rate)(¥Þ¥¤¥Ê¥¹¶âÍø)¤ò¡Çcarry tax¤È¤¤¤¦·Á¤Ç²Ý¤¹¤ë¤³¤È¤Ç¤¢¤ë¡¢¤È¤·¤Æ¤¤¤ë¡£

¥¹¥¦¥§¡¼¥Ç¥óÃæ±û¶ä¹Ô¤Î¥Þ¥¤¥Ê¥¹¶âÍø¥¹¥­¡¼¥à

¥¹¥¦¥§¡¼¥Ç¥óÃæ±û¶ä¹Ô(Riksbank)¤Ï¡¢¤³¤ÎWillem Buiter¤Î¹Í¤¨Êý¤Î´ð¤Ë¡¢º£Ç¯¤Î7·î¤«¤é¡¢¼¡¤Î¤è¤¦¤Ê¥¹¥­¡¼¥à¤ò¼Â»ÜÃæ¤Ç¤¢¤ë¡£

¤¹¤Ê¤ï¤Á¡¢2009ǯ7·î2Æü¤Ë¡¢Riksbank¤Ï¡¢À¯ºö¶âÍø(¥ì¥Ý¡¦¥ì¡¼¥È¡¢Repo Rate)¤ò¡¢¤½¤ì¤Þ¤Ç¤Î0.5¥Ñ¡¼¥»¥ó¥È¤«¤é¡¢0.25¥Ñ¡¼¥»¥ó¥È¤Ë°ú¤­²¼¤²¤¿¡£

Ʊ»þ¤Ë¡¢2009ǯ7·î8Æü¤«¤é¤Ï¡¢Riksbank¤Ë¸ýºÂ¤ò»ý¤Ä¾¦¶È¶ä¹Ô¤ÎͶâ¸ýºÂ¤ÎͶâ¶âÍø(Deposit Rate)¤ò¡¢¥Þ¥¤¥Ê¥¹0.25¥Ñ¡¼¥»¥ó¥È¤Ø¡¢Riksbank¤«¤é¾¦¶È¶ä¹Ô¤Ø¤ÎÂߤ·½Ð¤·¶âÍø¤ò¡¢0.75¥Ñ¡¼¥»¥ó¥È¤ØÊѹ¹¤·¤¿¡£

¾¦¶È¶ä¹Ô¤ÎͶâÊ¿»Ä¤¬¤¤¤¯¤é¤«¤Ë¤â¤è¤ë¤¬¡¢ÍýÏÀŪ¤Ë¤Ï¡¢À¯ºö¶âÍø¤ò0.5¥Ñ¡¼¥»¥ó¥È¤«¤é¡¢0.25¥Ñ¡¼¥»¥ó¥È¤Ë°ú¤­²¼¤²¤Æ¤â¡¢Ãæ±û¶ä¹Ô¤Î¾¦¶È¶ä¹Ô¤ËÂФ¹¤ëͶâ¶âÍø¤ò¥Þ¥¤¥Ê¥¹0.25¥Ñ¡¼¥»¥ó¥È¤Ë¤¹¤ë¤³¤È¤Ë¤è¤Ã¤Æ¡¢¾¦¶È¶ä¹Ô¤ËÂФ¹¤ë¼Â¼Á¶âÍø¤Ï¡¢¤â¤È¤Î0.5¥Ñ¡¼¥»¥ó¥È¤È¼Â¼ÁƱ¤¸¿å½à¤Ë°Ý»ý¤Ç¤­¡¢ÈóÉéÀ©Ì󤫤é°ìÄê¤Î²ò½ü¤¬¤Ç¤­¤ë¡¢¤È¤¤¤¦¡¢¥Õ¥í¡¼¥Æ¥£¥ó¥°¤Î¹Í¤¨Êý¤Ë´ð¤Å¤¯¤â¤Î¤Î¤è¤¦¤À¡£

¤³¤ì¤òÆüËܤÎÆü¶ä¤ËÅö¤Æ¤Ï¤á¤Æ¤ß¤ë¤È¼¡¤Î¤è¤¦¤Ë¤Ê¤ë¤Ç¤¢¤í¤¦¡£

¸½ºß¡¢Íø©¥¼¥í¤ÎÆüËܶä¹ÔÅöºÂͶâ¤ò¥Þ¥¤¥Ê¥¹¶âÍø¤È¤·¡¢¡Ý0.25¥Ñ¡¼¥»¥ó¥È¤Ë¤·¡¢ÌµÃ´¥³¡¼¥ë(¥ª¡¼¥Ð¡¼¥Ê¥¤¥Èʪ)¥ì¡¼¥È¤ò0.75¥Ñ¡¼¥»¥ó¥È¤Ë¤¹¤ë¡¢¤È¡¢Æ±¤¸°ÕÌ£¤Ë¤Ê¤ë¤Î¤À¤í¤¦¡£

¤¿¤À¡¢
¥Þ¥Í¥¿¥ê¡¼¥Ù¡¼¥¹¡á¡Ö­¡ÆüËܶä¹Ô·ôȯ¹Ô¹â¡×¡Ü¡Ö­¢²ßʾήÄ̹â¡×¡Ü¡Ö­£Æü¶äÅöºÂͶâ¡×
¤Ê¤Î¤Ç¡¢­£¤Î¥Þ¥¤¥Ê¥¹¶âÍø²½¤Ë¤è¤Ä¤Æ¡¢­£¤ÎÊ¿»Ä¤¬¸º¾¯¤¹¤ë¤Ç¤¢¤í¤¦Ê¬¤ò¡¢­¡­¢¤Ç¤É¤ÎÄøÅÙÊ䤦¤«?¤È¤¤¤¦¤È¤³¤í¤Ë¡¢Ãæ±û¶ä¹Ô¥Ù¡¼¥¹¤Ç¤ÎºÛÎ̤ÎÉý¤¬Áý¤¨¤Æ¤¯¤ë¤Î¤«¤â¤·¤ì¤Ê¤¤¡£
º£¤Þ¤Ç¡¢­£¤Î»Ä¹â¤Ï¡¢Í¿·ï¤Ç¤·¤«²á¤®¤Ê¤«¤Ã¤¿¤Î¤Ç¤¢¤í¤¦¤«¤é¡£

¤Þ¤¿¡¢¥¹¥¦¥§¡¼¥Ç¥ó¤Î¾ì¹ç¤Ï¡¢¾¦¶È¶ä¹Ô¤ÎÃæ±û¶ä¹Ô¤Ø¤Îͤ±¶â¤Î¤ß¤òÂоݤˤ·¤Æ¤¤¤ë¤Î¤À¤«¤é¡¢¤ä¤ä¡¢¸ÂÄêŪ¤Ê¥Þ¥¤¥Ê¥¹¶âÍøÀ¯ºö¤È¤â¸À¤¨¤ë¤Î¤À¤¬¡¢¤³¤ì¤¬¾¦¶È¶ä¹Ô¤Î¸Ä¿Í¸ýºÂͶâ¶âÍø¤Ë¤Þ¤Ç¤âµÚ¤Ö¤Ë¤Ï¡¢¤â¤¦°ì¹©Éפ¬É¬ÍפʤΤ«¤â¤·¤ì¤Ê¤¤¡£

¤Ê¤ó¤«¡¢¤³¤ì¤ò¸«¤ë¤È¡¢FX¼è°ú¤Ë¤ª¤¤¤Æ¡¢¥í¥ó¥°¤â¥·¥ç¡¼¥È¤â¡¢¥Þ¥¤¥Ê¥¹¤Î¥¹¥ï¥Ã¥×¶âÍø¤È¤Ê¤Ã¤Æ¤·¤Þ¤¦¡¢¤È¤¤¤¦¤è¤¦¤Ê¤³¤È¤òÏ¢ÁÛ¤·¤Æ¤·¤Þ¤¦¤Î¤À¤¬¡£

¥¤¥ó¥°¥é¥ó¥É¶ä¹Ô(BoE)¤Ç¤â¡¢Æ±Íͤιͤ¨Êý¤ò¸¡Æ¤¤Î¤è¤¦¤À¡£

¥¤¥ó¥°¥é¥ó¥É¶ä¹Ô¤Ç¤Ï¡¢QE(quantitative easing)¤È¸Æ¤Ð¤ì¤ëÎÌŪ´ËÏÂÁ¼ÃÖ¤ÈƱ»þ¤Ë¡¢KingÁíºÛ¤Ï¡¢9·î»þÅÀ¤Ç¡¢¥Þ¥¤¥Ê¥¹¶âÍø¤Ë¤Ä¤¤¤Æ¡¢¥¹¥¦¥§¡¼¥Ç¥ó¤ÎÎã¤ò°ú¤­¹ç¤¤¤Ë½Ð¤·¤Æ¡¢¡Ö¥¹¥¦¥§¡¼¥Ç¥ó¤Î¤ä¤êÊý¤ÏÇÓ½ü¤·¤Ê¤¤¡£¥Þ¥¤¥Ê¥¹¶âÍø¤Ï¡¢¤Ò¤È¤Ä¤Î¹Í¤¨Êý¤Ç¤¢¤ë¡£¡×¤È¡¢Á°¸þ¤­¤Î¥³¥á¥ó¥È¤ò¤·¤Æ¤¤¤ë¡£

»²¹Í¡ÖWill UK interest rates go negative? ¡×
¡ÖTaxing currency as a way out of a liquidity trap¡×

Willem Buiter¤¬¹Í¤¨¤Æ¤¤¤ë¡¢¤è¤ê¥É¥é¥¹¥Æ¥£¥Ã¥¯¤Ê¥¹¥­¡¼¥à

¤³¤ì¤é¤Î¹Í¤¨Êý¤Î¸µ¤Ë¤Ê¤Ã¤Æ¤¤¤ëWillem Buiter¤Ï¡¢¤µ¤é¤Ë¡¢¥É¥é¥¹¥Æ¥£¥Ã¥¯¤Ê¹Í¤¨Êý¤ò»ý¤Ã¤Æ¤¤¤ë¤è¤¦¤À¡£

°ì¸À¤Ç¸À¤¨¤Ð¡¢¡ØƱ¤¸¶â(¥«¥Í)¤Ç¤â¡¢»Ä¹â¤È¤·¤ÆÊÝÍ­¤·¤Æ¤¤¤ì¤Ð¡¢»þ´Ö²ÁÃͤλ½ý¤òÌȤì¤ë¤¬¡¢Ä̲ߤȤ·¤Æ¸ò´¹µ¡Ç½¤ò¹Ô»È¤¹¤ë¤È»þ´Ö²ÁÃͤλ½ý¤ò¼õ¤±¤ë¤Î¤Ç¡¢¿Í¡¹¤Ï¡¢Ä̲ߤȤ·¤Æ¤Îµ¡Ç½¹Ô»È(¾ÃÈñ)¤òÀè±ä¤Ð¤·¤Ë¤·¡¢¾ÃÈñ¤»¤º¡¢»Ä¹â¤È¤·¤Æ²¹Â¸¤¹¤ë¤¿¤á¤Ë¡¢¥Ç¥Õ¥ì¤Î櫤¬À¸¤Þ¤ì¤ë¡£¤À¤«¤é¡¢»Ä¹â¤Î²ÁÃͤÈÄ̲ߤβÁÃͤò¥¤¥³¡¼¥ë¡¦¥Õ¥Ã¥Æ¥£¥ó¥°¤Ë¤¹¤ë¤¿¤á¤Ë¡¢»Ä¹â¤ËÂФ·¤Æ¡¢¥­¥ã¥ê¡¼¥¤¥ó¥°¡¦¥¿¥Ã¥¯¥¹¤È¤¤¤¦¤Ù¤­¤â¤Î¤ò²Ý¤·¡¢ÊÝÍ­»Ä¹â¤ËÂФ·¤Æ¤â¡¢»þ´Ö»½ý¤¬µ¯¤­¤ë¤è¤¦¤Ë¤¹¤ì¤Ð¤¤¤¤¡£¡Ù¤È¤¤¤¦¹Í¤¨Êý¤Ë¤â¤È¤Å¤¯¤â¤Î¤Î¤è¤¦¤Ç¡¢¤³¤Î¹Í¤¨Êý¤Ï¡¢¸å¤Ë½Ò¤Ù¤ëGreg Mankiw¤Î¹Í¤¨Êý¤È¤â¡¢¤¢¤¤Ä̤¸¤Æ¤¤¤ë¡£

¤¹¤Ê¤ï¤Á¡¢Willem Buiter»á¤Ï¡¢Ì¾ÌܶâÍø¤¬ÈóÉéÀ©Ìó¤ò¼õ¤±¤Ê¤¤¤¿¤á¤Ë¡¢¼¡¤Î»°¤Ä¤ÎÊýË¡¤¬¤¢¤ë¤È¤·¤Æ¤¤¤ë¡£(¤«¤Ê¤ê¥É¥é¥¹¥Æ¥£¥Ã¥¯¤Ê°Æ¤Ç¤Ï¤¢¤ë¡£)

­¡Ä̲ߤòÇѻߤ·¡¢¹ṉ̃¤¹¤Ù¤Æ¤¬¡¢Ãæ±û¶ä¹Ô¤Ë¸ýºÂ¤ò»ý¤Ä¡£¤½¤Î¾ì¹ç¡¢¤½¤Î¸ýºÂ¤ËÂФ·¤Æ¤Ï¡¢¥×¥é¥¹¤Î¶âÍø¤È¥Þ¥¤¥Ê¥¹¤Î¶âÍø¤ÎξÊý¤¬»þ¤Ë±þ¤¸¤Æ¡¢¤«¤«¤ë¡£

­¢Ä̲ߤÎÊÝÍ­¤ËÂФ·¤Æ¡¢¥­¥ã¥ê¡¼¤Ë±þ¤¸¤ÆÀǶ⤬¤«¤«¤ë¡£

­£¿·¤·¤¤²ßʾ¤ÎƳÆþ(rallod¤È¤¤¤¦Ì¾¤ÎÀ¤³¦Ä̲ß)¤Ë¤è¤Ã¤Æ¡¢¸ýºÂ¤Î»Ä¹â¤È¤·¤Æ²ÁÃͤȡ¢¸ò´¹¼êÃʤȤ·¤Æ¤ÎÄ̲ߤβÁÃͤȤò¡¢¥Ç¥«¥Ã¥×¥ê¥ó¥°¤¹¤ë¡£

»²¾È¡ÖThe wonderful world of negative nominal interest rates, again¡×

¤³¤Î¤¦¤Á¡¢¤È¤¯¤Ë­¢¤Î¹Í¤¨Êý¤Ï¡¢Ä̲߲ÁÃͤâÏ·²½¤·¤¦¤ë¤È¤¤¤¦¹Í¤¨Êý¤Ç¤¢¤ê¡¢¥ª¥×¥·¥ç¥ó¤Î¥¿¥¤¥à¡¦¥Ç¥£¥±¥¤(Ëþ´ü¤¬¶á¤Å¤¯¤Ë¤Ä¤ì¤Æ¡¢¥ª¥×¥·¥ç¥ó¤Î»þ´Ö²ÁÃͤ¬¸º¤Ã¤Æ¤¤¤¯¡£)¤Î¹Í¤¨Êý¤Ë»÷¤Æ¤¤¤ë¡£

¥Þ¥¤¥Ê¥¹¶âÍø¤ÎȯÁۤθµ¤Ï¡¢ÃÏ°èÄ̲ߤλÏÁÄ¥²¥¼¥ë¤Ë¤¢¤ê

¤³¤Î­¢¤Î¹Í¤¨Êý¤ò¤µ¤é¤Ë¤µ¤«¤Î¤Ü¤ë¤È¡¢ÃÏ°èÄ̲ߤÎÁĤȤ⤤¤¨¤ë¸ºß¤Î¥²¥¼¥ë(Silvio Gesell)¤Î¹Í¤¨Êý¤Ë¹Ô¤­Ã夯¤³¤È¤¬¤Ç¤­¤ë¡£

¤¹¤Ê¤ï¤Á¡¢¥²¥¼¥ë¤Ï¡¢Ä̲ߤؤΥ¹¥¿¥ó¥×¤òµÁ̳ÉÕ¤±¤ë¤È¤¤¤¦°Æ¤òÄ󾧤·¡¢¤³¤ì¤Ë¤è¤Ã¤Æ¡¢Ä̲ߤβÈÄíÆâË䢤ò¤µ¤±¤ë¤³¤È¤ò°Õ¿Þ¤·¤¿¡£

¤Ò¤é¤¿¤¯¤¤¤¨¤Ð¡¢¡ÖËè·î10±ßʬ¤Î¥¹¥¿¥ó¥×¤òŽ¤é¤Ê¤¤¤È1Ëü±ß»¥¤Ï»È¤¨¤Þ¤»¤ó¤è¡×¤È¤¤¤¦¤è¤¦¤Ê°Æ¤Î¤è¤¦¤À¡£²ÈÄíÆâ¤Ç²ßʾ¤òË䢤·¤Æ¤¤¤ì¤Ð¡¢¤½¤ì¤ËÂФ¹¤ë¥­¥ã¥ê¡¼¥¤¥ó¥°¡¦¥³¥¹¥È¤¬¤«¤«¤ë¤È¤¤¤¦¥·¥¹¥Æ¥à¤Ç¤¢¤ë¡£

Greg Mankiw¤Î¥Þ¥¤¥Ê¥¹¶âÍø¤Î¹Í¤¨Êý

°ìÊý¡¢Greg Mankiw¤Î¥Þ¥¤¥Ê¥¹¶âÍø¤Î¹Í¤¨Êý¤Ï¡¢¼¡¤Î¤è¤¦¤Ê¤â¤Î¤Ç¤¢¤ë¡£

¡Ö¶â¤ò¼Ú¤ê¤¿¤è¤ê¤â¾¯¤Ê¤¯ÊÖ¤¹¤³¤È¤ò¾ò·ï¤Ë¡¢¶â¤òÂߤ¹¤³¤È¤Ï¡¢¥Þ¥¤¥Ê¥¹¶âÍø¤Î³µÇ°¤¬¤¢¤ì¤Ð²Äǽ¤Ç¤¢¤ë¡£
r¤ò¼Â¼ÁÍøΨ¤È¤·¤Æ¡¢º£Æü¤Î¾¦ÉʲÁ³Ê¤ò¥Ù¡¼¥¹¤Ë¤·¤Æ¡¢ÌÀÆü¤Î¾¦ÉʲÁ³Ê¤ÎÁêÂвÁ³Ê¤ò¤¢¤é¤ï¤¹¤È¤¹¤ë¤È¡¢1/(1+r)¤Ç¤¢¤é¤ï¤µ¤ì¤¦¤ë¡£
·ÐºÑÍýÏÀ¤ÎÃæ¤Ç¡¢¤³¤ÎÌÀÆü¤Î¾¦ÉʲÁ³Ê¤ÎÁêÂвÁ³Ê¤ò°ì°Ê²¼¤Ë¤¹¤ëɬÍפȤ¹¤ë·ÐºÑÍýÏÀ¤Ï¤¢¤ë¤Î¤«?
ºß¸ËÉéô¤È¤¤¤¦¤â¤Î¤¬¤¢¤ë¸Â¤ê¡¢»ä¤Ï°ì°Ê²¼¤ËÁêÂвÁ³Ê¤Ï¤Ê¤ê¤¦¤ë¤È»×¤¦¡£
¤ê¤ó¤´¤Î²Á³Ê¤¬¤Ê¤·¤Î²Á³Ê¤ËËþ¤¿¤Ê¤«¤Ã¤¿¾ì¹ç¡¢ÌÀÆü¤Î¾ÃÈñ²Á³Ê¤Ï¡¢º£Æü¤Î²Á³Ê¤ËËþ¤¿¤Ê¤¤¡£
¤â¤·¡¢¿Í¡¹¤¬¡¢¾ÃÈñ¤¹¤ë¤³¤È¤ò±ä´ü¤¹¤ë¤³¤È¤ò˾¤ó¤Ç¤¤¤¿¤È¤¹¤ë¤È¡¢ÌÀÆü¤Î¾ÃÈñ¤Ï¡¢º£Æü¤Î¾ÃÈñ¤è¤ê¤â¡¢¤è¤ê¹â²Á³Ê¤È¤Ê¤é¤¶¤ë¤òÆÀ¤Ê¤¤¡£
¤³¤Î¤³¤È¤Ï¡¢Ê¿¶Ñ¤Î¼Â¼ÁÍøΨ(r)¤¬Éé¤Ç¤¢¤ë¤³¤È¤ò°ÕÌ£¤·¤Æ¤¤¤ë¡£¡×

¤¤¤Ã¤Æ¤ß¤ì¤Ð¡¢»Ä¹â¤È¤·¤Æ»ý¤Ã¤Æ¤¤¤ì¤Ð¥­¥ã¥ê¡¼¥¤¥ó¥°¡¦¥³¥¹¥È¡¦¥¼¥í¤Ç¸º²Á¤·¤Ê¤¤¤Î¤Ç¡¢¤Ò¤È¤Ó¤È¤Ï¡¢»Ä¹â¤òÄ̲ߤȤ·¤Æ¤Îµ¡Ç½¤ò¹Ô»È¤»¤º¡¢¾ÃÈñ¤òÀè±ä¤Ð¤·¤·¤Æ¡¢»Ä¹â¤È¤·¤ÆÂࢤ·¤Æ¤¤¤ë¡¢¤È¤¤¤¦¤Î¤¬¡¢º£¤Î¥Ç¥Õ¥ì¤Î櫤赶§¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£

¤¤¤Ä¤Þ¤Ç¤âÉå¤é¤Ê¤¤¤ê¤ó¤´¤Ê¤é¤Ð¡¢·è¤·¤Æ¡¢º£Æü¡¢Ç㤦¤³¤È¤Ï¤Ê¤¤¤À¤í¤¦¡£

Greg Mankiw¤Î¥Þ¥¤¥Ê¥¹¶âÍø¤Î¹Í¤¨Êý¤Ë¤Ä¤¤¤Æ¤Ï¡¢¼¡¤Î¥µ¥¤¥È¤ò¤´»²¾È
¡ÖObservations on Negative Interest Rates ¡×¡ÖMore on Negative Interest Rates ¡×
¡ÖNegative Interest Rates¡×

¤¤¤Ä¤Þ¤Ç¤âÉå¤é¤Ê¤¤¤ê¤ó¤´¤Ê¤é¤Ðº£Æü¤ÏÇã¤ï¤Ê¤¤

²¿¤ä¤é¡¢¤³¤Î¹Í¤¨Êý¤Ï¡¢¤Þ¤¹¤Þ¤¹¡¢¥ª¥×¥·¥ç¥ó¤Î¹Í¤¨Êý¤Ë¶Ë»÷¤·¤Æ¤¯¤ë¡£

¤Ä¤Þ¤ê¡¢¥­¥ã¥ê¡¼¥¤¥ó¥°¡¦¥³¥¹¥È¤¬¥¼¥í¤Ç¤Ê¤¤¸Â¤ê¡¢ÌÀÆü¤Î¾ÃÈñ²Á³Ê¤Ï¡¢º£Æü¤Î¾ÃÈñ²Á³Ê¤è¤ê¤â¡¢»þ´Ö²ÁÃͤλ½ý¤ò¼õ¤±¤ë¤È¤¤¤¦¤³¤È¤Ç¤¢¤ë¡£

¤ê¤ó¤´¤¬Éå¤ë»þ´ü¤¬¡¢Ëþ´üÆü(¤¿¤È¤¨¤Ð°ì½µ´Ö¸å)¤È¤¹¤ì¤Ð¡¢Ëþ´üÆü¤è¤ê¤â¡¢¤è¤ê´üÀè(¤Ä¤Þ¤ê¡¢º£Æü)¤Î¤Û¤¦¤¬¡¢»þ´Ö²ÁÃͤ¬Â¿¤¤¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£

¹¬¤«ÉÔ¹¬¤«¡¢¸½ºß¤ÎͶâ»Ä¹â¥Ù¡¼¥¹¤Ç¤Ï»þ´Ö²ÁÃͤλ½ý¤ò¼õ¤±¤Ê¤¤¤Ë¤â¤«¤«¤ï¤é¤º¡¢¤½¤Î»Ä¹â¤¬°ú¤­½Ð¤µ¤ì¡¢Ä̲ߤȤ·¤Æ¸ò´¹¼êÃʤε¡Ç½¤ò¤¹¤ëÃʤˤʤë¤È¡¢¤½¤ÎÂвÁ¤È¤Ê¤ë¾¦ÉʲÁÃͤϡ¢»þ´Ö²ÁÃͤλ½ý¤ò¼õ¤±¤ë¤Î¤À¤«¤é¡¢¿Í¡¹¤Ï¡¢Ä̲ߤò»È¤ï¤º¤Ë¡¢¾ÃÈñ¤ò±ä´ü¤·¡¢»Ä¹â¤È¤·¤Æί¤á¹þ¤à¤³¤È¤Ç¡¢¥Ç¥Õ¥ì¤Î櫤¬»Å¹þ¤Þ¤ì¤ë¡¢¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ê¤½¤¦¤À¡£

Ͷâ»Ä¹â¤¬Ä̲ߤȤ·¤Æ¸ò´¹¼êÃʤȤ·¤Æ¾ÃÈñ¤Ë¸þ¤«¤ï¤»¤ë¤¿¤á¤Ë¤Ï¡¢¥ª¥×¥·¥ç¥ó¤Ë¤ª¤±¤ëËþ´üÆü¤Ë¶á¤Å¤¯¤Û¤É»þ´Ö²ÁÃͤ¬¸º²Á¤¹¤ë¤È¤¤¤¦³µÇ°¤¬Æ³Æþ¤µ¤ì¤Ê¤¤¤È¡¢»Ä¹â¤È¤·¤ÆÂࢤµ¤ì¡¢Ä̲ߤȤ·¤Æ¾ÃÈñ¤Ë²ó¤é¤Ê¤¤¡£

¥ª¥×¥·¥ç¥ó¤¬SQÆü¤Ë¶á¤¯¤Ê¤ì¤Ð¤Ê¤ë¤Û¤É¡¢¼è°ú¤¬³èȯ²½¤¹¤ë¤Î¤Ï¡¢¤³¤Î¥¿¥¤¥à¡¦¥Ç¥£¥±¥¤¤¬¤¢¤ë¤¬¤¿¤á¤È¡¢¼«¤éÇã¤Ã¤Æ¤¤¤¿¥ª¥×¥·¥ç¥ó¤Î¹Ô»È²Á³Ê¤¬OTM¤È¤Ê¤Ã¤Æ¥Ñ¡¼¤È¤Ê¤Ã¤Æ¤·¤Þ¤¦¤³¤È¤Ë¤è¤ë¤â¤Î¤Ç¤¢¤ë¡£

¤³¤ì¤é¤ÎÆó¤Ä¤ÎÍ×°ø¤¬¡¢Ëþ´üÆüÁ°¤ÎÈ¿ÂÐÇäÇã¤ò²Ã®¤µ¤»¤Æ¤¤¤ë¤Î¤Ç¤¢¤ë¡£

¥Þ¥¤¥Ê¥¹¶âÍøÀ¯ºö¤Ï¡¢¥Ó¥Ã¥°¥×¥Ã¥·¥åºâÀ¯À¯ºö¤È¤Î¥ß¥Ã¥¯¥¹¡¦¥Ý¥ê¥·¡¼¤¬É¬Í×

¤â¤Ã¤È¤â¡¢»ä¤«¤é¤¤¤ï¤»¤ì¤Ð¡¢¤³¤ì¤éWillem Buiter¤ÈGreg Mankiw¤Î¡ÖÄ̲ߤλĹâ¤È¤·¤Æ¤ÎÊÝÍ­¤Ë¤â¡¢Ä̲ߤκ߸ˤȤ·¤Æ¤Î¡¢¥­¥ã¥ê¡¼¥¤¥ó¥°¤Ë¸«¹ç¤Ã¤¿¸º²Á¤ò¡×¤È¤¤¤¦¹Í¤¨Êý¤Ë¤Ï»¿À®¤·¤¦¤ë¤¬¡¢»þ´Ö²ÁÃÍ(¥»¡¼¥¿)¤Î¤â¤¦¤Ò¤È¤Ä¤Î¦Ì̤Ǥ¢¤ë¡ÖËþ´ü¤Ë¶á¤Å¤¯¤Û¤É¡¢¥Ü¥é¥Æ¥£¥ê¥Æ¥£¤Î¾å¾º(¥¬¥ó¥Þ¤ä¥Ù¥¬)¤¬¤¢¤ë¡×¤È¤¤¤¦»ÅÁȤߤ¬¤Ê¤±¤ì¤Ð¡¢ÊÒ¼êÍî¤Á¤Î¤è¤¦¤Ë»×¤¨¤ë¡£

¤Ä¤Þ¤ê¡¢¤³¤Î¤³¤È¤Ï¡¢¶âÍ»À¯ºö¤Î²ÝÂê¤Ç¤Ï¤Ê¤¯¡¢ºâÀ¯À¯ºö¤Î²ÝÂê¤Ç¤¢¤ê¡¢¤½¤ì¤Ï¡¢ÌÀÆü¤Î¾¦ÉʲÁÃͤÎÎô²½¤òËɤ®¡¢ÌÀÆü¤Î¾¦ÉʲÁÃͤξ徺¤ò¾·¤­¤¦¤ë¤è¤¦¤Ê¥Ó¥Ã¥°¡¦¥×¥Ã¥·¥åÀ¯ºö¤Ç¤¢¤ë¤È»ä¤Ï»×¤¦¤Î¤À¤¬¡¢¤É¤¦¤Ê¤ó¤À¤í¤¦?

¤³¤ì¤Ï¡¢¤¢¤ë°ÕÌ£¡¢¥¤¥ó¥Õ¥ì¥¿¡¼¥²¥Ã¥ÈÀ¯ºö¤È¤Î¥ß¥Ã¥¯¥¹¡¦¥Ý¥ê¥·¡¼¤È¤Ê¤ë¤«¤â¤·¤ì¤Ê¤¤¡£

¤ï¤«¤ê¤ä¤¹¤¤É½¸½¤Ë¤Ê¤ë¤«¡¢¤ï¤«¤ê¤Ë¤¯¤¤É½¸½¤Ë¤Ê¤ë¤«¤Ï¡¢¤Á¤ç¤Ã¤È¡¢¤¢¤ì¤À¤¬¡¢¿åÌ̤ËÉ⤫¤ÖÄà¤ê¤ÎÉ⤭¤¬¡¢¤À¤ó¤À¤ó¡¢ÄÀ¤ó¤Ç¡¢Æ°¤¤¤Æ¤¤¤ë¤«¤É¤¦¤«¸«¤¨¤Ê¤¯¤Ê¤Ã¤Æ¤­¤Æ¤¤¤ë¤È¤­¤Ë¡¢¥¤¥ó¥Õ¥ì¥¿¡¼¥²¥Ã¥ÈÀ¯ºö¤¬¡¢´û¸¤ÎÉ⤭¤Î¾å¤ËËÀ¤ò­¤·¤Æ¡¢¸«¤¨¤ä¤¹¤¯¤¹¤ë¤Î¤Ç¤¢¤ì¤Ð¡¢¥Þ¥¤¥Ê¥¹¶âÍøÀ¯ºö¤Ï¡¢É⤭¤ÎÉ⤯Ãæ¿´¤ò²¼¤²¤Æ¤·¤Þ¤Ã¤Æ¡¢É⤭¤ò¿åÌ̤˽Ф·¤Æ¤·¤Þ¤¦¡¢¤È¤¤¤¦À¯ºö¤Ã¤Æ¤³¤È¤Ç¤É¤¦¤À¤í¤¦?

Äã¶âÍøÀè¿Ê¹ñ¤Ç¤¢¤ëÆüËܤˤª¤¤¤Æ¤â¡¢¤½¤í¤½¤í¡¢¥Þ¥¤¥Ê¥¹¶âÍø¤Î¥¹¥­¡¼¥à¹½ÃۤΤ¿¤á¤Î¸¡Æ¤¤¬Æü¶äÀ¯ºöÅö¶É¤Ç¤Ê¤µ¤ì¤ë¤Ù¤­»þ¤ËÍè¤Æ¤¤¤ë¤Î¤«¤â¤·¤ì¤Ê¤¤¡£

Æ£´¬·ò»Ë»á¤â¡¢¤¹¤Ç¤Ë¡¢ÆüËܤΥǥե©¥ë¥È¤Ë¤Ä¤Ê¤¬¤ëÇËÌÇŪ¤ÊĹ´ü¶âÍø¹âÆ­¤ò¤ß¤³¤·¤Æ¤Î¡¢¥Þ¥¤¥Ê¥¹¶âÍø¤ÎÆüËܤؤÎƳÆþ¤ò¡¢Á᤯¤«¤éÄó¸À¤·¤Æ¤¤¤ë¤è¤¦¤À¡£

»²¹Íʸ¸¥
¡ØSweden: negative interest rates and quantitative easing¡Ù
¡ØUNCONVENTIONAL MONETARY POLICY: FIGHT DEFLATION BY TAXING CURRENCY¡Ù
¡ÖOvercoming the Zero Bound on Nominal Interest Rates: Gesell’s Currency Carry Tax vs. Eisler’s Parallel Virtual Currency.¡×
¡ÖJapan¡Çs Lost Decade: Origins, Consequences, and Prospects For Recovery ¡×
¡Ø Ãæ±û¶ä¹Ô¤ÈÄ̲ßȯ¹Ô¤ò½ä¤ëË¡À©ÅÙ¤Ë ¤Ä¤¤¤Æ¤Î¸¦µæ²ñÊó¹ð½ñ¡Ù

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£


2009/11/20 Friday

¤Ê¤ó¤Ç¡¢¤¤¤Þ¤µ¤é¡¢¥Ç¥Õ¥ìÀë¸À¤Ê¤Î?

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 22:26:55

2009ǯ11·î20Æü
¡¡
º£Æü¤Î¡¡¿ûľ¿ÍÉûÁíÍý¤Î¡¢Í­¸ú¤ÊºâÀ¯Âбþºö¤ò¼¨¤µ¤Ê¤¤¤Þ¤Þ¤Ç¤Î¡¢¤³¤È¤¢¤é¤À¤Æ¤Æ¤Î¡Ø¥Ç¥Õ¥ìÀë¸À¡Ù¤ËÂФ·¤Æ¡¢¡Ø¤¤¤Þ¤µ¤é¡¢²¿¤Ç?¡Ù¤È¤Î´ñ°Û¤Î´¶¤òÊú¤«¤ì¤¿Êý¤Ï¡¢»ä¤ò´Þ¤á¤Æ¡¢Â¿¤«¤Ã¤¿¤Î¤Ç¤Ï¤Ê¤«¤í¤¦¤«?

¡ØËÜÀÐÄ®Æüµ­¡Ù¤µ¤ó¤â¡¢Æ±Íͤδ¶ÁÛ¤òϳ¤é¤µ¤ì¤Æ¤¤¤ë¡£

¤¹¤Ç¤Ë¡¢Äã¶âÍø¤Ë¤â¤«¤«¤ï¤é¤º¡¢¥Ç¥Õ¥ì¸ú²Ì¤Ç¡¢ÆüËܤμ¼Á¶âÍø¤Ï¡¢¥¤¥®¥ê¥¹¤òÈ´¤¤¤Æ¡¢¥×¥é¥¹¤È¤Ê¤Ã¤Æ¤¤¤ë¤³¤È¤Ï¡¢Ã¯¤·¤â¤ï¤«¤Ã¤Æ¤¤¤ë¤³¤È¤Ç¤¢¤ë¡£
(¼Â¼Á¶âÍøÈæ³Ó¡á̾ÌܶâÍø¡Ý¥¤¥ó¥Õ¥ìΨ
ÆüËÜ2.7¥Ñ¡¼¥»¥ó¥È(̾ÌܶâÍø¡á0.1¥Ñ¡¼¥»¥ó¥È)¡¢¥¤¥®¥ê¥¹2.1¥Ñ¡¼¥»¥ó¥È(̾ÌܶâÍø¡á0.5¥Ñ¡¼¥»¥ó¥È)
»²¹Í¡ÖREAL INTEREST RATE FORECASTS¡×

¡ÖÆü¶ä¤Ø¤Î¡È°µÎϡɤȡȸ£À©¡É¤¬ÁÀ¤¤¡×¤È¤Î¸«Êý¤â¤¢¤ë¤¬¡¢¤Ç¤Ï¡¢Æü¶ä¤Ë²¿¤¬¤Ç¤­¤ë¤«¤È¤Ê¤ì¤Ð¡¢À¯ºö¶âÍø¤Ï¤¹¤Ç¤Ë¡¢ÈóÉéÀ©Ìó¤Î¸µ¤Ë¤Ê¤Ã¤Æ¤«¤éµ×¤·¤¤¤·¡¢ÎÌŪ´ËϺö¤Ë¤·¤Æ¤â¡¢Æü¶ä¼«¿È¤¬¤¤¤Ã¤Æ¤¤¤ë¤È¤ª¤ê¡¢¤½¤ì¤Ë¤è¤ëʪ²Á°ú¤­¾å¤²¸ú²Ì¤Ë¤Ï¡¢¸Â³¦¤¬¤¢¤ë¤è¤¦¤À¡£

È·»³À¯¸¢¤Ï¡¢»Ò¶¡¼êÅö¤Æ¤äÇÀ¶È¼Ô¸ÍÊ̽êÆÀÊä½þ¤Ê¤É¤Î¡¢Ä¾ÀÜ»Ùʧ¤¤Åª¤ÊÊä½õ¶â¤Î¸òÉդˤè¤Ã¤Æ¤Î²È·×¼ûÍפÎÁýÂç¤ò°Õ¿Þ¤·¤Æ¤¤¤ë¤é¤·¤¤¤¬¡¢¤³¤ì¤È¤Æ¤â¡¢Àè¤Ë»ä¤Î¥Ö¥í¥°µ­»ö¡Ø´¹¶â²óÏ©¹½ÃۤΥǥ¶¥¤¥ó¤Ê¤­¡¢¹ṉ̃ÁíÁ¼ÃÖ²½¤Î¤ß¤ò¤á¤¶¤¹¡¢Ì±¼çÅÞÀ¯¸¢¤Î·ÐºÑÀ¯ºö¤Î¤¢¤ä¤Þ¤ê¡Ù¤Ë¤â½ñ¤¤¤¿¤È¤ª¤ê¡¢¤³¤ì¤é¤ÎÀ¯ÉܻٽФϡ¢¤¹¤Ù¤Æ¡¢¥Ç¥Õ¥ì¤Îæ«( Liquidity Trap)¤Ë¤Ä¤«¤Þ¤Ã¤Æ¡¢²È·×ÆâË䢶â¤È¼ÚÆþ¶â½þ´Ôºâ¸»¤È²½¤·¤Æ¤·¤Þ¤¦²ÄǽÀ­¤¬¹â¤¤¡£

¤À¤«¤é¤È¤¤¤Ã¤Æ¡¢º£¤Î̱¼çÅÞÀ¯¸¢¤Ë¤Ï¡¢¥Ó¥Ã¥°¡¦¥×¥Ã¥·¥åÀ¯ºö¤Ï¤Ç¤­¤Ê¤¤¡£

°ÕÃÏ°­¤Ê¸«Êý¤ò¤¹¤ì¤Ð¡¢À¯Éܦ¤¬¡¢¤³¤ì¤é¤ÎľÀÜ»Ùʧ¤¤·¿Êä½õ¶â¤Î·Êµ¤ÉâÍȸú²Ì¤Î¸Â³¦¤òÃΤ俤Τǡ¢Æü¶ä¦¤Ë¡¢¤½¤ÎÀÕǤ¤ò¤Õ¤Ã¤¿¤Î¤Ç¤Ï¤Ê¤¤¤Î¤«?¤È¤â¡¢¤«¤ó¤°¤é¤ì¤ëº£Æü¤Î¥Ç¥Õ¥ìÀë¸À¤À¡£

¤À¤Ã¤¿¤é¡¢¤³¤È¤µ¤é¡¢¥Ç¥Õ¥ì¤òÂ¥¿Ê¤·¤«¤Í¤Ê¤¤¡¢±ß¹âÍÆǧȯ¸À¤ò¡¢Æ£°æºâ̳Âç¿Ã¤Ï¡¢¤Ê¤¼¡¢¤³¤Î½©°Ê¹ß¡¢¼¹Ù¹¤Ë¡¢¹ñºÝ¼Ò²ñ¤Ëȯ¿®¤·¤Ä¤Å¤±¤¿¤Î¤«?

¤½¤Î¥¨¥¯¥¹¥­¥å¡¼¥º¤È¤·¤Æ¡¢¶ñÂÎŪ¤ÊÆâ¼û¿¶¶½ºö¤âÄ󼨤·¤Ê¤¤¤Þ¤Þ¡¢Æ£°æºâ̳Âç¿Ã¤Ï¡¢¤Ê¤¼¡¢¡ØÆâ¼û¿¶¶½¡¢Æâ¼û¿¶¶½¡Ù¤È¡¢¶«¤Ó¤Þ¤ï¤Ã¤¿¤Î¤«?

Æü¶ä¤ËĹ´ü¹ñºÄ°ú¼õ¤Þ¤Ç¤âÂ¥¤·¤Æ¤¤¤ë¤Î¤Ç¤¢¤Ã¤¿¤é¡¢ºâÀ¯Ë¡Âè5¾ò¤¿¤À¤·½ñ¤Ï¡¢¹ñ²ñ¤ÎµÄ·è¤Ê¤ó¤Ç¤¹¤«¤é¡¢¤½¤ì¤³¤½¡¢¤ªÆÀ°Õ¤ÎÀ¯¼£¼çƳ¤Ç¡¢¤µ¤Ã¤µ¤ÈÌîÅÞÉԺߤǤª¤ä¤ê¤Ë¤Ê¤ì¤Ð¤¤¤¤¤À¤±¤ÎÏäÀ¡£

¤½¤·¤Æ¡¢º£Æü¤Î¥Ç¥Õ¥ìÀë¸À¸å¡¢Ä¹´ü¶âÍø¤ÏÄã²¼¤·¡¢¹ñºÄ²Á³Ê¤Ï¾å¾º¤·»Ï¤á¤Æ¤¤¤ë¡£

³ô²Á¤Ï¤¤¤Ã¤½¤¦²¼Íî¡¢±ß¹â¤Ï¤¤¤Ã¤½¤¦¿ÊĽ¤È¤¤¤Ã¤¿¾õ¶·¤À¡£

¤È¤¯¤Ë¡¢½µÌÀ¤±¤Î³°¹ñ°ÙÂػԾì¤Ï¡¢°ì¼ï¤Î¡Ø°Â¿´´¶¤È³Î¿®´¶¤ò»ý¤Ã¤Æ¡¢¤¤¤Ã¤½¤¦¤Î±ß¹â¡Ù¤Ø¤È·¹¤¯¤Ç¤¢¤í¤¦¡£

¹ñÆâÈǤΥ­¥ã¥Ô¥¿¥ë¡¦¥Õ¥é¥¤¥È¤¬¤¹¤Ç¤Ë»Ï¤Þ¤Ã¤Æ¤·¤Þ¤Ã¤Æ¤¤¤ë¤È¤¤¤¦ÍÍÁê¤À¡£

¤½¤·¤Æ¡¢¤½¤ì¤¬°ìÃÊÍ¤ë¤È¡¢º£Å٤ϡ¢ËܳÊŪ¤ÊĹ´ü¶âÍø¤Î¾å¾º¡¦ÆüËܹñºÄ¤Ø¤Î¥Ç¥Õ¥©¥ë¥È·üÇ°¡¦±ßÇä¤ê¤Ë¤è¤ë±ß°Âȿž¤È¤¤¤¦¡¢¹ñºÝÈǤΥ­¥ã¥Ô¥¿¥ë¡¦¥Õ¥é¥¤¥È¤È¤¤¤¦¡¢µÕ¤Î¥¹¥Ñ¥¤¥é¥ë¤¬»Ï¤Þ¤ë¤Î¤Ç¤¢¤í¤¦¡£

¤Þ¤µ¤Ë¡¢ËܳÊŪ¤ÊÆüËÜÇä¤ê¤Ø¤Î³«»ÏÀë¸À¤¬¡¢º£Æü¤Î¡Ø¥Ç¥Õ¥ìÀë¸À¡Ù¤È¤Ê¤Ã¤Æ¤·¤Þ¤¦¡£

ÆÍÇ˸ý¤Ï¡¢²¿¤«¤¢¤ë¤Î¤«?

¤ä¤ëµ¤¤Ç¤¢¤ì¤Ð¡¢¤¤¤¯¤Ä¤«¤¢¤ë¤Î¤À¤í¤¦¡£

Âè°ì¤Ï¡¢ÈóÉéÀ©Ìó¤Î¸µ¤Ç¤Î»Ä¤ê¾¯¤Ê¤¤À¯ºö¶âÍø¤Î°ú¤­²¼¤²¶Ò¤Ç¤Ï¤¢¤ë¤¬¡¢Àº°ìÇդξ®¹ï¤ß¶âÍø°ú²¼¤²¤Ë¤è¤Ã¤Æ¡¢¿´ÍýŪ¤Ê¸ú²Ì¤ò¤Í¤é¤¦¡£

ÂèÆó¤Ï¡¢Æü¶ä¤Ë¤è¤ëÂçÉý¤ÊήưÀ­¶¡µë(¥Þ¥Í¥¿¥ê¡¼¥Ù¡¼¥¹³ÈÂç)¤ÈƱ»þ¤Ë¡¢Æü¶ä¤Ë¤è¤ë¹ñºÄ¤ÎÂçÎÌÇ㤤Æþ¤ì¤È¡¢À¯Éܤˤè¤ë¹ñºÄȯ¹Ô¤È¡¢¹ñºÄ¤Îȯ¹Ô¤Ë¤è¤ë¥Ó¥Ã¥°¡¦¥×¥Ã¥·¥å¤Ë¤è¤ëÂç·¿·Êµ¤ÉâÍȺö¤ÎÃå¼ê¤Ë¼è¤ê³Ý¤«¤ë¡£
¤Á¤Þ¤Á¤Þ¤·¤¿»ö¶È»Åʬ¤±Åª¤Ê¤â¤Î¤Ï¡¢¤³¤³¤é¤ÇÂǤÁ»ß¤á¤È¤¹¤ë¡£

Âè»°¤Ï¡¢Æü¶ä¤Ë¤è¤ëÊƹñºÄ¤ÎÂçÎ̹ØÆþ¤Ç¤¢¤ê¡¢¤³¤ì¤Ë¤è¤Ã¤Æ¡¢¥Ð¥¤¥Ñ¥¹Åª¤Ê¡¢¼Â¼ÁŪ°ÙÂزðÆþ¤òÁÀ¤¦¡£

¤³¤ó¤Ê¤È¤³¤í¤À¤í¤¦¤«¡£

ÂèÆó¡¦Âè»°¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤¤¤º¤ì¤â¡¢ÅÙ¶»¤¬É¬ÍפÊÂçµ»¤À¡£

¤·¤«¤â¡¢Ì±¼çÅÞÀ¯¸¢¤Ï¡¢¥Ó¥Ã¥°¡¦¥×¥Ã¥·¥åÀ¯ºö¤¬¡¢µµ°æ¤µ¤ó¤ò½ü¤¤¤Æ¤Ï¡¢·ù¤¤¤ÈÍè¤Æ¤¤¤ë¡£

¤·¤«¤·¡¢»ä¤Î¥Ö¥í¥°¡Ø¥ê¥Á¥ã¡¼¥É¡¦¥¯¡¼»á¤Î¡Ö¥¢¥á¥ê¥«¤ÏÆüËܤβáµî¤Î¼ºÇԤ˳ؤ١×ÏÀ¡Ù¤Ç¤â½Ò¤Ù¤¿¤è¤¦¤Ë¡¢¥¯¥ë¡¼¥°¥Þ¥ó»á¤Ï¡¢¼¡¤Î¤è¤¦¤Ë¸À¤Ã¤Æ¤¤¤ë¡£

¡ÖÅöÌ̵ðÂç²½¤¹¤ëÀ¯ÉܻٽФϡ¢À¯ÉܤκâÀ¯¼ý»Ù¤ò°­²½¤µ¤»¤Ï¤¹¤ë¤¬¡¢·ÐºÑ¤ò»Ù¤¨¤ë¼ÂºÝ¤ÎºâÀ¯¥³¥¹¥È¤Ï¡¢¤â¤Ã¤È¾®¤µ¤¤¤Ï¤º¤À¡£
´Êñ¤Ë·×»»¤·¤Æ¤â(Back-of-the-envelope calculations )¡¢ºâÀ¯»Ù½Ð¤¬¡Ö¤¿¤ÀÈÓ¡×(Free Lunch)¤Ë¤Ï½ª¤ï¤é¤Ê¤¤¤³¤È¤ÏÌÀ¤é¤«¤Ç¤¢¤ë¡£¡×

¤Ä¤Þ¤ê¡¢¤¤¤Þ¤äµ¤Â©±â¡¹¤¿¤ëÆüËܷкѤˤȤäƤϡ¢¥Ó¥Ã¥°¡¦¥×¥Ã¥·¥å¤È¤¤¤¦AED(¿´Â¡¤Ë¥·¥ç¥Ã¥¯¤òÍ¿¤¨¡¢ÁÉÀ¸¤µ¤»¤ë½ùºÙÆ°´ï)¤¬É¬ÍפȤ¤¤¦¤ï¤±¤Ç¤¢¤ë¡£

¤Þ¤¢¡¢¤³¤³¤Þ¤Ç¤ß¤ë¤È¡¢¥Ð¡¼¥Ê¥ó¥­¤µ¤ó¤¬²áµî¤ÎÆüËֱܹé¤Ç¡¢ÆüËܤΥ¤¥ó¥¿¥²Çɤˤµ¤µ¤²¤¿Èëºö(Ž¢Æü¶ä¤¬¹ñºÄ¤ò¹ØÆþ¤·Â³¤±¤ì¤Ð¤¤¤Ä¤«¤Ïɬ¤º¥¤¥ó¥Õ¥ì¤ò¾·Íè¤Ç¤­¤ë¤Ï¤º¤Ç¤¢¤ë¡£Ž£¤È¤¤¤¦¥Ð¡¼¥Ê¥ó¥­¤ÎÇØÍýË¡)¤½¤Î¤â¤Î¤Î°ìÉô¼Â¹Ô¤È¤Ê¤ë¤è¤¦¤Ê¤Î¤À¤¬¡¢¤É¤¦¤â¡¢º£¤Î¡¢È·»³À¯¸¢¤Ë¤·¤Æ¤â¡¢Æü¶äÁíºÛ¤Ë¤·¤Æ¤â¡¢¡Ö¤Á¤ó¤Þ¤ê¤È¥«¥·¥³Ì̤·¤¿¡×ÌÌ¡¹¤·¤«¤¤¤Ê¤¤¤È¤³¤í¤«¤é¡¢µµ°æÀŹᤵ¤ó¤ÏÊ̤Ȥ·¤Æ¡¢¤³¤ì¤Û¤É¤ÎÂçµ»¤¬¤Ç¤­¤ëÅÙ¶»¤È´ïÎ̤ò¡¢»ý¤Á¹ç¤ï¤»¤Æ¤¤¤ë¤È¤Ï»×¤ï¤ì¤Ê¤¤¤Î¤À¤¬¡£

·ÐºÑ¶¨Îϳ«È¯µ¡¹½¡Ê£Ï£Å£Ã£Ä¡Ë¤Î¥¢¥ó¥Ø¥ë¡¦¥°¥ê¥¢»ö̳ÁíĹ¤Ï¡Ö¥Ç¥Õ¥ì¤ÈÆ®¤¨¡×¤ÈÆüËܤò¼¸Ó£¤·¡¢°Å¤Ë¹ñºÄÇ㤤Àڤꥪ¥ÚÁý³Û¤Ê¤É¤ò´Þ¤à¹­ÈϤÊÎÌŪ´ËÏÂÁ¼ÃÖ¤ò¼¨º¶¤·¤¿¤È¤¤¤¦¤Î¤À¤¬¡¢¤½¤Î¤è¤¦¤ÊÌïË¥ºö¤Ï¤â¤Î¤È¤â¤»¤º¡¢¥Ç¥Õ¥ì¤Î櫤ϡ¢È·»³¿·À¯¸¢¤ÎÌܶÌÀ¯ºö¤Ç¤¢¤ëľÀÜ»Ùʧ¤¤ÅªÊä½õ¶â¤Î¤â¤Ä¸ú²Ì¤ò¡¢²»¤â¤Ê¤¯²È·×ÆâË䢶â¤È¤·¤Æ¡¢ÄÀÅ¡¦µÛÃ夵¤»¤ë¤¿¤á¤Î¥¹¥­¡¼¥à¤È¤·¤Æ¤ÎÌò³ä¤ò³Î¼Â¤Ë²Ì¤¿¤½¤¦¤È¤·¤Æ¤¤¤ë¤è¤¦¤À¡£

¤È¤³¤í¤Ç¡¢ÀÄ»³³Ø±¡Âç³Ø¤Î¹ÁŰͺ¤µ¤ó¤È¤¤¤¦Êý¤¬¡¢ÀijؤΥá¥ë¥Þ¥¬¡ÖÀijأ֡ݣΣţԥޥ¬¥¸¥ó¡×(2003/2/5 »þÅÀ¤Ç¤Î¤«¤Ê¤ê¸Å¤¤µ­»ö¤Ç¤¹¤¬¡£)¤Ç¤³¤ó¤ÊÄó°Æ¤ò¤·¤Æ¤¤¤¿¤¬¡¢¼Â¸½À­¤Ï¤É¤¦¤Ê¤ó¤À¤í¤¦?

¤«¤Ê¤ê¡¢¥È¥ó¥Ç¥â°Æ¤À¤¬¡¢¥Ç¥Õ¥ì¤Î櫲ò¾Ãºö¤È¤·¤Æ¤Ï¡¢¤Á¤ç¤Ã¤È¶½Ì£¤ò¤Ò¤«¤ì¤ëÄó°Æ¤Ç¤Ï¤¢¤Ã¤¿¡£

¡Ö¹âÎð¼Ô¤ÏÄã¶âÍø¤Ç¤âºÇ¤â°ÂÁ´À­¤Î¹â¤¤¹ñºÄ¤òÁª¹¥¤·¤Æ¤ª¤ê¡¢£²·î£´Æü¤Îȯ¹Ô¤µ¤ì¤¿¸Ä¿Í¸þ¤±¹ñºÄ¤Î¹ØÆþ´õ˾¤Ïȯ¹Ô³Û¤Î²¿Çܤˤâ¤Ê¤Ã¤Æ¤¤¤ë¡£
¤³¤ÎºÝ¡¢¹âÎð¼Ô¸þ¤±¤ËǯÍø1.5¡ó¤Î¹â¶âÍø¹ñºÄ¤ò30Ãû±ßµ¬ÌÏȯ¹Ô¤·¡¢¤½¤Î»ñ¶â¤ò¤â¤Ã¤Æȯ¹ÔºÑ¤ß³ô¼°Áí³Û¤Î10¿ô¡ó¤ò¹ØÆþ¤¹¤ì¤Ð³ô¼°»Ô¾ì¤Î¼ûµë¤Ï°ìÅ٤˵Õž¤·¡¢³ô¼°¤Ï¤½¤ÎÀµ¾ï¤Ê²Á³Ê¤Ë¤Þ¤Ç²óÉü¤¹¤ë¤Ç¤¢¤í¤¦¡£¡×

¤Þ¤¢¡¢¸Ä¿Í¸þ¤±¡¢¤È¤¯¤Ë¡¢¹âÎð¼Ô¸ÂÄê¤Ç¤Î¹â¶âÍø¹ñºÄ¤òȯ¹Ô¤·¤Æ¡¢¥Ç¥Õ¥ì¤Î櫤赶§¤Î²ÈÄíÆâË䢶â¤ò°ú¤­½Ð¤¹¤È¤¤¤¦ÀïË¡¤Î¤è¤¦¤À¤¬¡¢¤½¤Î¹â¶âÍø¹ñºÄ¤Î½þ´Ô»þ¤Þ¤Ç¡¢ÆüËܷкѤ¬»ý¤Áľ¤·¤Æ¤¤¤ì¤Ð¡¢·ë²Ì¥ª¡¼¥é¥¤¤ÎÏäʤó¤À¤¬¡¢¤â¤·¡¢¤½¤¦¤Ç¤Ê¤¤¤È¡¢¸½ºß(¹ñ¤ÎÀǼý¤ËÂФ¹¤ëÍøʧ¤¤Èñ¤ÎÈæΨ¤¬10ǯ¤Ö¤ê¤Ë20¡óĶ)ƱÍÍ¡¢²áµî¤Î¹â¶âÍø¹ñºÄ¤Î¶âÍø»Ùʧ¤¤¤Ë¡¢¹ñ¸Ë¤Ï¤µ¤é¤Ë²Ð¤Î¼Ö¤È¤¤¤¦»öÂ֤ˤʤäƤ·¤Þ¤¦¤Î¤À¤¬¡£

Willem Buiter(¥¤¥ó¥°¥é¥ó¥É¶ä¹Ô)¤Ë¤è¤ì¤Ð¡¢¥Ç¥Õ¥ì¤Î櫤«¤éƨ¤ì¤ë¤¿¤á¤Ë¤Ï¡¢Æó¤Ä¤Î¥ª¥×¥·¥ç¥ó¤·¤«¤Ê¤¤¤È¤·¤Æ¤¤¤ë¡£

¤Ò¤È¤Ä¤Ï¡¢¼ûÍ×´­µ¯ºö¤Ç¤¢¤ê¡¢¤â¤¦¤Ò¤È¤Ä¤Ï¡¢”Taxing currency”¤Ë¤è¤Ã¤Æ¡¢¡ØÉé¤Î̾ÌܶâÍø¡Ù(negative nominal interest rate)(¥Þ¥¤¥Ê¥¹¶âÍø)¤ò’carry tax¤È¤¤¤¦·Á(ÃÏ°èÄ̲ߤÎÁĤȤ⤤¤¨¤ë¸ºß¤ÎSilvio Gesell¤¬¹Í¤¨½Ð¤·¤¿Ä̲ߤؤΥ¹¥¿¥ó¥×¤òµÁ̳ÉÕ¤±¤ë¤È¤¤¤¦°Æ¤Ë»÷¤¿¤â¤Î¤Î¤è¤¦¤À¡£¡ÖËè·î10±ßʬ¤Î¥¹¥¿¥ó¥×¤òŽ¤é¤Ê¤¤¤È1Ëü±ß»¥¤Ï»È¤¨¤Þ¤»¤ó¤è¡×¤È¤¤¤¦¤è¤¦¤Ê°Æ¤Î¤è¤¦¤À¡£²ÈÄíÆâ¤Ç²ßʾ¤òË䢤·¤Æ¤¤¤ì¤Ð¡¢¤½¤ì¤ËÂФ¹¤ë¥­¥ã¥ê¡¼¥¤¥ó¥°¡¦¥³¥¹¥È¤¬¤«¤«¤ë¤È¤¤¤¦¥·¥¹¥Æ¥à¤Î¤è¤¦¤À¡£)¤Ç²Ý¤¹¤ë¤³¤È¤Ç¤¢¤ë¤È¤¤¤¦¡£

¥Þ¥¤¥Ê¥¹¶âÍø¤Ï¡¢¥¹¥¦¥§¡¼¥Ç¥óÃæ±û¶ä¹Ô(Riksbank)¤Ç»î¹Ôºø¸íÃæ¤Ç¤¢¤ë¡£

2009ǯ7·î2Æü¤Ë¡¢Riksbank¤Ï¡¢À¯ºö¶âÍø(¥ì¥Ý¡¦¥ì¡¼¥È¡¢Repo Rate)¤ò¡¢¤½¤ì¤Þ¤Ç¤Î0.5¥Ñ¡¼¥»¥ó¥È¤«¤é¡¢0.25¥Ñ¡¼¥»¥ó¥È¤Ë°ú¤­²¼¤²¤ë¤ÈƱ»þ¤Ë¡¢2009ǯ7·î8Æü¤«¤é¤Ï¡¢Riksbank¤Ë¸ýºÂ¤ò»ý¤Ä¾¦¶È¶ä¹Ô¤ÎͶâ¸ýºÂ¤ÎͶâ¶âÍø(Deposit Rate)¤ò¡¢¥Þ¥¤¥Ê¥¹0.25¥Ñ¡¼¥»¥ó¥È¤Ø¡¢Riksbank¤«¤é¾¦¶È¶ä¹Ô¤Ø¤ÎÂߤ·½Ð¤·¶âÍø¤ò¡¢0.75¥Ñ¡¼¥»¥ó¥È¤ØÊѹ¹¤·¤Æ¤¤¤ë¡£
¤³¤ì¤é¤Î¥Þ¥¤¥Ê¥¹¶âÍø¥¹¥­¡¼¥à¤Ï¡¢, Greg Mankiw ¤ä¡¢Willem Buiter¤Î¹Í¤¨Êý¤Ë±è¤Ã¤¿¤â¤Î¤À¡£

¾¦¶È¶ä¹Ô¤ÎͶâÊ¿»Ä¤¬¤¤¤¯¤é¤«¤Ë¤â¤è¤ë¤¬¡¢ÍýÏÀŪ¤Ë¤Ï¡¢À¯ºö¶âÍø¤ò0.5¥Ñ¡¼¥»¥ó¥È¤«¤é¡¢0.25¥Ñ¡¼¥»¥ó¥È¤Ë°ú¤­²¼¤²¤Æ¤â¡¢Ãæ±û¶ä¹Ô¤Î¾¦¶È¶ä¹Ô¤ËÂФ¹¤ëͶâ¶âÍø¤ò¥Þ¥¤¥Ê¥¹0.25¥Ñ¡¼¥»¥ó¥È¤Ë¤¹¤ë¤³¤È¤Ë¤è¤Ã¤Æ¡¢¾¦¶È¶ä¹Ô¤ËÂФ¹¤ë¼Â¼Á¶âÍø¤Ï¡¢¤â¤È¤Î0.5¥Ñ¡¼¥»¥ó¥È¤È¼Â¼ÁƱ¤¸¿å½à¤Ë°Ý»ý¤Ç¤­¡¢ÈóÉéÀ©Ì󤫤é°ìÄê¤Î²ò½ü¤¬¤Ç¤­¤ë¡¢¤È¤¤¤¦¡¢¥Õ¥í¡¼¥Æ¥£¥ó¥°¤Î¹Í¤¨Êý¤Ë´ð¤Å¤¯¤â¤Î¤Î¤è¤¦¤Ç¤¹¤Í¡£

¤³¤ì¤òÆüËܤˤ¢¤Æ¤Ï¤á¤Æ¤ß¤ë¤È¡¢Íø©¥¼¥í¤ÎÆüËܶä¹ÔÅöºÂͶâ¤ò¥Þ¥¤¥Ê¥¹¶âÍø¤È¤·¡¢¡Ý0.25¥Ñ¡¼¥»¥ó¥È¤Ë¤·¡¢ÌµÃ´¥³¡¼¥ë(¥ª¡¼¥Ð¡¼¥Ê¥¤¥Èʪ)¥ì¡¼¥È¤ò0.75¥Ñ¡¼¥»¥ó¥È¤Ë¤¹¤ë¡¢¤È¤¤¤¦¤³¤È¤Ê¤ó¤Ç¤·¤ç¤¦¤«¤Í?

¤¿¤À¡¢
¥Þ¥Í¥¿¥ê¡¼¥Ù¡¼¥¹¡á¡Ö­¡ÆüËܶä¹Ô·ôȯ¹Ô¹â¡×¡Ü¡Ö­¢²ßʾήÄ̹â¡×¡Ü¡Ö­£Æü¶äÅöºÂͶâ¡×
¤Ê¤Î¤Ç¡¢­£¤Î¥Þ¥¤¥Ê¥¹¶âÍø²½¤Ë¤è¤Ä¤Æ¡¢­£¤ÎÊ¿»ÄÇÉ¡¢¸º¾¯¤¹¤ëʬ¤ò¡¢­¡­¢¤Ç¤É¤ÎÄøÅÙÊ䤦¤«?¤È¤¤¤¦¤È¤³¤í¤Ë¡¢Ãæ±û¶ä¹Ô¥Ù¡¼¿Þ¤Ç¤ÎºÇÎɤÎÉý¤¬Áý¤¨¤Æ¤¯¤ë¤Î¤«¤â¤·¤ì¤Ê¤¤¡£
º£¤Þ¤Ç¡¢­£¤Î»Ä¹â¤Ï¡¢Í¿·ï¤Ç¤·¤«²á¤®¤Ê¤«¤Ã¤¿¤Î¤Ç¤¢¤í¤¦¤«¤é¡£

¥¤¥ó¥°¥é¥ó¥É¶ä¹Ô¤Ç¤â¡¢Æ±Íͤιͤ¨Êý¤ò¸¡Æ¤¤Î¤è¤¦¤À¡£

¥¹¥¦¥§¡¼¥Ç¥ó¤Î¥¼¥í¶âÍø¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ØSweden: negative interest rates and quantitative easing¡Ù¤Ê¤É¤ò¤´»²¾È

¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ØUNCONVENTIONAL MONETARY POLICY: FIGHT DEFLATION BY TAXING CURRENCY¡Ù¤Ê¤É¤â¤´»²¾È

Greg Mankiw¤Î¥Þ¥¤¥Ê¥¹¶âÍø¤Î¹Í¤¨Êý¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ÖObservations on Negative Interest Rates ¡×¡ÖMore on Negative Interest Rates ¡×¤Ê¤É¤ò¤´»²¾È

Willem Buiter¤Ï¡¢Ì¾ÌܶâÍø¤¬ÈóÉéÀ©Ìó¤ò¼õ¤±¤Ê¤¤¤¿¤á¤Ë¡¢¼¡¤Î»°¤Ä¤ÎÊýË¡¤¬¤¢¤ë¤È¤·¤Æ¤¤¤ë¡£(¤«¤Ê¤ê¥É¥é¥¹¥Æ¥£¥Ã¥¯¤Ê°Æ¤Ê¤Î¤Ç¡¢¤Ó¤Ã¤¯¤ê¤µ¤ì¤Ê¤¤¤è¤¦¤Ë)
­¡Ä̲ߤòÇѻߤ·¡¢¹ṉ̃¤¹¤Ù¤Æ¤¬¡¢Ãæ±û¶ä¹Ô¤Ë¸ýºÂ¤ò»ý¤Ä¡£¤½¤Î¾ì¹ç¡¢¤½¤Î¸ýºÂ¤ËÂФ·¤Æ¤Ï¡¢¥×¥é¥¹¤Î¶âÍø¤È¥Þ¥¤¥Ê¥¹¤Î¶âÍø¤ÎξÊý¤¬»þ¤Ë±þ¤¸¤Æ¡¢¤«¤«¤ë¡£
­¢Ä̲ߤÎÊÝÍ­¤ËÂФ·¤Æ¡¢¥­¥ã¥ê¡¼¤Ë±þ¤¸¤ÆÀǶ⤬¤«¤«¤ë¡£
­£¿·¤·¤¤²ßʾ¤ÎƳÆþ(rallod¤È¤¤¤¦Ì¾¤ÎÀ¤³¦Ä̲ß)¤Ë¤è¤Ã¤Æ¡¢¸ýºÂ¤Î»Ä¹â¤È¤·¤Æ²ÁÃͤȡ¢¸ò´¹¼êÃʤȤ·¤Æ¤ÎÄ̲ߤβÁÃͤȤò¡¢¥Ç¥«¥Ã¥×¥ê¥ó¥°¤¹¤ë¡£
¤³¤ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢¡ÖThe wonderful world of negative nominal interest rates, again¡×¤ò¤´»²¾È

Ä̲߲ÁÃͤâÏ·²½¤·¤¦¤ë¤È¤¤¤¦¹Í¤¨Êý¤Ï¡¢¥ª¥×¥·¥ç¥ó¤Î¥¿¥¤¥à¡¦¥Ç¥£¥±¥¤(Ëþ´ü¤¬¶á¤Å¤¯¤Ë¤Ä¤ì¤Æ¡¢¥ª¥×¥·¥ç¥ó¤Î»þ´Ö²ÁÃͤ¬¸º¤Ã¤Æ¤¤¤¯¡£)¤Î¹Í¤¨Êý¤Ë»÷¤Æ¤¤¤ë¡£

¤¤¤µ¤µ¤«¡¢¥Á¥ó°Æ¤Ë°¤¹¤ë¥Ç¥Õ¥ì¤Îæ«Âкö¤À¤¬¡¢¤³¤Î¤è¤¦¤Ê°Æ¤ËÆüËܤΥǥեìÂкö¤òµá¤á¤ë³Ø¼Ô¤â¤¤¤ë¤è¤¦¤À¡£
»²¹Í¡ÖOvercoming the Zero Bound on Nominal Interest Rates: Gesell’s Currency Carry Tax vs. Eisler’s Parallel Virtual Currency.¡×
¡ÖJapan¡Çs Lost Decade: Origins, Consequences, and Prospects For Recovery ¡×
ÆüËܸìʸ¸¥¤Ç¤Ï¡¢¤³¤Î¤¢¤¿¤ê¡Ø Ãæ±û¶ä¹Ô¤ÈÄ̲ßȯ¹Ô¤ò½ä¤ëË¡À©ÅÙ¤Ë ¤Ä¤¤¤Æ¤Î¸¦µæ²ñÊó¹ð½ñ¡Ù¤¬»²¹Í¤Ë¤Ê¤ë¤Î¤«¤â¤·¤ì¤Ê¤¤¡£

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

2009/11/19 Thursday

¥¦¥¯¥é¥¤¥Ê¤ÇÂçÎÌ»àË´¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤Ï¡¢ÇÙÁÈ¿¥¤Ç½¸Ã椷ÊÑ°Û¤·¤Æ¤¤¤ë¤³¤È¤¬È½ÌÀ

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 23:41:36

¤³¤Î¥µ¥¤¥È¤Ë¤ª¤¤¤Ç¤¤¤¿¤À¤¤¤¿Êý¤Ø

¤³¤Î¾ðÊó¤Ï11·î19Æü»þÅÀ¤Ç¤Î¾ðÊó¤Ç¤¹¡£
º£²ó¤Î¥¦¥¯¥é¥¤¥Ê¤ò½é¤á¤È¤·¤¿H1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊѰۤˤĤ­¤Þ¤·¤Æ¤Ï¡¢¤³¤Î¥µ¥¤¥È°Ê³°¤Ë¤â¡¢»ä¤Î¥Ö¥í¥°µ­»ö¤Ç¤Ï¡¢²¼µ­¤Ç¼è¤ê¾å¤²¤Æ¤ª¤ê¤Þ¤¹¤Î¤Ç¡¢¤¢¤ï¤»¤Æ¤´»²¾È¤¯¤À¤µ¤¤¡£
¤¢¤¿¤é¤·¤¤µ­»ö½ç¤Ç¤¹¡£

D225GÊÑ°ÛH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ËÂФ·¤Æ¥ï¥¯¥Á¥óÉÔÁ´¤¢¤ê¤ÈWHO³Îǧ (11·î28Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¡¦¥Î¥ë¥¦¥§¥¤¡¦¹á¹Á¶¦Ä̤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹ÊѰۤˤĤ¤¤Æ(11·î25Æü»þÅÀ)
³Ð½ñ-ÀìÌç²È¤¬¡¢¥¦¥¯¥é¥¤¥Ê¤ÎH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¡¦¥¦¥¤¥ë¥¹¤ÎD225GÊÑ°Û¤¬Ç٤˽¸Ã椷¤Æ¤¤¤ë¤³¤È¤Ë´Ø¿´¤ò»ý¤Ã¤Æ¤¤¤ëÍýͳ(11·î22Æü»þÅÀ)
¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´ (11·î9Æü»þÅÀ)

2009ǯ11·î19Æü
¡¡
¤«¤Í¤Æ¤«¤é¤³¤Î¥Ö¥í¥°¡Ö¥¦¥¯¥é¥¤¥Ê¤ÇH1N1¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷¼Ô¤¬¸ÆµÛ´ï¼À´µ¤ÇÂçÎÌ»àË´¡×¤Ê¤É¤Ç¤âÅÁ¤¨¤Æ¤¤¤ë¥¦¥¯¥é¥¤¥Ê¤Ç¤Î¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ë¤è¤ë»àË´¤À¤¬¡¢¤³¤³¤ËÍè¤Æ¡¢¤³¤ì¤Ë¤è¤ë»à¼Ô¤Ï¡¢344¿Í¤Ë㤷¤¿¤È¤Î¤³¤È¤Ç¤¢¤ë¡£

°ìÆü¤¢¤¿¤ê16¿Í¤º¤Ä»àË´¼Ô¤¬Áý²Ã¤·¤Æ¤¤¤ë¤È¤¤¤¦¥Ú¡¼¥¹¤Î¤è¤¦¤Ç¤¢¤ë¡£

¤³¤³¤ËÍè¤Æ¡¢¥¦¥¤¥ë¥¹¤Î¥·¡¼¥±¥ó¥¹¤âȯɽ¤µ¤ì¤¿¤¬¡¢¤³¤ì¤Ë¤è¤ë¤È¡¢10¸¡ÂΤΤ¦¤Á¡¢4¸¡ÂΤˡ¢HA¤Ë¤ª¤¤¤Æ¡¢D225GÊÑ°Û¤ò¼¨¤·¤Æ¤¤¤¿¤È¤¤¤¦¡£

D225GÊÑ°Û¤òµ¯¤³¤·¤Æ¤¤¤ë¥¦¥¤¥ë¥¹Ì¾¤Ï²¼µ­¤Î¤È¤ª¤ê¤Ç¤¢¤ë¡£

A/Lviv/N6/2009
A/Ternopil/N11/2009
A/Ternopil/N10/2009
A/Lviv/N2/2009

¤³¤Î¤¦¤Á¡¢1¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢¹¢¤«¤é¤Î¤â¤Î¤Ç¤¢¤ê¡¢3¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢ÇÙÁÈ¿¥¤«¤é¤Î¤â¤Î¤Ç¤¢¤Ã¤¿¡£

¤³¤Î4¸¡ÂΤòºÎ¼è¤·¤¿´µ¼Ô¤Ï¤¤¤º¤ì¤â»àË´¼Ô¤Ç¤¢¤Ã¤¿¡£

É¡°öƬ¤«¤é¤Î¸¡ÂΤˤĤ¤¤Æ¤Ï¡¢D225GÊѰۤϸ«¤é¤ì¤Ê¤«¤Ã¤¿¤È¤¤¤¦¡£

¤³¤Î¤³¤È¤«¤é¡¢D225GÊÑ°Û¤¬¡¢ÇÙÁÈ¿¥¤Ë½¸Ã椷¤Æ¸«¤é¤ì¤ë¤Î¤«¤É¤¦¤«¤¬¡¢´Ø¿´¤Î¤â¤È¤È¤Ê¤Ã¤Æ¤¤¤ë¤è¤¦¤À¡£

¤½¤Î¤¿¤á¤Ë¤Ï¡¢¤³¤ÎÇÙÁÈ¿¥¤«¤é¤Î¸¡ÂΤ¬É¡°öƬ¤«¤é¤ÎÇ´±Õ¤«¤é¤­¤Æ¤¤¤ë¤â¤Î¤«¤É¤¦¤«¤òÁáµÞ¤Ë¸¡ºº¤·¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¤È¤·¤Æ¤¤¤ë¡£

¤Ê¤¼¤Ê¤é¡¢¾åµ¤Æ»¤Ç¤Î¥¦¥¤¥ë¥¹¤¬¤Û¤È¤ó¤É¤Ê¤¯¡¢Ç٤˥¦¥¤¥ë¥¹¤¬½¸Ã椷¤Æ¤¤¤ë²ÄǽÀ­¤¬¶¯¤¤¤«¤é¤À¡£

¶Ëü¤Ë¤Ï¡¢É¡°öƬ¤«¤é¤Î¸¡ÂΤǤϡ¢±¢À­¤ò¼¨¤¹¤³¤È¤¹¤é¤¢¤ë¤«¤é¤À¡£

CDC¤Î¸«²ò¤Ç¤Ï¡¢¥é¥Ô¥Ã¥É¡¦¥Æ¥¹¥È¤Ç¤Ï¡¢10¥Ñ¡¼¥»¥ó¥È¤«¤é70¥Ñ¡¼¥»¥ó¥È¤Î¶Ò¤Ç¤Î´¶Å٤κ¹¤¬¤¢¤ë¤È¤¤¤¦¡£

¤·¤¿¤¬¤Ã¤Æ¡¢¾õ¶·¤Ë¤è¤Ã¤Æ¤Ï¡¢¼ÂÂÖ¤Î10¥Ñ¡¼¥»¥ó¥È¤·¤«¡¢ÍÛÀ­¤ò¼¨¤µ¤Ê¤¤¾ì¹ç¤â¤¢¤ë¤È¤¤¤¦¡£

±¢À­¤ò¼¨¤·¤Æ¤¤¤ë¥é¥Ô¥Ã¥É¡¦¥Æ¥¹¥È¤Î¥µ¥ó¥×¥ë¤Ï¡¢¤³¤Î¾ì¹ç¡¢¤è¤êÀººº¤ò¤¹¤ë¤³¤È¤¬É¬ÍפǤ¢¤ë¤È¤¤¤¦¡£

¤³¤ÎD225GÊÑ°Û¤¬ÇÙÁÈ¿¥¤Ë½¸Ã椷¤Æ¤¤¤ë¤È¤¤¤¦¤³¤È¤Ï¡¢H1N1¥¦¥¤¥ë¥¹¤¬ÇÙÁÈ¿¥¤Ë½¸Ã椷¤Æ¤¤¤ë¤³¤È¤ò°ÕÌ£¤·¤Æ¤ª¤ê¡¢¤³¤Î¤³¤È¤¬¡¢¥µ¥¤¥È¥«¥¤¥ó¸½¾Ý¤ò°ú¤­µ¯¤³¤·¤Æ¤¤¤ë¤È¸«¤ë¸þ¤­¤â¤¢¤ë¤è¤¦¤À¡£

¤³¤ÎD225GÊѰۤϡ¢¤³¤ì¤Þ¤Ç¡¢¤¹¤Ç¤Ë¡¢¥Ö¥é¥¸¥ë¡¦¥µ¥ó¥Ñ¥¦¥í¡¢Ãæ¹ñ¡¦Zhejiang¡¢ÆüËÜ¡¦¹­Åç¡¢¥¢¥á¥ê¥«¡¦¥Æ¥­¥µ¥¹¡¢¥¢¥á¥ê¥«¡¦¥¸¥ç¡¼¥¸¥¢¡¢¥¢¥á¥ê¥«¡¦¥Ë¥å¡¼¥è¡¼¥¯¡¢¥á¥­¥·¥³¡¢¥¹¥Ú¥¤¥ó¡¦¥«¥¿¥í¥Ë¥¢¤Ç¸«¤é¤ì¤¿ÊѰۤǤ⤢¤ë¡£

¤·¤«¤·¡¢D225GÊÑ°Û¤¬¸«¤é¤ì¤¿¤È¤¤¤¦¤³¤È¤Ï¡¢¤³¤Î¥¦¥¤¥ë¥¹¤Î°äÅÁ»ÒŪ¤ÊÎò»ËÇØ·Ê(multiple genetic backgrounds via recombination)¤ò¸ì¤ë¤â¤Î¤Ç¤¢¤ë¤È¤¹¤ë¸«Êý¤â¤¢¤ë¡£

¤¹¤Ê¤ï¤Á¡¢»°¼ï¤Î¥¦¥¤¥ë¥¹¤ÎºÆ·ë¹ç(triple reassortant viruses)¤Ë¤ß¤é¤ì¤ëÊѰۤǤ¢¤ë¤È¤¤¤¦Àâ¤Ç¤¢¤ë¡£

¤½¤ÎÍýͳ¤È¤·¤Æ¡¢1918ǯ¤«¤é1919ǯ¤Ë¤«¤±¤Æ¤Î¥¹¥Ú¥¤¥ó¤«¤¼¤Ë¤ª¤¤¤ÆºÎ¼è¤µ¤ì¤¿Æó¤Ä¤Î¥¦¥¤¥ë¥¹¡¡A/New York/1/1918 ¤È¡¡A/London/1/1919¡¡¤Ë¤â225¤Ë¤ª¤¤¤Æ¡¢Æ±ÍͤÎD225GÊÑ°Û¤¬¸«¤é¤ì¤¿¤³¤È¤Ë¤Ä¤¤¤Æ¤Î·üÇ°¤«¤éÍè¤Æ¤¤¤ë¤â¤Î¤Ç¤¢¤ë¡£

°ìÊý¡¢¥Î¥ë¥¦¥§¥¤¤Ë¤ª¤¤¤Æ¤â¡¢Æ±ÍͤÎÊÑ°Û¤ò»ý¤Ä´µ¼Ô¤¬È¯¸«¤µ¤ì¤¿¡£

H3¥Ê¥ó¥Ð¥ê¥ó¥°¤Ç¤Ï¡¢¥Ý¥¸¥·¥ç¥ó222¤¬¥Ý¥¸¥·¥ç¥ó225¤Ë¤¢¤¿¤ë¡£

¤Þ¤¿¡¢¥í¥·¥¢¤Ë¤ª¤¤¤Æ¤Ï¡¢A/Vladivostok/1/2009Æó¡¢Æ±ÍͤÎÊÑ°Û¤¬¸«¤Ä¤«¤Ã¤Æ¤¤¤ë¡£

¥Î¥ë¥¦¥§¥¤¤Î¾ì¹ç¤Ï¡¢70¿Í¤Ë¤Ä¤¤¤Æ¸¡ºº¤ò¤·¡¢¤½¤Î¤¦¤Á¡¢8¿Í¤Î´µ¼Ô¤Ï»àË´¤·¤Æ¤¤¤ë¡£

D225GÊÑ°Û¤¬¸«¤é¤ì¤¿¤Î¤Ï¡¢¤³¤Î¤¦¤Á¤Î5¿Í¤Ç¤¢¤ê¡¢¤½¤Î¤¦¤Á¤Î2¿Í¤Ï»àË´¤·¤Æ¤¤¤ë¡£

¾¤Î»°¿Í¤Ï¡¢½¸Ãæ¼£Îż¼¤ËÆþ¤Ã¤Æ¤ª¤ê¡¢½Å¾É¤Ç¤¢¤ë¡£

¤³¤³¤Ç¤â¡¢¥¦¥¯¥é¥¤¥Ê¤ÈƱ¤¸¤¯¡¢ÊÑ°Û¥¦¥¤¥ë¥¹¤Ï¡¢Ç٤˽¸Ã椷¤Æ¡¢È¯¸«¤µ¤ì¤Æ¤¤¤ë¤È¤¤¤¦¡£

¥Ý¡¼¥é¥ó¥É¤Ë¤ª¤¤¤Æ¤â¡¢¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¤Ë¤è¤ë»à¼Ô¤¬µÞÁý¤·¤Æ¤¤¤ë¤¬¡¢¤³¤ì¤é¤Ë¤âD225GÊÑ°Û¤¬¤¢¤Ã¤¿¤«¤É¤¦¤«¤Ë¤Ä¤¤¤Æ¤Ï¡¢º£¤Î¤È¤³¤í¡¢³Îǧ¤Ç¤­¤Æ¤¤¤Ê¤¤¤è¤¦¤À¡£

È÷¹Í

¤³¤ì¤Þ¤ÇD225GÊÑ°Û¤ò¤ß¤»¤¿¥¦¥¤¥ë¥¹Ì¾°ìÍ÷(¥¦¥¯¥é¥¤¥Êʬ¤ò½ü¤¯)

01¡¡A/******/index/2009/02/01 (A/swine-flu/index/2009-02-01(H1N1))
02¡¡A/Hiroshima/201/2009/06/17
03¡¡A/Georgia/01/2009/04/27
04¡¡A/Zhejiang-Yiwu/11/2009/09/06
05¡¡A/Zhejiang/DTID-ZJU03/2009/09/07
06¡¡A/Zhejiang/DTID-ZJU02/2009/09/07
07¡¡A/Sao Paulo/53206/2009/07/19
08¡¡A/Sao Paulo/53225/2009/08/01
09¡¡A/New York/04/2009/04/
10¡¡A/Catalonia/NS1706/2009/07/29
11¡¡A/Mexico/InDRE4114/2009//
12¡¡A/Texas/11/2009/04/23
13¡¡A/Texas/05/2009/04/15
14¡¡A/Mexico/3955/2009/04/02
15¡¡A/Cancun-NY/Index/2009/04/15

»²¹Í
¡ÖH5N1Experts.org - View Single Post - swine flu sequences ¡×
my supposed index-strain , the virus which I consider the best candidate¡¡for the original ancestor virus of all ****** .
Presumably the virus¡¡which jumped from swine to a human or (IMO less likely) which reassorted in a human

A/swine-flu/index/2009-02-01(H1N1)
A/******-match/1-2/07(H3N2)¡¡(A/Mexflu-match/1-2/07(H3N2))
A/Sw/Index/triple-reassortant/1998(H3N2)

»²¹Í
¡ÖAntigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans¡×

»²¹Í
¡ÖA/Mexflu-match/1-2/07(H3N2)¡×

»²¹Í
¡ÖUkraine Dead Increase to 344 - Sequences Released¡×

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

ÌîÅĺâ̳ÉûÂç¿Ã¤¬¡Ö¸ÍÊ̽êÆÀÊä½þÀ©Å٤ˤĤ¤¤ÆÇþ¡¦ÂçƦÀè¹Ô¤ò¼¨º¶¡×¤È¤¤¤¦¤Î¤À¤¬¡£

Filed under: ̤ʬÎà — ´ÉÍý¿Í @ 19:51:56

2009/11/19(Thu)
¡¡
¡ÖÌîÅIJÂɧºâ̳ÉûÂç¿Ã¤Ï£±£¹Æü¤Îµ­¼Ô²ñ¸«¤Ç¡¢¥Þ¥Ë¥Õ¥§¥¹¥È¡ÊÀ¯¸¢¸øÌó¡Ë¤Î´ØϢͽ»»°µ½Ì¤Ç¾ÇÅÀ¤È¤Ê¤Ã¤Æ¤¤¤ëÇÀ²È¤Ø¤Î¸ÍÊ̽êÆÀÊä½þÀ©Å٤ˤĤ¤¤Æ¡ÖËÜÍè¤Ï¡Ê¼«µëΨ¸þ¾å¤òÌܻؤ¹¡ËÇþ¤äÂçƦ¤ÎÊý¤¬½çÈÖ¤ÏÀè¤À¡×¤È½Ò¤Ù¡¢¥³¥á¤ÎÀè¹Ô¼Â»Ü¤òÌܻؤ¹ÇÀ¿å¾Ê¤ËºÆ¹Í¤òÂ¥¤¹¹Í¤¨¤òɽÌÀ¤·¤¿¡£
Çþ¤äÂçƦ¤ÎÊý¤¬Í½»»Á¼ÃÖ¤¬¾¯¤Ê¤¯ºÑ¤à¤È¤ß¤é¤ì¤Æ¤¤¤ë¡£¡×

¤È¤¤¤¦µ­»ö¤Ê¤Î¤À¤¬¡¢¤³¤³¤Ë¤Ï¡¢Â礭¤ÊÌäÂ꤬¤Ò¤È¤Ä¤¢¤Ã¤Æ¡¢¤³¤ì¤Þ¤Ç¤ÎÃÏ°èÄó°ÆÂбþ·¿¤Î¡Ö»ºÃϤŤ¯¤ê¸òÉÕ¶â¡×¤Îή¤ì(»ÔĮ¼ñ°Ì¤Ë¡ÖÃÏ°è¿åÅÄÇÀ¶È¿ä¿Ê¶¨µÄ²ñ¡×ÀßÃÖ¢ª¡Ö¿åÅÄÇÀ¶È¥Ó¥¸¥ç¥ó¡×ºöÄꢪ¿åÅÄÇÀ¶È¸òÉնⱿ±Ä¶¨²ñ¤«¤é¸òÉÕ¶â¸òÉÕ)¤¬¡¢°ìÊѤ·¤Æ¤·¤Þ¤¤¡¢¿åÅÄÍø³èÍѼ«µëÎϸþ¾å»ö¶È¤Ç¤Ï¡¢Á´¹ñ°ìΧñ²Á¤Î¸òÉդȤʤꡢÃÏ°è¤Ç¤ÎÀïάºîʪ¤Ø¤Î¥¤¥ó¥»¥ó¥Æ¥£¥Ö¤¬Æ¯¤«¤Ê¤¯¤Ê¤Ã¤Æ¤·¤Þ¤¦¡¢¤È¤¤¤¦°ìÂç½ÅÍ×·ç´Ù¤¬ÏªÄ褷¤Æ¤·¤Þ¤¦¤Î¤À¡£

ÇÀ¶È´Ø·¸¼Ô¤ÎÃæ¤Ë¤Ï¡¢¡Ö¤»¤Ã¤«¤¯¡¢£µÇ¯Á°¤ÎÊÆÀ¯ºö²þ³×¤Ç¡¢Ã±²Á¤ÎÀßÄê¤òÃÏ°è´Ø·¸¼Ô¤¬ÀïάŪ¤Ë¡¢¼«¤é¤Ç¤­¤ë¤è¤¦¤Ë¤·¤¿¤Î¤Ë¡¢½õÀ®Ã±²Á¤ÎÀßÄê¤Ë´Ø¤¹¤ëÃÏ°è¤ÎºÛÎ̸¢¤ò¼è¤ê¾å¤²¡¢ºÆ¤Ó¡¢¹ñ¤ËÊ־夵¤»¤ë¤Ä¤â¤ê¤Ê¤Î¤«¡£¡×¤Ê¤É¤È¤¤¤­¤Þ¤¯¶Ú¤â¤¢¤ë¤è¤¦¤À¡£

¤¿¤È¤¨¤Ð¡¢¤¢¤ë»ºÃϤǤθ½ºß¤Î»ºÃϺî¤ê¸òÉÕ¶â¤Îñ²Á¤Ï¡¢²¼µ­¤Î¤è¤¦¤Ë¤Ê¤Ã¤Æ¤¤¤ë¡£

žºîºîÉÕ10¥¢¡¼¥ë¤¢¤¿¤ê½õÀ®¶â³Û

Çþ¡¦ÂçÇþ15000±ß¡¢
²ÖÒÃ11000±ß¡¢
²Ì¼ù6000±ß¡¢
°ìÈÌÌîºÚ6000±ß¡¢
·Ê´Ñ·ÁÀ®11000±ß¡¢
»ôÎÁºîʪ[»ºÃϤŤ¯¤ê¸òÉÕ¶â22000±ß¡Ü¿·¼õµëÄ´À°¥·¥¹¥Æ¥àÄêÃå¸òÉÕ¶â16000±ß]¡Ë

¤³¤ì¤¬¡¢¿åÅÄÍø³èÍѼ«µëÎϸþ¾å»ö¶È¤Ç¤Ï¡¢Á´¹ñ°ìΧ¤È¤Ê¤Ã¤Æ¤·¤Þ¤¦¤³¤È¤Ç¡¢¸½ºß¡¢¤³¤ì¤é¤Î»ºÃϤǤϡ¢¤è¤¦¤ä¤¯ÄêÃå²½¤·¤¿¤³¤ì¤é»ö¶È¤ÎºÆ¹½ÃÛ¤òÇ÷¤é¤ì¤Æ¤¤¤ë¡¢¤È¤¤¤¦Í­ÍͤΤ褦¤Ç¤¢¤ë¡£

¿åÅÄÍø³èÍѼ«µëÎϸþ¾å»ö¶È¤Ç¤Ï¡¢²¼µ­¤Î¤È¤ª¤ê¤È¤Ê¤Ã¤Æ¤¤¤ë

Çþ¡¢ÂçƦ¡¢»ôÎÁºîʪ¡¡35000±ß
¿·µ¬¼ûÍ×ÊÆ80000±ß
¤½¤Ð¡¢ºÚ¼ï¡¢²Ã¹©ÍÑÊÆ20000±ß
¤½¤Î¾ºîʪ¡ÝÃÏ°è¤ÇÀßÄê²Äǽ¡¡10000±ß

¤Þ¤À¡¢Ã±²Á¤Ï¡¢ºÇ½ª·èÄꤵ¤ì¤Æ¤¤¤Ê¤¤ÍͤÀ¤¬¡¢À¸»ºÀ©¸Â¤òÀߤ±¤Æ¤¤¤Ê¤¤¤È¤¤¤¦Í׷狼¤é¤¹¤ì¤Ð¡¢¾åµ­¤Îñ²Á¤Ç¤¤¤±¤ë¤Ï¤º¤Ï¤Ê¤¯¡¢¾åµ­Ã±²Á¤ò¤«¤Ê¤ê²¼²ó¤ë¤³¤È¤Ë¤Ê¤ë¤À¤í¤¦¡£

¤³¤Î¥¸¥ì¥ó¥Þ¤Ï¡¢¤½¤â¤½¤â¡¢¿·À¯¸¢¤Î¿åÅÄÍø³èÍѼ«µëÎϸþ¾å»ö¶È¤¬¡¢ÉÊÌܲ£ÃÇŪ¤Ç¤â¤Ê¤¯¡¢À¸»ºÀ©¸ÂŪ¤Ç¤â¤Ê¤¤¡¢¤È¤¤¤¦¡¢À­³Ê¤ò¤â¤Ã¤Æ¤¤¤ë¤¬¤¿¤á¤Î½ÉÌ¿¤È¤â¸À¤¨¤ë¡£

¤¹¤Ê¤ï¤Á¡¢ÀÐÇËÌÐÁ°ÇÀÎӿ建Âç¿Ã¤Î¡ØÊÆÀ¯ºö¤ÎÂ裲¼¡¥·¥ß¥å¥ì¡¼¥·¥ç¥ó·ë²Ì¤ÈÊÆÀ¯ºö²þ³×¤ÎÊý¸þ¡Ù¹½Áۤˤâ¤È¤º¤¯¡Ö¸ºÈ¿ÁªÂòÀ©¥×¥é¥¹Ä¾ÀÜ»Ùʧ¤¤¡×¤È¤¤¤¦¥¹¥­¡¼¥à¤«¤é¡¢¿åÅÄÍø³èÍѼ«µëÎϸþ¾å»ö¶È¤¬°ïæ¤Ç¤­¤Æ¤¤¤Ê¤¤¤È¤¤¤¦¤³¤È¤Ç¤â¤¢¤ë¡£

ľÀÜ»Ùʧ¤¤¤È¤¤¤¦Ì¾Á°¤¬¤Ä¤¤¤Æ¤Ï¤¤¤ë¤â¤Î¤Î¡¢¤½¤ì¤Ï¡¢¤¿¤À¡¢¡Ö¾©Îå¶âŪ¤Ê»Ùʧ¤¤¤Î·ÁÂÖ¤¬À¸»º¼Ô¤Øľ¤Ë»Ùʧ¤ï¤ì¤ë¡Ù¤È¤¤¤¦¤Î¤ß¤Î°ÕÌ£¤Î¤è¤¦¤Ç¡¢WTOÇÀ¶È¶¨Äê¤ËÄê¤á¤é¤ì¤¿Ä¾ÀÜ»Ùʧ¤¤¤ÎÄêµÁ¤Ç¤¢¤ë¡ÖÉÊÌܲ£ÃÇŪ¤Ç¤¢¤ê¡¢À¸»ºÍÞÀ©Åª¤Ç¤¢¤ê¡¢À¸»º²Á³Ê¤ËÂФ·¤Æ¤âÈÎÇä²Á³Ê¤ËÂФ·¤Æ¤â¥Ë¥å¡¼¥È¥é¥ë¤ÊľÀÜ»Ùʧ¤¤¡×¤Î³µÇ°¤È¤Ï¡¢Ãø¤·¤¯ÐªÎ¥¤·¤¿¡Ø¥¤¥ß¥Æ¡¼¥·¥ç¥ó¡¦Ä¾ÀÜ»Ùʧ¤¤¡Ù¤Î¥¹¥­¡¼¥à¤Ç¤¢¤ë¡£

(ÀÖ¾¾¹ñ̳Âç¿Ã¤ÎÅúÊÛ
¡¡¤³¤ì¤ÏÈó¾ï¤Ë¤ï¤«¤ê¤ä¤¹¤¯¿½¤·¾å¤²¤ë¤È¡¢¸ÍÊ̽êÆÀÊä½þ¤Ç¤¹¤«¤é¡¢¸ÍÊ̤ËľÀܤª¶â¤ò»Ùʧ¤¤¤Þ¤¹¤è¡¢¸òÉÕ¶â¤òʧ¤¤¤Þ¤¹¤è¤È¡£¤â¤Ã¤È¶Ëü¤Ë¸À¤¨¤Ð¡¢¹ñ¤Îµ¡´Ø¤Ç¤¢¤ê¤Þ¤¹ÇÀÀ¯¶É¤«¤é¡¢ÇÀ¶È¼Ô¤Î¡¢¤³¤ì¤ÏÇÀ¶¨¤Ë¸ýºÂ¤¬¤¢¤ë¤«¤â¤·¤ì¤Þ¤»¤ó¡¢Í¹Êضɤ«¤â¤·¤ì¤Þ¤»¤ó¡¢¤½¤³¤ËľÀÜ»Ùʧ¤¤¤Þ¤¹¤è¡¢¿¶¤ê¹þ¤ß¤ò¤·¤Þ¤¹¤è¤È¤¤¤¦¤³¤È¤Ê¤ó¤Ç¤¹¡£
¡¡º£¤Þ¤Ç¤Ï¤¤¤í¤¤¤í¤ÊÃÄÂΤòÄ̤¸¤Æʧ¤Ã¤Æ¤¤¤Þ¤·¤¿¤¬¡¢»ä¤É¤â¤Î¸À¤Ã¤Æ¤¤¤ë¸ÍÊ̤Ȥ¤¤¦¤Î¤Ï¤½¤¦¤¤¤¦°ÕÌ£¤Ê¤ó¤Ç¤¹¡£Ä¾ÀÜ»Ùʧ¤¤¤Þ¤¹¤è¡¢¤½¤¦¤¤¤¦¤³¤È¤Ê¤ó¤Ç¤¹¡£¤¼¤Ò¤½¤¦¤¤¤¦¤³¤È¤Ç¸æÍý²ò¤¤¤¿¤À¤­¤¿¤¤¡£)(www)(¤Þ¤¢¡¢ÀÖ¾¾Âç¿Ã¤Ë¤Ï¡¢ÂçÊѼºÎé¤Ê¤Î¤À¤¬¡¢¤³¤ÎÄøÅ٤Τ´Ç§¼±¤Î¤è¤¦¤Ç¤¢¤ë¡£Ã²¤«¤ï¤·¤¤¡£)

¤³¤³¤¤¤é¤Ç¡¢Ì±¼çÅÞÀ¯¸¢¤Î³§¤µ¤ó¤Ï¡¢¡ØľÀÜ»Ùʧ¤¤¡Ù¤Î¿¿¤Î°ÕÌ£¤òºÆ³Îǧ¤µ¤ì¡¢¥¹¥­¡¼¥à¤ÎºÆ¹½Ãۤˤ¢¤¿¤é¤ì¤¿¤é¤è¤í¤·¤¤¤Î¤Ç¤Ï¤Ê¤«¤í¤¦¤«¡£

¿åÅÄÍø³èÍѼ«µëÎϸþ¾å»ö¶È¤¬¸ºÈ¿ÁªÂòÀ©¥¹¥­¡¼¥à¤ÎÇÉÀ¸Êª¤Ç¤¢¤ë°Ê¾å¡¢¤³¤ÎÌîÅĺâ̳ÉûÂç¿Ã¤Î¤¤¤ï¤ì¤ë¤è¤¦¤Ê¡¢¥³¥áÌäÂê¤ÈžºîºîʪÌäÂê¤È¤Î¥¹¥­¡¼¥à¤Î¥Ä¥¤¥óÀÚ¤êÎ¥¤·¹½ÁۤϤʤ«¤Ê¤«¤à¤º¤«¤·¤¯¡¢¤³¤Ã¤Á¤¬·è¤Þ¤é¤Ê¤±¤ì¤Ð¡¢¤¢¤Ã¤Á¤â·è¤á¤é¤ì¤Ê¤¤¡¢¤È¤¤¤Ã¤¿¥È¡¼¥È¥í¥¸¡¼¤ÎÎزö¤Ë¡¢ÇÀÎӿ建¾Ê¤ÏǺ¤Þ¤µ¤ì¤ë¤³¤È¤Ë¤Ê¤ë¤Î¤À¤í¤¦¡£

¥é¥É¥ä¡¼¥É¡¦¥­¥Ã¥×¥ê¥ó¥°(Rudyard Kipling)¤Î¡ÖÅì¤ÈÀ¾¤Î¥Ð¥é¡¼¥É¡×(¡ÈThe Ballad of East and West¡É 1892)¤Ë¤Ê¤¾¤é¤¨¤Æ¸À¤¨¤Ð¡¢

¡Ö¤¢¤¢¡¢¥³¥á¤Ï¥³¥á¡¢Å¾ºîºîʪ¤Ïžºîºîʪ¡¢¤³¤ÎÆó¤Ä¤¬¸ò¤ï¤ë¤³¤È¤Ï·è¤·¤Æ¤Ê¤¤¡£
ÂçÃϤȶõ¤¬¿À¤Î¿³È½¤ÎÁ°¤ËΩ¤ÄºÇ¸å¤Î¤È¤­¤Þ¤Ç¡£
¤·¤«¤·¡¢¤¿¤¬¤¤¤ËÃϤβ̤Ƥ«¤éÍè¤è¤¦¤È¤â¡¢Æó¿Í¤Îͦ¼Ô¤¬¸þ¤«¤¦¤È¤­¤Ë¤Ï¡¢ ¥³¥á¤â¤Ê¤¯Å¾ºîºîʪ¤â¤Ê¤¯¡¢¹ñ¶­¤â¤Ê¤¯¡¢Ì±Â²¤äÀ¸¤Þ¤ì¤Î°ã¤¤¤â¤Ê¤¤¡ª¡×
(Oh, East is East, and West is West, and never the twain shall meet,Till Earth and Sky stand presently at God’s great Judgment Seat;
But there is neither East nor West, Border, nor Breed, nor Birth,
When two strong men stand face to face, tho¡Ç they come from the ends of the earth!)

¤Þ¤µ¤Ë¡¢ÆüËܤˤª¤¤¤Æ¤Ï¡¢Çþ¡¢ÂçƦ¡¢¥³¥á¤Ï¡¢¥·¥ã¥à¤Î»°·»Äï¤Ê¤Î¤Ç¤¢¤ë¡£

¡¡

¤ªÃΤ餻:

ÆüËܤ«¤é¥·¥«¥´¤Î¥ª¥×¥·¥ç¥óÇäÇ㤬¤Ç¤­¤ë¤¿¤á¤Î¥Þ¥Ë¥å¥¢¥ë
¡Ö¥·¥«¥´¡¦¥ª¥×¥·¥ç¥óÇäÇãÀïά¥Þ¥Ë¥å¥¢¥ë¡×
(A4ÈÇ297¥Ú¡¼¥¸¡¢5,900±ß¡¢CD-ROMÈǤÏ4,800±ß)
¤ò¤³¤Î¤¿¤Ó½ñ¤­¾å¤²¡¢È¯´©¤·¤Þ¤·¤¿¡£

ÆâÍÆ¡¦Ìܼ¡¤Î¤´³Îǧ¤ä¤ªµá¤á¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£

¤ªÆÁÍѤʥÀ¥¦¥ó¥í¡¼¥ÉÈÇ-ÅŻҽñÀÒPDF¥Õ¥¡¥¤¥ë(297¥Ú¡¼¥¸¡¢3,980±ß)¤´´õ˾¤Î¾ì¹ç¤Ï¡¢¤³¤Á¤é¤ò¥¯¥ê¥Ã¥¯¤·¤Æ¤¯¤À¤µ¤¤¡£